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ABSTRACT 
 
The renal excretion of organic anions, including a variety of endogenous substances, 
xenobiotics and their metabolites, involves an organic anion transport system with 
multiple specificity.  The well characterized basolateral uptake step of this process 
involves the organic anion transporter 1 (OAT1), recently cloned from the rat, mouse 
and flounder, which mediates the uptake of an organic anion in exchange for an 
intracellular dicarboxylate.  This study represents the first reported cloning of a human 
OAT1 homologue, hROAT1, which was cloned via a degenerate PCR-based approach.  
The hROAT1 reading frame encodes a 550 amino acid protein with a calculated 
molecular mass of 60 kDa, and has significant homology to previously cloned OAT1 
homologues.  To enable heterologous expression in the Xenopus laevis oocyte system, 
an hROAT1 expression clone was constructed by subcloning the hROAT1 reading 
frame between the 5 and 3 UTRs of the flounder sodium dicarboxylate cotransporter, 
fNaDC-3.  Expressed in Xenopus laevis oocytes, hROAT1 mediated the uptake of 
p-aminohippurate (PAH), the model substrate for this system.  This uptake had an 
approximate Km of 10 µM, and was inhibited by probenecid, dicarboxylates including 
the probable physiological exchange partner α-ketoglutarate, and the loop diuretics 
bumetanide and furosemide.  Uptake also showed chloride dependence, characteristic of 
the basolateral organic anion/dicarboxylate exchange in renal systems.  Mutation of two 
amino acids, Lys382 and Arg466, positions positively charged in all OATs and 
negatively charged or neutral in the related organic cation transporters (OCTs), 
abrogated transport function.  Deletion of exons 9 and 10 also resulted in a non-
functional transporter.  Deletion of exon 10 alone, which contains a consensus site for 
phosphorylation by casein kinase II, increased transport by approximately two-fold.  A 
second member of the OAT family, hOAT2, was also cloned from the human kidney.  
The hOAT2 cDNA encodes a protein of 541 amino acids, with high homology to the 
previously identified rat OAT2.  The sequences of hOAT2 and hNLT, a second human 
OAT2 homologue cloned from the liver, are identical apart from exon 10, which is 
completely divergent and contains alternate protein kinase consensus sites.  hOAT2 and 
hNLT appear to represent tissue-specific transcripts from the same gene.  The observed 
effect on hROAT-mediated transport of deleting exon 10, and the apparent tissue-
specific expression of the tenth exon of hOAT2 suggest an as yet unexplored role for 
exon 10 in the regulation of these transporters. 
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1 INTRODUCTION 
 
A great number of the potentially toxic compounds in the human body are organic 
anions, including both endogenous compounds and xenobiotics such as industrial and 
environmental toxins, pharmaceutical agents, and plant and animal toxins.  These 
compounds often exist in the ionized form at physiological pH, or are converted to more 
hydrophilic metabolites in the liver and kidney (Roch-Ramel and Diezi 1997).  In the 
kidney, many substances are exchanged between the blood and the tubular lumen, 
enabling the excretion of potential toxins and the conservation of valuable metabolites.  
Renal excretion consists of a combination of filtration at the glomerulus and secretion in 
the proximal tubule, which possesses transport systems with multiple specificity that 
efficiently secrete a multitude of organic anions of varied structure.   
 
1.1 THE MULTISPECIFIC ORGANIC ANION TRANSPORT SYSTEM (OAT) 
 
Many organic anions secreted in the kidney are transported by the classical organic 
anion transport system, which consists of a well-defined active basolateral uptake step 
involving organic anion / α-ketoglutarate exchange, and a poorly characterized luminal 
efflux step (Roch-Ramel 1998).  The importance of this process is shown by the 
observation that organic anion secretion has been found in the kidney of almost all 
vertebrates, as well the renal systems of some invertebrates (Dantzler 1989, Pritchard 
and Miller 1991).  The original physiological role of the multispecific organic anion 
transport system is believed to be the secretion of endogenous anionic compounds, such 
as cyclic nucleotides, prostaglandins and uremic toxins (Gemba et al 1983, Podevin and 
Boumendil-Podevin 1975, Irish 1979, Prescott et al 1993). 
 
The clinical relevance of the organic anion / α-ketoglutarate exchanger is that many 
anionic drugs and nephrotoxins are thought to be substrates for the system.  
Cephalosporin-based antibiotics such as cephaloridine, and mycotoxins such as 
ochratoxin A are both taken up by proximal tubule cells via this system, causing 
metabolic disorders (Endou 1998).  In the case of ochratoxin A, nephrotoxicity is 
prevented by probenecid, the classical inhibitor of the multispecific organic anion 
system (Jung and Endou 1989).  The model substrate for the organic anion transporting 
system is para-aminohippurate, or PAH, a product of 4-aminobenzoate metabolism.  
1. Introduction  3 
This substance is efficiently secreted and is extracted to over 90% during the first pass 
through the kidney (Roch-Ramel and Diezi 1997) and is used diagnostically to 
determine renal plasma flow.  Almost all studies of the renal organic anion transporting 
system have utilized PAH as a substrate.   The chemical structures of PAH and 
probenecid are shown in Figure 1.1 below. 
 
 
FIGURE 1.1:  Compounds interacting with the organic anion transporting system.  The compounds 
in this figure all interact with the multispecific organic anion transporting system of the kidney: PAH 
(top) is the model substrate, probenecid (bottom) is the classical inhibitor and α-ketoglutarate (middle) is 
an intracellular exchange partner for organic anion uptake.  Properties common to most substances 
interacting with this system are a hydrophobic region and ionization at physiological pH. 
 
Although the functional characteristics of the multispecific organic anion transport 
system have been known for many years, transport proteins mediating the active 
basolateral of organic anions have only recently been identified.  These proteins, which 
have now been cloned from several different species, are termed OAT1 (for organic 
anion transporter 1), and all are functionally and structurally related (Lopez-Nieto et al 
1997, Sekine et al 1997, Sweet el al 1997, Wolff et al 1997).  In contrast, the protein(s) 
responsible for the less well-defined luminal efflux of organic anions have yet to be 
identified.    
 
1.1.1 Specificity of basolateral organic anion uptake 
The compounds classed as substrates of the renal organic anion transport system were 
identified by inhibition of their excretion, usually by PAH or probenecid (Møller and 
Sheikh 1983).  These compounds belong to many chemical classes, as seen in Table 1.1.  
Subsequent studies carried out to determine the structural requirements of substrates of 
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the system relied on inhibition of PAH uptake by the test substance (Ullrich 1997).  
Although this approach undoubtedly identifies compounds that interact with the carrier, 
it provides no evidence as to whether they are actually translocated (Roch-Ramel 1998).   
Nevertheless, the affinity of the transporter for compounds identified as inhibitors, or 
potential substrates, is influenced by four factors: hydrophobicity, charge, charge 
distribution, and charge strength (Ullrich 1997).  The classical organic anions, 
monovalent hydrophobic anions with a negative or partial negative charge, interact best 
with the transporter.  These compounds require a hydrophobic moiety of at least 4 Å in 
length.  The system also interacts with divalent anions, including some zwitterions, for 
which optimal interaction with the transporter requires a charge separation of 6-7 Å.  In 
addition, these compounds may contain a hydrophobic moiety of up to 10 Å in length.  
The affinity of the transporter for both mono- and divalent anions increases with 
hydrophobicity and charge strength.  Finally, non-ionizable hydrophobic compounds 
also interact with the transporter. 
 
Chemical class Examples Properties 
Conjugated compounds p-Aminohippurate Classical substrate, diagnostic agent 
Benzoate derivatives Probenecid 
Salicylate 
Bumetanide 
Classical inhibitor 
Analgesic 
Loop diuretic 
Acetate and proprionate 
derivatives 
Diodrast 
Indomethacin 
Ethacrynic Acid 
Contrast agent 
Analgesic 
Loop diuretic 
Heterocyclic carboxylates Benzylpenicillin 
Cephaloridin 
β-lactam antibiotic 
β-lactam antibiotic 
Sulfonamides Acetazolamide Carbonic anhydrase inhibitor 
Other heterocyclic compounds Urate End product of purine degradation 
Sulfonates Phenol red Diagnostic dye 
Amino acid derivatives Methotrexate Antitumor drug,  folic acid derivative 
Miscellaneous Prostaglandin E2 
cAMP 
Local hormone 
Second messenger molecule 
TABLE 1.1:  Examples of substrates of the classical organic anion transport system of the kidney.  
The substances in this table are excreted by the kidney via a process that can be inhibited by PAH, 
probenecid, or another representative substrate of the classical organic anion transport system (Møller and 
Sheikh 1983).   
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1.1.2 Site of organic anion secretion in the kidney 
The site of organic anion transport was first demonstrated by studies of the secretion of 
the organic anion phenol red in aglomerular marine teleosts (Marshall and Grafflin 
1928, Shannon 1938).  This was not only the first demonstration of the existence of 
renal secretion, but because the kidney of these fish consists almost entirely of proximal 
tubule, this also proved that organic anion secretion occurs in the proximal tubules 
(Marshall and Grafflin 1928, Shannon 1938).  Later studies in the chicken, flounder and 
mammals confirmed the proximal tubule to be the site of organic anion secretion 
(Chambers and Kempton 1933, Cortney et al 1965, Forster 1948, Malvin et al 1958).  In 
fact, secretion takes place in the proximal tubule of representative species from all five 
vertebrate classes (Dantzler and Wright 1997).  
 
1.1.3 Basolateral uptake by the organic anion transporting system 
Early studies demonstrated that secreted anions are concentrated in proximal tubule 
cells and the tubular lumen, suggesting distinct basolateral and luminal steps.  In 
addition, the inside-negative potential of the proximal tubule cell requires uphill 
transport supported by the finding that inhibiting energy production reduces uptake.  
However, no direct coupling to ATP hydrolysis could be demonstrated (Maxild 1978, 
Podevin and Boumendil-Podevin 1975, Ross and weiner 1972, Sheikh et al 1981).  For 
many years it was also known that the sodium gradient is essential to the functioning of 
the organic anion transporting system.  Although sodium-organic anion cotransport was 
initially suggested as the mechanism for the basolateral uptake of organic anions, such a 
process was never demonstrated (Berner and Kinne 1976, Kasher et al 1983, Kinsella et 
al 1979).    
 
Almost 20 years elapsed before the link between metabolic energy production and 
organic anion uptake was elucidated.  An important finding was that an outwardly 
directed gradient of unlabelled PAH with an inwardly directed sodium gradient 
stimulated the uptake of labelled PAH (Kasher et al 1983, Eveloff 1987), which lead to 
the suggestion that PAH uptake might occur via exchange for an anionic metabolite 
(Pritchard and Miller 1993).  Furthermore, anionic metabolites such as dicarboxylates, 
which are taken up across the basolateral membrane by direct coupling to the sodium 
gradient, could stimulate PAH uptake (Kippen and Klinenberg 1978, Ullrich et al 1987).  
The current model for basolateral PAH uptake was first proposed by Burckhardt and co-
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workers (Shimada et al 1987) and Pritchard (Pritchard 1987).  In this model, the ATP-
dependent step involved in generation of the sodium gradient by the Na+-K+-ATPase 
drives sodium-dicarboxylate cotransport into the cell, which, by creation of an 
outwardly directed dicarboxylate gradient, drives organic anion uptake via 
dicarboxylate-organic anion exchange.  The net effect predicted by this model is that of 
uptake of sodium with the organic anion and recycling of the anionic exchange partner, 
at the cost of one molecule of ATP per organic anion imported.  This process is termed 
tertiary active transport, as the uptake of the organic anion is driven by ATP hydrolysis 
two steps removed.  The model was verified by subsequent vesicle studies and also by 
new and reevaluated studies with intact tissue, all of which demonstrated that certain 
dicarboxylates were able to stimulate the uptake of PAH (Pritchard 1987, Shimada et al 
1987, Sullivan and Grantham 1992).   
 
In the currently accepted model, α-ketoglutarate is believed to act as the physiological 
exchange partner for basolateral PAH uptake.  Of the dicarboxylates capable of 
exchanging with organic anions, α-ketoglutarate is the most abundant in proximal 
tubule cells (Terlouw et al 2000).   In addition, the physiological concentrations of α-
ketoglutarate and its ability to stimulate PAH uptake in vesicles and intact tubules 
support this assumption (Shimada et al 1987, Chadsudthipong and Dantzler 1991 and 
1992).  Intracellular concentrations of around 100 to 200 µM combined with plasma 
concentrations of 5-12 µM provide the gradient required to drive organic anion uptake 
(Boyd and Goldstein 1979, Lemieux et al 1980, Martin et al 1989, Rocchiccioli et al 
1984); concentrations similar to the plasma concentration also maximally stimulate 
PAH uptake into vesicles or tissue slices (Pritchard 1988, Pritchard 1990).  In addition 
to its metabolic production, α-ketoglutarate is also taken into proximal tubule cells via 
sodium-dependent cotransport at the basolateral and luminal membranes, maintaining 
the necessary outwardly directed gradient (Dantzler and Wright 1997).  This uptake has 
been calculated to contribute approximately half of the exchangeable α-ketoglutarate 
for organic anion exchange (Welborn et al 1998). 
 
1.1.4 Cellular model of the basolateral uptake of organic anions 
In recent years the proposed model for basolateral organic anion uptake has been 
strengthened by the cloning and characterization of the transporters responsible for this 
functionally coupled system.  The organic anion / dicarboxylate exchanger and the 
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sodium-dicarboxylate cotransporter from several species have now been cloned and 
characterized (Sweet et al 1997, Wolff et al 1997, Sekine et al 1997, Steffgen et al 
1999).  The model is shown in Figure 1.2.   Organic anion (PAH) uptake in exchange 
for an intracellular dicarboxylate (α-ketoglutarate) is mediated by the organic anion 
transporter 1, OAT1. Recycling of α-ketoglutarate back into the cell, together with three 
sodium ions, occurs via the sodium-dicarboxylate cotransporter, NaDC-3, and the 
sodium ions are pumped out of the cell by the Na+-K+-ATPase, at the cost of one 
molecule of ATP. 
 
 
 
 
Figure 1.2:  Model of basolateral organic anion transport in proximal tubule cells.  The current 
model for basolateral organic anion uptake involves import of an organic anion, represented here by PAH, 
in exchange for an intracellular dicarboxylate (α-ketoglutarate), by OAT1.  The intracellular pool of α-
ketoglutarate is maintained by metabolism and import by NaDC-3, which returns α-ketoglutarate to the 
cell together with three sodium ions, in a process driven by the inwardly directed sodium gradient.  The 
Na+-K+-ATPase pumps the sodium ions from the cell and is the energy consuming step of the system. 
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1.1.5 Cytoplasmic transport of organic anions 
Following basolateral uptake, organic anions must arrive at the luminal membrane to 
enable secretion to be completed.  From the few studies to have addressed this process, 
it appears that organic anions are not uniformly distributed within the cell.  Fluorescein, 
a fluorescent substrate of the organic anion transporting system, was shown to be 
compartmentalized in renal cells after uptake, possibly within vesicles (Miller et al 
1993).   It has also been shown that fluorescein is taken up into the mitochondria of 
proximal tubule cells, via a process involving at least three metabolite carriers (Terlouw 
et al 2000).  Although there is insufficient evidence to allow conclusions to be drawn, it 
has been suggested that intracellular binding or sequestration may protect the cell from 
the nephrotoxic effects of many of the substrates of the organic anion transporting 
system (Crawford 1991). 
 
1.1.6 Luminal exit 
In comparison with the well-defined process of uptake of organic anions into the cell 
across the basolateral membrane, events at the luminal membrane are less clear. Vesicle 
studies have shown that this process is both saturable and probenecid sensitive, and that 
this transport is not driven by the sodium gradient (Berner and Kinne 1976, Dantzler 
1974).  Early results were complicated by the differences observed in species that 
reabsorb urate, the end product of purine metabolism, compared with urate-secreting 
species (Aronson 1989, Martinez et al 1990).  The presence of an anion exchange 
system capable of transporting PAH has been shown, although the characteristics of this 
system would be more likely to mediate reabsorption of organic anions rather than their 
efflux, and it is thought that this system probably mediates urate reabsorption (Aronson 
1989).  Other studies have demonstrated a probenecid-sensitive potential-dependent 
system in luminal membrane vesicles, which could mediate the transport of organic 
anions down an electrochemical gradient into the lumen (Kinsella et al 1979, Eveloff et 
al 1979).  Despite the characterization of these systems in brush-border membrane 
vesicles, they have yet to be demonstrated in situ (Roch-Ramel 1998).  Figure 1.3 shows 
the model of organic anion transport at the luminal membrane. 
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Figure 1.3: Model of the luminal efflux of organic anions in proximal tubule cells.  This model shows 
two functionally characterized systems for luminal efflux of organic anions (PAH), for which the proteins 
responsible have yet to be identified.  As discussed in the text, the organic anion exchanger (bottom) 
would probably mediate organic anion reabsorption.  The facilitated transporter (top) would be driven by 
the electrochemical gradient. 
 
 
1.2 STUDIES OF ORGANIC ANION TRANSPORT IN THE HUMAN 
KIDNEY 
 
It is well known that the human kidney efficiently excretes PAH, however, 
physiological studies with human tissue have been limited by the availability of source 
material.  In one of the few studies of PAH uptake by basolateral vesicles derived from 
human proximal tubules (Guisan and Roch-Ramel 1995), it was shown that PAH uptake 
was stimulated by external oxoglutarate only when combined with an inward sodium 
gradient, consistent with the proposed model for basolateral PAH uptake.  At the 
luminal membrane, the presence of a system similar to that found at the basolateral 
membrane has been demonstrated (Roch-Ramel et al 1996).  In brush-border (luminal) 
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membrane vesicles, PAH uptake was cis-stimulated by α-ketoglutarate only in the 
presence of an inwardly directed sodium gradient.  However, as mentioned in the 
previous section, such a system would favour the reabsorption of PAH from the tubular 
lumen, rather than excretion. 
 
1.3 PREVIOUSLY CLONED OAT1 HOMOLOGUES 
 
At the beginning of this study, proteins with the properties of the basolateral 
multispecific organic anion transport system had been cloned and characterized from 
the rat and flounder kidney. The rat homologue was cloned independently by two 
groups and named OAT1 (Sekine et al 1997) and ROAT1 (Sweet et al 1997), 
respectively.  A flounder homologue, fROAT, appeared a short time later (Wolff et al 
1997).  In addition, a homologous protein previously cloned from the mouse kidney, 
named NKT (for novel kidney transporter), had been isolated, but no function had been 
demonstrated (Lopez-Nieto et al 1997).   
 
The rat OAT1/ROAT1 clones were isolated by functional expression in Xenopus laevis 
oocytes.  When injected into oocytes, the protein mediates the uptake of PAH with an 
estimated Km of approximately 15 µM (Sekine et al 1997) or 70 µM (Sweet et al 1997).  
Preincubation of the OAT1-injected oocytes with glutarate lead to a two to three-fold 
increase in PAH uptake (Sekine et al 1997, Sweet et al 1997), and a ten-fold increase 
was observed in oocytes co-injected with rNaDC-1, a rat sodium-dicarboxylate 
cotransporter (Sekine et al 1997). Transport of PAH was also cis-inhibited by diverse 
endogenous and exogenous organic anions, and furthermore, OAT1 mediated uptake of 
among others, labelled α-ketoglutarate, methotrexate and urate (Sekine et al 1997).  In 
situ hybridization patterns suggested that OAT1 is most strongly expressed in the S2 
portion of the proximal tubule (Sekine et al 1997).  These observations lead the authors 
to conclude that OAT1 represents the protein mediating the multispecific organic anion-
dicarboxylate exchange at the basolateral membrane of the proximal tubule.   
 
The flounder OAT1, fROAT, was also cloned by functional expression in Xenopus 
laevis oocytes (Wolff et al 1997).  The PAH uptake mediated by fROAT showed an 
apparent Km of 20 µM, and was probenecid sensitive.  In cis-inhibition studies the 
dicarboxylates α-ketoglutarate, glutarate, and suberate, as well as urate and the loop 
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diuretic bumetanide inhibited PAH uptake.  The functional characteristics suggest that 
fROAT is the basolateral organic anion-dicarboxylate exchanger of the flounder kidney. 
 
In addition to the functional similarities detailed above, the OAT1 homologues also 
exhibit similarities on the sequence level; the rat OAT1 and mouse NKT are 93 % 
identical, and both are 46 % identical to the flounder fROAT.  Furthermore, a sequence 
database search reveals homology to another organic anion transporter isolated from the 
rat liver, NLT (Simonson et al 1994) subsequently renamed rOAT2 based on its 
functional properties (Sekine et al 1998), and homology to members of a family of 
proteins mediating the renal transport of organic cations, OCT1 (Gründemann et al 
1994) and OCT2 (Okuda et al 1996), as seen in Table 1.2 below.    
 
 OAT1/ROAT NKT fROAT NLT OCT1 OCT2 
OAT1/ROAT - 95 68 56 49 49 
NKT 93 - 67 57 49 49 
fROAT 46 46 - 55 49 47 
NLT 37 37 37 - 48 49 
OCT1 31 33 32 31 - 83 
OCT2 31 32 31 31 69 - 
 
Table 1.2:  Sequence homologies of OAT1 and related proteins.  The table shows sequence identities 
and homologies for six related proteins known at the beginning of the study.  Values in bold represent 
sequence identity and those in normal type represent the similarity, calculated using the NCBI  Blast 
server, www.ncbi.nlm.nih.gov/BLAST/. 
 
The rat OAT1, fROAT and NKT cDNAs encode proteins of 551, 562 and 546 amino 
acids, respectively, and hydropathy analysis predicts twelve putative transmembrane 
domains with internal N- and C-termini; a model of the membrane topology of the rat 
OAT1 is shown in Figure 1.4.  
 
Further shared structural features are shown in Table 1.3.  These include conserved 
cysteine residues and consensus sites for N-linked glycosylation within the large 
extracellular loop between the first and second transmembrane domains, consensus sites 
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Figure 1.4:  Membrane topology model of the rat OAT1.  This model shows the putative model for 
membrane organization of the rat OAT1, as predicted by TopPred 2 (von Heijne 1992), consisting of 
twelve transmembrane domains (I-XII), a large extracellular loop between transmembrane domains 1 and 
2, a large intacellular loop between transmembrane domains 6 and 7, and intracellular N- and C-termini. 
 
for phosphorylation by various protein kinases within the large intracellular loop 
between transmembrane domains six and seven, and further protein kinase consensus 
sites in the C-terminus. 
 
 
 OAT1/ROAT NKT fROAT 
GenBank accession number AB004559/AAC18772 NP_032792 Z97028 
Length of ORF (amino acids) 551 546 562 
Number of transmembrane domains 12 12 12 
Conserved cysteines 4 4 4 
N-glycosylation sites 5 5 3 
Protein kinase consensus sites  PKC 
                                                  PKA
                                                 CKII
4 
- 
3 
4 
- 
3 
7 
2 
4 
  
Table 1.3: Sequence features shared by the cloned OAT1 homologues.  The GenBank accession 
numbers are those from the original publications.  The number of transmembrane domains was predicted 
with the TopPred 2 server (von Heijne 1992).  Conserved cysteines are those present within the large 
extracellular loop of all OATs and OCTs.  The presence and location of N-glycosylation and protein 
kinase consensus sites was determined with the Prosite database .  PKC = protein kinase C, PKA = 
cAMP-associated protein kinase, CKII = casein kinase II. 
 
H2N COOH
II II III IV V VI VII VIII IX X XI XII
extracellular
intracellular
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1.4 AIMS OF THE PRESENT STUDY 
 
The major aim of this study was to isolate and characterize a human homologue of the 
basolateral organic anion-dicarboxylate exchanger, OAT1.  The human kidney is known 
to efficiently excrete organic anions such as PAH, and this process has been shown to 
share the functional characteristics of the previously cloned OAT1 homologues. Using 
sequence data available from rat, flounder and mouse OAT1 homologues, an organic 
anion transporter isolated from the rat liver, as well as cloned members of the organic 
cation transporter (OCT) family, it was hoped to identify suitable regions from which 
primers could be designed to PCR-amplify a human OAT1 homologue.  If successful 
this would present a rapid means of isolating a clone, thus abrogating the need for the 
time-consuming construction and screening of a cDNA library.  A secondary aim was to 
investigate the renal expression of OAT2 in the human kidney. The characteristics of 
the rat OAT2, low PAH affinity and function as a facilitatory transporter, are similar to 
those demonstrated for luminal PAH transport in vesicle studies.  The presence of 
OAT2 in the kidney would therefore make it a candidate for the luminal efflux of 
organic anions. 
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2 MATERIAL 
 
2.1 Bacteria 
 
Bacterial strains used for cloning and maintenance of plasmid constructs are listed in 
Table 2.1.    
 
strain  company genotype 
INVaF  Invitrogen F´, endA1, recA1, hsdR17 (rk
-, mk
+), supE44, thi-1, gyrA96, relA1, 
    Φ80lacZ∆M15∆(lacZYA-argF)U169 
TOP10F Invitrogen  F´ {lacIq Tn10(TetR)}, mcrA, ∆(mrr-hsdRMS-mcrBC), Φ80lacZ∆M15  
    ∆lacX74, deoR, recA1, araD139,  ∆(ara-leu)7697, galU, galK,  
    rpsL (StrR), endA1, nupG 
XL10 Gold Stratagene Tetr∆ (mcrA)183, ∆(mcrCB-hsdSMR-mrr)173, endA1, supE44, thi-1 
     recA1, gyrA96, relA1, lac Hte [F proABlacIqZ∆M15 Tn10 (Tetr)  
    Amy Camr] 
XL10-Gold Kmr Stratagene Tetr∆ (mcrA)183, ∆(mcrCB-hsdSMR-mrr)173, endA1, supE44, thi-1,  
    recA1, gyrA96, relA1 lac Hte [F proABlacIqZ∆M15 Tn10 (Tetr) Tn5 
     (Kanr) Amy] 
XL1-Blue Stratagene recA1, endA1, gyrA96, thi-1, hsdR17, supE44, relA1,  
    lac [F proAB lacIqZ∆M15 Tn10 (Tetr)] 
 
Table 2.1.  Bacterial (E. coli) strains used in this study.   
 
 
2.2 Plasmid vectors 
 
The plasmid vectors used for cloning and maintenance of PCR amplicons, cell 
transfection and cRNA synthesis are listed in Table 2.2.   
 
plasmid   properties      source 
pPCR-script  ColE1 origin, ampicillin resistance, lacZ reporter, T7 and Stratagene 
   T3 RNA polymerase promoters. 
pCRII.1   ColE1 origin, ampicillin and kanamycin resistance, lacZ Invitrogen 
   reporter, TA-cloning site, T7 RNA polymerase promoter.    
pSPORT  pUC origin, ampicillin resistance, lacZ reporter and   Gibco 
   lacI repressor, T7 and SP6 RNA polymerase promoters. 
pCR-Blunt II-TOPO pMB1 origin, ccdB lethal gene, kan gene, lacZα reporter, Invitrogen 
   kanamycin resistance, T7and SP6 RNA polymerase 
   promoters, TOPO-cloning site. 
pGEMHE  X origin, X. laevis β-globin gene 5 and 3UTRs,  Liman et al 1992 
   ampicillin resistance, T7 RNA polymerase promoter 
 
Table 2.2:  Vector plasmids used in this study.   
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2.3 Oligonucleotide Primers 
 
General PCR reactions for the screening and sequencing of clones, and incorporation of 
restriction sites, were carried out with sequence-specific primers from NAPS or 
Interactiva. Sequence specific primers for 5 and 3 RACE, sequence analysis, 
amplification of full-length clones and mutagenesis were obtained from NAPS or 
Interactiva. 
 
Oligonucleotides used for RT-PCR, PCR-based cloning, PCR screening of clones, 
sequencing, generation of mutants, and cRNA synthesis are listed in Table 2.3. 
 
A.  Primers used in the cloning characterization and mutational analysis of hROAT1 
name   sequence     use 
5.1a      TIATGGCNWSNCAYAAY degenerate primer for hROAT1 cloning;  
        specific to the 5end (forward) 
5.2 a   GGIACITGYGCNGCNTWY degenerate primer for hROAT1 cloning 
        specific to the 5end (forward) 
3.1 a  ARNCCRTARTANGCRAA degenerate primer for hROAT1 cloning 
        specific to the 3end (reverse) 
3.2 a  NCCRAADATNACYTGDAT degenerate primer for hROAT1 cloning 
        specific to the 3end (reverse) 
3.3 a  GCNARRCANCCYTTNCC degenerate primer for hROAT1 cloning 
        specific to the 3end (reverse) 
Si GTTCTTGCTGAGGTTGGCATCGGCAG hROAT1-specific 5 RACE primer 
So GAGGTGAAGCGGAGGCAGGACTCAG hROAT1-specific 5 RACE primer 
GSP1 TTCCTCTGCCTCTCCATGCTGTG hROAT1-specific 3 RACE primer 
GSP2 AGGGCTTTGGAGTCAGCATCTAC hROAT1-specific 3 RACE primer 
QoQi-dT CGCAGATGTACGTCCTACCATCGCCTCT- universal RACE primer
-AGACCAGCCTACGAGC(T)17
Qo:    CGCAGATGTACGTCCTACCATCGCC universal RACE primer
Qi: ATCGCCTCTAGACCAGCCTACGAGC universal RACE primer
hR5 b  TCTAGATGGCCTTTAATGACCTCCTGCARC amplification of the hROAT1 ORF, 5-
specific 
hR3 b  TCAAAATCCATTCTTCTCTTGTGCT amplification of the hROAT1 ORF, 3- 
        specific 
hR 5 +Bam b GGATCCATGGCCTTTAATGACCTCCTGCARC as for hR5, with BamHI recognition  
        sequence 
hR 3 +Xba b TCTAGACCTCAAAATCCATTCTTCTCTTGTGC as for hR3, with XbaI recognition sequence 
hR578f  TCCTCTCGGGCATGGCTCTGGC sequencing primer 
hR599r  GCCAGAGCCATGCCCGAGAGG  sequencing primer 
hR1153f GGGCTTCCTTGTCATCAACTCCC  sequencing primer 
hR1174r GGGAGTTGATGACAAGGAAGCCC  sequencing primer 
R5UTR GAGCTGTCCAGACCCCCG 5UTR cloning, specific for the rOAT1 
5UTR
M5UTR AAGGAGGGGCAGCCCACCAG 5UTR cloning, specific for the NKT 
5UTR
hR5 UTR b AAGTGAGGAGAAGCTGCAAGG  Specific for the hROAT1 5UTR sequence 
K382A-f GGACCTGCCTGCCGCGCTTGTGGGCTTCC Forward primer for the generation of the  
        hROAT1 K382A point mutation 
K382A-r GGAAGCCCACAAGCGCGGCAGGCAGGTC Reverse primer for the generation of the  
        hROAT1 K382A point mutation 
R466D-f GCAGCACCATGGCCGACGTGGGCAGCATCG Forward primer for the generation of the  
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        hROAT1 R466D point mutation 
R466D-r CGATGCTGCCCACGTCGGCCATGGTGCTGC Reverse primer for the generation of the  
        hROAT1 R466D point mutation 
hROAT1A AACTTCGGATCCATGTGCGCCTTCCGGCT- Forward primer for generation of an  
   -CCTCTC    hROAT1 N-terminal deletion; with 
        BamHI site and artificial start  
        codon 
hR-5deletion ATTAAAGGCCATGGATCCCCAGAGGAAA Reverse primer for the above reaction; with  
        BamHI site 
hR-exon 10 GCTATCTAGACTCACCTGCTCTCCAGG- Forward primer for generation of hROAT1  
   -TCCTG     mutant lacking exon 10; with XbaI  
        site
hR-exons 9&10 GCTATCTAGACTCACCGGATCATTGTG- Forward primer for generation of hROAT1  
   -GGATAC    mutant lacking exons 9 and 10;  
        with XbaI site
hR-3 deletion AATGGATTTTGAGGTCTAGACCC  Reverse primer for the reaction above with  
        XbaI site and artificial stop codon  
 
B.  Primers used in the cloning of hOAT2 
h2-hEST1 ATGGGCTTTGAGGAGCTGCTG  Specific to the hEST containing the putative  
        start codon of hOAT2 
h2-hEST3 CTTTCTCTCCACGTCCTGGCTG  Specific to the last NLT-homologous 3end  
        sequence of hEST3 
h2-3RACE CAGACAGACAGGGATGGGGC  hOAT2-specific 3RACE primer 
h2-5end + Bam GGATCCATGGGCTTTGAGGAGCTGCTG Specific to the 5end of hOAT2; includes  
        BamHI site 
h2-3end + Xba TAATTCTAGATATCACACGTACACAGA- Specific to the 3end of hOAT2; includes  
   -CACAG     XbaI site 
h2-513fb CTGCTGCTGGTAGCCTAC   hOAT2-specific sequencing primer 
h2-531rb  GTAGGCTACCAGCAGCAG   hOAT2-specific sequencing primer 
h2-1072fb CTATTACGGCCTGAGTCTG   hOAT2-specific sequencing primer 
h2-1090rb AGACTCAGGCGGTAATAGG   hOAT2-specific sequencing primer 
hNLT-3´end TTAGTTCTGGACCTGCTTCATGGG Specific to the 3end of the liver-specific  
        hOAT2 isoform (hNLT)
C.  Primers used to construct the hOAT2:hROAT1 chimera 
hR2-5´+Bam ATGCGGATCCATGGGCTTTGAGGAGCT- hOAT2 5end-specific primer with BamHI  
   -GCT     site
hR1-3´+Xba TAGCTCTAGACTCAAAATCCATTCTTC- hROAT1 3end-specific primer with XbaI  
   -TCTTGTGC    site
chimera(2:1)-f GCCTCTGGTGGGTGCCTTCGGCCCGCT- Bipartite primer for creation of the  
   -GGCACTCC    hOAT2:hROAT1 chimera via  
        overlapping PCR
chimera(2:1)-r GGAGTGCCAGCGGGCCGAAGGCACCCA- Bipartite primer for creation of the  
   -CCAGAGGC    hOAT2:hROAT1 chimera via  
        overlapping PCR
 
D.  Primers specific to sequence of vectors used in this study 
T7 c  GTAATACGACTCACTATAGGGC  Specific for T7 RNA polymerase promoter 
T3 c  AATTAACCCTCACTAAAGGG  Specific for T3 RNA polymerase promoter 
SP6 c  ATTTAGGTGACACTATAG   Specific for SP6 RNA polymerase promoter 
M13forward c GTAAAACGACGGCCAGT   vector specific 
M13reverse c GGAAACAGCTATGACCATG   vector specific 
 
Table 2.3  Oligonucleotide primers used in this study.  Primers were ordered from Interactiva, except a 
= Eurogentec, b = NAPS, c = MWG.  Sequence details: A= adenosine, G= guanosine, C= cytosine, T= 
thymine, R= A or G, S= G or C, W=, Y= C or T, N= A,G, C or T,  I= inosine. 
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2.4 Enzymes 
 
All restriction enzymes were purchased from New England Biolabs Inc (Beverly, MA, 
USA) or MBI Fermentas (Vilnius, Lithuania).  Various DNA polymerases were used 
according to the application (the polymerase used for each application is detailed in 
Methods) and were purchased from Stratagene (La Jolla, CA, USA), Invitrogen 
(Carlsbad, CA, USA), or PAN Systems (Aidenbach, Germany).  T4 DNA ligase was 
purchased from Boehringer Mannheim (Mannheim, Germany), and calf intestinal 
alkaline phosphatase was purchased from New England Biolabs (Beverly, MA, USA). 
 
2.5  Kits 
 
All kits used are listed in Table 2.4 below 
 
A.  Nucleic acid purification 
QIAquick Gel Extraction Kit  QIAgen (Hilden, Germany) 
QIAprep Spin Miniprep Kit 
Oligotex mRNA minikit 
PCR purification kit 
 
Nucleotrap Extraction Kit  Macherey-Nagel (Düren, Germany) 
NucleoSpin Extract 2 in 1 
 
B.  PCR cloning kits 
TA Cloning Kit   Invitrogen (Carlsbad, CA, USA) 
TOPO TA Cloning Kit 
TOPO XL PCR Cloning Kit 
ZeroBlunt TOPO Cloning Kit 
 
PCR-Script Amp Cloning Kit   Stratagene (La Jolla, CA, USA) 
 
C.  Mutagenesis 
QuikChange Site-directed Mutagenesis Kit Stratagene (La Jolla, CA, USA) 
 
D.  cRNA synthesis 
T7 mMessage mMachine Kit  Ambion (Austin, TX, USA) 
 
E.  RT-PCR 
Omniscript RT-PCR   QIAgen (Hilden, Germany) 
 
 
Table 2.4:  Kits used in this study. 
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2.6 Chemicals 
 
All chemicals used in this study were obtained from Sigma, Merck, Applichem, Serva, 
Roth or Boehringer, unless otherwise stated in the text.  Radioactively labelled 
chemicals were obtained from NEN. 
 
2.7 Sequence analysis software 
 
Table 2.5 lists the software and online servers used to analyse raw sequence data, 
perform sequence alignments, identify putative secondary structures of protein 
sequences and consensus sequences for enzyme recognition sites, and primer design.  
 
A. Software 
Program  Use     Reference 
Wisconsin Pack various sequence analyses   Genetics Computer Group Inc 
Generunner primer design    Hastings Software Inc 
Chromas sequence reading program   Technelysium Pty Ltd 
EZ-fit  enzyme kinetic    Perella Scientific Inc 
Quattro Pro evaluation of uptake experiments  Borland international Inc 
SigmaPlot statistical analyses   Jandel Corporation 
 
B.  Online sequence analysis servers 
Program  Use     Reference 
MAP  multiple sequence alignments  http://genome.cs.mtu.edu/map.html 
Genebee multiple sequence alignments  http://www.genebee.msu.su/ 
Translation tool N sequence to aa sequence  http://www.expasy.ch/tools/dna.html 
Webcutter restriction maps    http://www.medkem.gu.se/cutter/ 
TopPred 2 secondary structure prediction  http://www.biokemi.su.se/~server/toppred2/ 
Blast  finds similar database sequences  http://www.ncbi.nlm.nih.gov/BLAST/ 
Prosite  consensus sites in a sequence  http://www.ebi.ac.uk/searches/prosite 
Entrez Browser sequence retrieval   http://www.ncbi.nlm.nih.gov/Entrez/ 
 
Table 2.5: Software used in this study.  Manufacturer or website is given. N = nucleotide, aa = amino 
acid. 
 
2.8 Equipment 
 
Appliance   Model    Manufacturer 
Thermocycler   2400   Perkin Elmer (Norwalk CT, USA) 
    Omn-E HBTRE  Hybaid Ltd (Teddington, England) 
    PTC-200  MJ Research (Watertown MI, USA) 
Vortexer   REAX 1   Heidolph Elektro (Kelheim, Germany) 
    REAX Top  Heidolph Elektro (Kelheim, Germany) 
    MS1   IKA (Staufen, Germany) 
Dissection microscope  Stemi1000  Zeiss (Jena, Germany) 
Nanoliter injector     World Precision Instruments (Sarasota  
         FL, USA) 
Scintillation counter  1500 Tri-Carb  Packard Instrument Co (Meriden CT,USA) 
    2100 TR  Packard Instrument Co (Meriden CT,USA) 
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Centrifuges   Biofuge fresco  Heraeus (Osterode, Germany) 
    5417R   Eppendorf (Hamburg, Germany) 
    1394   Hettich (Stockholm, Sweden) 
    C-1200   National Labnet Co (Woodbridge NJ, USA) 
    RC-5B   Sorvall (Newtown, CT, USA) 
Spectrophotometer  Novaspec II  Pharmacia (Uppsala, Sweden) 
    GeneQuant II  Pharmacia (Uppsala, Sweden) 
Power pack   P24   Biometra (Göttingen, Germany) 
    LKB Bromma 2297 Pharmacia (Uppsala, Sweden) 
    LKB Bromma 2303  Pharmacia (Uppsala, Sweden) 
Gel chambers   Midi   MWG-Biotech (Ebersberg, Germany) 
    VEU 2001  Pharmacia (Uppsala, Sweden) 
Shaking incubator  3031   GFL (Burgwedel, Germany) 
Circulating water baths  D8   Haake (Karlsruhe, Germany) 
Speed vac concentrator  SVC 100E  Savant (Holbrook NY, USA) 
Refrigerated aspirator  Unijet II   UniEquip (Martinsried, Germany) 
Gel documentation  Gel Print 2000 I  Biophotonics (Ann Arbor, MI, USA) 
UV transilluminator  TM40   UVP Inc (Upland, CA, USA) 
pH meter   pH-Meter 611  Orion Research Inc (Beverly MA, USA) 
Balance    1474   Sartorius (Göttingen, Germany) 
Automated DNA sequencer ABI Prism  Applied Biosystems (Laguna Beach  
        CA, USA) 
Heated magnetic stirrer  RCT B   IKA (Staufen, Germany) 
Microwave   Privileg 8017, 8521 Quelle Schikedenz (Fürth, Germany)  
Electroporator   Easyject   Equibio (Monchelsea, England)
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3 METHODS 
 
3.1 MOLECULAR 
 
3.1.1 cDNA Synthesis 
 
The first step in cloning hROAT1 and hOAT2 was the synthesis of cDNA.  To clone 
hROAT1, cDNA was synthesized from human kidney total mRNA using the 
Superscript system (Life Technologies).   
 
Reagents: 
NotI primer    1 µg 
Superscript II RT  200 units/µg mRNA 
mRNA in DEPC water 1-5 µg 
5x first strand buffer  250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 mM MgCl2 
DTT    0.1 mM 
dNTP    500 µM each dATP, dCTP, dGTP, dTTP 
DEPC water    to 20 µl 
 
Synthesis was carried out as per the manufacturers instructions (37 °C 1 hour), with the 
following exceptions: 40 U RNasin (Promega) was added to each reaction; random 9-
mers and QoQidT17 were substituted for the NotI primer to generate template for 5 
RACE and 3 RACE, respectively.  First strand cDNA was then used as the template for 
subsequent PCR reactions. 
 
For hOAT2, human liver and kidney cDNA were synthesized from poly(A) RNA.  The 
poly(A) fraction was first isolated from total RNA using a poly(dT) column (Qiagen).  
This was then reverse-transcribed into cDNA using the Omniscript reverse transcription 
kit (Qiagen). 
 
Reagents: 
10x RT buffer   composition not provided by manufacturer 
dNTPs    500 µM each dATP, dCTP, dGTP, dTTP 
Oligo-dT primer  1 µM 
RNase inhibitor  10 units 
Omniscript RT  4 units 
template RNA   50 ng 
RNase-free water  to 20 µl 
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After thorough mixing the reaction was incubated at 37 °C for 1 hour.  For subsequent 
PCR reactions 2 µl aliquots were used as the template.  The remainder of the reaction 
was stored at 20 °C for future use. 
 
3.1.2 Polymerase Chain Reaction 
 
The polymerase chain reaction, or PCR, is a powerful technique with many applications 
in basic research.  Devised by Kary Mullis (Mullis 1990), PCR enables the specific 
exponential amplification of DNA regions for which flanking sequence information is 
available.  Based on the known flanking sequence, a pair of oligonucleotides primers, 
usually 20-25 nucleotides in length, are designed with homology to the 5 and 3 ends 
of the target sequence (outlined in Figure 3.1).  These are then added in molar excess to 
a DNA sample containing the sequence of interest, together with a thermostable DNA 
polymerase and dNTPs, and the mix is then subjected to a regimen of temperature 
cycling.  Initial heating leads to disassociation (denaturation) of the complementary 
strands of the target sequence (or template) and is followed by rapid cooling to a 
temperature permissive for the hybridisation (annealing) of the oligonuleotide primers 
to the template.  The temperature is then raised to a temperature optimal for the function 
of the thermostable DNA polymerase, allowing extension of the DNA sequence of 
interest from the site of primer annealing (polymerisation).  From this process of 
denaturation, annealing and polymerisation, one copy of the target sequence is 
synthesized from each template molecule to which the primers annealed; with each 
successive cycle, the number of copies doubles, yielding an exponential increase in 
copies of the target sequence.   
Of the great number of applications of PCR, many were used in this work.  Synthesis of 
the template cDNA from poly(A)-RNA (reverse transcriptase (RT) PCR), amplification 
of the initial PCR product of hROAT1 (degenerate PCR), construction of expression 
clones, mutational analysis, and generation of the hOAT2:hROAT1 chimera all relied 
on methods derived from the classical PCR. 
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Figure 3.1: The PCR principle.  The basis of the polymerase chain reaction is outlined here.  Following 
denaturation of the target DNA sequence (double black line) at 94-95 °C, primers flanking this region 
(grey arrows) are allowed to bind at the permissive temperature.  Raising the temperature to that optimal 
for polymerase function leads to extension (extended grey arrows) from the primer sequence, and a 
doubling in copies of the target sequence.  Repeating this process yields an exponential increase in copy 
number. 
 
Sequence of interest
Denaturation, 
primer annealing
Extension
Denaturation, 
primer annealing
Extension
n cycles
~2  moleculesn
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3.1.2.1 Standard PCR 
A standard PCR was used to screen all transformed bacterial clones to minimize 
plasmid isolation from false positives.  Suspected positive clones were first transferred 
with a sterile toothpick to a standard 20 µl PCR reactions, and the same toothpick was 
then used to inoculate 50 µl LB media.  The PCR contained one primer specific for the 
vector and one primer specific for the insert (Table 2.3), and consisted of 25 cycles of 
94 °C for 20 s, 50-55 °C for 15 s (depending on primers used), and 72 °C for 30-90 s 
(depending on length of expected product; 1 minute / kb).  Clones yielding a positive 
PCR result were then used to inoculate a 2-5 ml overnight culture.    
 
3.1.2.2 Degenerate PCR 
 
PCR can be applied to the cloning of a cDNA based on the amino acid sequence of a 
protein of interest.  Moreover, where the sequences of a family of proteins are known, 
these can be used to clone a homologue from a novel species.  To do this, degenerate 
primers representing all possible nucleotide sequences encoding a stretch of conserved 
amino acids are used in a PCR.  In addition, inosine can be incorporated at highly 
degenerate positions to reduce overall numbers in the primer pool.  To amplify 
hROAT1 from a human renal cDNA template, a PCR-based homology cloning strategy 
incorporating degenerate primers was used.  The degenerate primers were designed 
based on a amino acid sequence alignment of  previously cloned members of the related 
OAT (fROAT, OAT1/ROAT1, NKT and NLT) and OCT  (rOCT1, rOCT2) families 
(Figure 4.1).  From this alignment, regions were chosen that indicated both greatest 
homology between the organic anion transporters whilst at the same time maximal 
divergence from the organic cation transporters.  The regions selected for primer 
synthesis are highlighted and the primer sequences are presented in Table 4.1 with the 
degeneracy factor of each primer shown.  The degenerate primers were synthesized by 
Eurogentec.  The composition and parameters for PCR using degenerate primers were 
determined empirically.  The degenerate PCR consisted of the following components: 
5x PCR buffer, 200 µM of each dNTP, 1.5 mM MgCl, 200 ng of each primer, 2 units 
Taq polymerase, with nanopure water to a volume of 50 µl.  The successful PCR was 
carried out with primers 5.1 and 3.2 (Table 2.3).  A 35 cycle PCR comprised: 94°C for 
30s, 40°C for 1 min, 50°C for 1 min, and 72°C for 1.5 min.  PCR products were cloned 
into pCR2.1 (Invitrogen) and sequenced.  
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3.1.2.3 Rapid amplification of cDNA ends (RACE) 
Following the amplification of an initial PCR product from the gene or cDNA of 
interest, the clone can be extended in both the 5 and 3 directions using a technique 
known as rapid amplification of cDNA ends (RACE), using either a cDNA or RNA 
template (Frohman et al 1988), outlined in Figure 3.2.  From the cloned sequence, 
primers are designed which are oriented in the direction of the missing sequence.  For 3 
RACE, PCR is carried out with a gene-specific primer in combination with a second 
primer consisting of a stretch of poly(dT) fused to a unique sequence which serves as 
the anchor sequence.  The product resulting from this PCR is then used as the template 
for a second, nested, PCR with a second gene-specific primer and a primer specific to 
the unique anchor sequence.  In 5 RACE, a similar process is carried out, preceeded by 
the generation of an synthetic poly-(A) tail using a terminal deoxynucleotidyltransferase 
(TdT).  The same anchor primer can then be used with primers specific to the 5 region 
of the known sequence in subsequent PCR. 
 
5 RACE 
Reagents: 
Tailing reaction 
Terminal Transferase  15 U 
Template   50 ng 
dATP    200 µM 
RNase-free H2O  to 20 µl 
 
    initial PCR   second (nested) PCR 
template   first strand cDNA (tailed) 1 µl initial PCR reaction 
anchor primer   QoQidT17, 20 ng  - 
RACE primer   Qo, 200ng   Qi, 200 ng 
gene-specific primer  So, 200ng    Si, 200 ng 
DNA polymerase  Takara Taq, 1 U  Takara Taq, 1 U 
 
The tailing reaction was incubated at 37 °C for 10 minutes, after which the reaction was 
stopped and the enzyme inactivated by incubation at 65 °C for 15 minutes.  The first 
stage PCR of the 5 RACE extension of the hROAT1 clone was performed with 20 ng 
of QoQidT17, plus 200 ng each of Qo (anchor-specific outer primer) and So (gene-
specific outer primer) and 1 U of Takara Taq-Polymerase.  PCR conditions were as 
follows: 3 cycles of 94°C for 20 sec, 42°C for 2 min, 72°C for 3 min, followed by 35 
cycles of 94°C for 20 sec, 65°C for 20 sec and 72°C for 1 min.  Second stage PCR was 
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performed with 1µl of the first stage products with 200 ng each of Qi (anchor-specific 
inner primer) and Si (sequence-specific inner primer) plus 1U Takara Taq-Polymerase.   
 
 
Figure 3.2:  Rapid amplification of cDNA ends  RACE.  5 and 3 RACE are shown, starting with a 
poly(A)-RNA template.  In 5 RACE, first strand reverse transcription cDNA synthesis, from a gene-
specific primer GSP1, is followed by a tailing reaction.  For 3 RACE, reverse transcription proceeds 
from the poly-A tail of the RNA template.  In 5 and 3 RACE, the first nest PCR reaction contains the 
QoQidT anchor primer together with the QoQidT-specific Qo primer, and a gene-specific primer GSP1, 
with the first strand cDNA as template. The second PCR involves internal primers and cDNA generated 
by the first PCR reaction 
 
Amplifications were for 35 cycles of 94°C for 20 sec, 65°C for 20 sec and 72°C for 1 
min.  PCR products (200 to 300 nucleotides) were cloned into pCR2.1 and sequenced.   
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3 RACE 
Reagents: 
    initial PCR    second (nested) PCR 
template   first strand cDNA, generated            1 µl initial PCR  
         with QoQidT17 primer        reaction 
RACE primer   Qo, 200ng    Qi, 200 ng 
gene-specific primer  GSP1, 200ng     GSP2, 200 ng 
buffer    composition not provided by manufacturer 
dNTPs    200 µM    200 µM 
DNA polymerase  Takara Taq, 1 U   Takara Taq, 1 U 
 
For 3' RACE extension of hROAT1, the first stage PCR contained 200 ng each of 
primers Qo and GSP1 (gene-specific primer 1).  PCR conditions were as follows: 94°C 
for 20 sec, 65°C for 30 sec and 72°C for 1.5 min for 35 cycles.  The second, nested, 
PCR was carried out with the Qi and GSP2 (a second template-specific primer), and 1 
µl of the first stage PCR product, with 30 cycles of the conditions used in the first stage.  
PCR products of approximately 800 base pairs, were cloned into pCR2.1 and 
sequenced.  
 
The 3 RACE for hOAT2 consisted of a half-nested PCR.  The initial PCR contained 
the reagents listed above, with the exception that the GSP1 primer was replaced with an 
hOAT2-specific primer, hOAT2-3RACE.  Following amplification as above, the first 
round products were reamplified with the internal RACE primer, Qo, and the hOAT2-
3RACE primer. 
 
3.1.2.4 Generation of high-fidelity cDNA clones:  
In order to generate cDNA clones corresponding as closely as possible to the expressed 
mRNA sequence, PCR was carried out with proof-reading DNA polymerases to 
maximize polymerization fidelity.  Of the many proof-reading polymerase 
commercially available, the PowerScript polymerase mix was used.  The advantages of 
this product are that it has high polymerase fidelity and is less sensitive to changes in 
the concentration of cations, template and primers in the PCR mix.   
 
Based on the sequence contig of hROAT1 constructed from the initial degenerate PCR 
product and 5 and 3 RACE reactions, sequence-specific primers with restriction sites 
incorporated where required, were designed to PCR-amplify full-length clones from 
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human kidney cDNA.  In the case of hOAT2, sequence-specific primers derived from 
the sequence of the expressed sequence tags (ESTs) retrieved from the human dbEST 
database were used to amplify an initial product comprising almost the entire reading 
frame.  The complete sequence was then amplified with a forward primer derived from 
this initial product, and a reverse primer derived from subsequent 3 RACE data. 
 
Reagents: 
template    cDNA 
sequence-specific 5 primer   20 pmol 
sequence-specific 3 primer  20 pmol 
Powerscript DNA polymerase 1 U 
dNTPS    200 µM each 
10x PCR buffer   composition not provided by manufacturer 
5x Optizyme enhancer  composition not provided by manufacturer 
MgCl2     2 mM 
 
The amplification with Powerscript polymerase was carried out as per the 
manufacturers instructions (PAN Systems), with 30 cycles of the following 
amplification parameters: 94°C for 20 sec, 55-60°C for 20 sec and 68-72°C for 4 min; 
followed by a final extension period of 10 min at 72°C.  The full-length cDNAs were 
cloned into pPCR-Script (Stratagene) or pCR-TOPO (Invitrogen), and polymerase 
fidelity was confirmed by sequencing.   
 
3.1.2.5 Deletion mutant construction 
To introduce large deletions into the hROAT1 reading frame and to remove the reading 
frame of fNaDC-3 during the construction of the expression clone, PCR with a proof-
reading polymerase was carried out.  The deletions were in essence a long PCR directed 
away from the region to be deleted, with primers incorporating appropriate 5-terminal 
restriction sites.  This process is detailed in Figure 3.3. 
 
Reagents: 
template    50 ng plasmid DNA 
forward primer (Table 2.3)  20 pmol 
reverse primer (Table 2.3)  20 pmol 
Powerscript DNA polymerase 1 U 
dNTPS    200 µM each 
10x PCR buffer   composition not provided by manufacturer 
5x Optizyme enhancer  composition not provided by manufacturer 
MgCl2     2 mM 
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The amplification was carried with 30 cycles of the following amplification parameters: 
94°C for 20 sec, 55-60°C for 20 sec and 68-72°C for 4 min, followed by a final 
extension period of 10 min at 72°C.  For the removal of the fNaDC-3 reading frame, 
detailed in 4.7, unique restriction sites were incorporated at each end of the 
amplification product to enable the directional ligation of the hROAT1 between the 5 
and 3 UTRs of fNaDC-3.  To delete N- and C-terminal parts of the hROAT1 reading  
 
Figure 3.3:  Deletion PCR.  The method used to construct deletion mutants and the hROAT1 
expression clone is outlined schematically.  Primers are designed which flank, and are directed away from 
the region within a plasmid clone to be deleted (grey circle, top), and a long PCR is carried out.  By 
incorporating the appropriate restriction sites in the primers, the amplification product (incomplete grey 
circle) can then be restricted and ligated either intramolecularly as in the construction of deletion mutants 
(bottom left) or to a second, similarly restricted DNA molecule (black line) as in the construction of the 
hROAT1 expression clone (bottom right). 
 
 
frame, the same unique restriction site was incorporated at both ends, and following 
restriction, this allowed intramolecular ligation of the amplification product to take 
intramolecular 
ligation
Region to 
be deleted
long PCR
restriction digestion
+
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place.  To maintain translation competence in subsequent cRNA syntheses, a start or 
stop codon was incorporated immediately after the restriction site within the primer.  
After ligation, products were transformed as described in 3.2.1.1.  
 
3.1.2.6 Overlapping PCR 
The construction of chimeric proteins is often carried out by making use of compatible 
restriction sites present in the DNA sequence of the proteins of interest.  However, this 
method is limited in that it depends on the occurrence of two compatible sites at the 
location desired for the junction point between the two protein fragments.  In contrast, 
the overlap PCR is ideally suited to the creation of a chimeric protein at any position 
required (Ishii et al 1998).  This PCR application is carried out with two plasmids, each 
containing one of the donor sequences from which the chimera is to be constructed, and 
bipartite primers which contain sequence specific to both donors and form the junction 
of the chimera (Figure 3.4).  By way of explanation, a chimera to be constructed from 
donor sequences A and B, can be represented by 5-AB-3, where A is the 5- terminal 
half of sequence the first donor, linked to B, the 3-terminal part of the second donor.  
To achieve this chimeric sequence, two rounds of PCR are required.  First, donors A 
and B are separately amplified in the first round using a specific primer and a bipartite 
primer, and in the second round the resulting amplification products are mixed with the 
two specific primers from the first round leading to amplification of a chimeric 
sequence.  The bipartite primers consist of a sequence at the 3 end specific for of the 
donors in the first round, fused to a sequence at the 5 end specific for the other donor.  
Thus, when the two initial amplification products are mixed, they can hybridize at the 
site of incorporation of the bipartite primer.  Such a duplex can be extended to create a 
double stranded chimeric sequence, which then acts as the template for the second 
round of PCR.   
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Figure 3.4:  Overlapping PCR.  Schematic representation of the overlapping PCR method.  In two 
separate PCRs, donor sequences 1 (black) and 2 (grey) are amplified.  Each reaction contains a donor-
specific primer (black and grey arrows) and a bipartite primer (arrow with oppositely coloured tail) 
containing a 5 end complementary to the other donor sequence.  This yields two PCR products (grey and 
black double lines) each with a terminus homologous to the other donor.  Mixing the two products allows 
annealing at the bipartite primer sequence (attached arrows) and extension, yielding a duplex chimeric 
sequence (black-gray double line) which acts as the template in a subsequent PCR. 
 
Reagents: 
    initial PCR  donor 1  initial PCR  donor 2 
template   50 ng hOAT2   50 ng hROAT1 
forward primer (Table 2.3) 20 pmol hR2-5´+Bam 20 pmol chimera(2:1)-f 
reverse primer (Table 2.3) 20 pmol chimera(2:1)-r 20 pmol hR1-3´+Xba 
buffer    (composition not supplied by manufacturer) 
optizyme enhancer  20 % v/v   20 % v/v 
dNTPs    200 µM each   200 µM each 
MgCl2    2 mM    2 mM 
DNA polymerase  Power Script, 1 U  Power Script, 1 U 
 
Donor 1 Donor 2
PCRPCR
Mix products
from initial PCR
Extension from 
bipartite primers
Overlap PCR
PCR-generated chimera
Annealing at 
primer sequence
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    Overlap PCR 
template   products of initial PCR, 40 ng each  
forward primer (Table 2.3) 20 pmol hR2-5´+Bam 
reverse primer  (Table 2.3) 20 pmol hR1-3´+Xba 
buffer    (composition not supplied by manufacturer) 
optizyme enhancer  20 % v/v 
dNTPs    200 µM each 
MgCl2    2 mM   
DNA polymerase  Power Script, 1 U 
 
The initial PCR comprised 30 cycles of: 94° for 10 s, 55° for 15 s, and 72° for 2 min, 
followed by a final extension period of 10 min at 72°.  The products were visualized by 
agarose gel electrophoresis and bands of the expected size were excised and purified 
using the Nucleo©Trap gel extraction kit (Macherey and Nagel).  After determining the 
concentration, 40 ng of each amplified donor were used as the template in an overlap 
PCR, comprising 30 cycles of: 94° for 10 s, 65° for 15 s, and 72° for 4 min, followed by 
a final extension period of 10 min at 72°.  Following amplification, a band of predicted 
size was purified as above and cloned into the pCR©-Blunt II-TOPO vector using the 
ZeroBlunt TOPO cloning kit, described in section 3.1.7.2.2.   Plasmid DNA from 
several positive transformants was isolated and sequenced to determine polymerase 
fidelity, and one chimera was subcloned into pSport between the fNaDC 5 and 3 
UTRs as described for construction of the expression clone detailed in section 4.1.2. 
 
3.1.3 Site-directed Mutagenesis 
 
In vitro mutation of targeted nucleotides, site-directed mutagenesis, allows controlled 
changes to be introduced into DNA molecules.  The QuikChange Site-Directed 
Mutagenesis Kit (Stratagene) was the method of choice for the generation and 
disruption of restriction enzyme recognition sites, correction of errors introduced by 
PCR amplification, and amino acid exchanges.  Unlike the difficult labour-intensive 
methods involving M13-based bacteriophage vectors and ssDNA rescue, the 
QuikChange kit enables mutagenesis to be carried out with most plasmids.  The basic 
principle of the method is the repeated extension, by Pfu polymerase, of the entire 
plasmid clone from two complementary primers, both of which contain the desired 
mutation.  This generates a mutant plasmid with staggered nicks, and the template can 
be removed by digestion with a methylation-dependent endonuclease, DpnI, which 
reacts only with the methylated template plasmid isolated from bacteria (with the target 
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sequence 5-Gm6ATC-3), and not the methyl-free polymerase-extended mutant.  The 
mutant plasmid can then be transformed into E. coli, where the nicks are repaired. 
 
 
 
Figure 3.5:  Site-directed mutagenesis.  A schematic representation of site-directed mutagenesis using 
the QuickChange mutagenesis kit.  A plasmid (bold circles) containing the gene of interest with site 
targeted for mutation (asterisk), is extended (arrows) from complementary primers (bold arcs) containing 
the desired mutation (closed circles).  The extension process continues until the site of primer annealing is 
reached, yielding an in vitro generated copy of the plasmid with staggered nicks (thin circles).  The parent 
plasmid template, originally isolated from a methylation-competent bacterial host, is methylated; the in 
vitro-extended copy is not.  The addition of DpnI leads to the digestion of the parent plasmid leaving the 
nicked copy, which is repaired in the bacterium following transformation 
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Reagents: 
Pfu DNA Polymerase  2.5 U/µl 
10x Reaction Buffer  100 mM KCl, 100 mM (NH4)2SO4, 200 mM Tris-HCl  
    (pH8.8), 20 mM MgSO4, 1 % Triton
® X-100,  
     1 mg/ml nuclease-free bovine serum albumin  
     (BSA) 
dNTP mix   composition not supplied by manufacturer 
Oligonucletide primers Specific forward and reverse primers for each mutation:  
    125 ng (Table 2.3) 
DpnI restriction enzyme 10 U/µl 
Competent cells  Epicurian Coli® XL1-Blue super-chemically competent  
    cells 
SOC medium   2 % Tryptone, 0.5 %  Yeast Extract, 10 mM NaCl, 2.5mM  
    KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose  
    (dextrose). 
 
To generate desired nucleotide base substitutions, sequence-specific primers with the 
appropriate mismatches were designed; these are listed in Table 2.3.  All primers used 
satisfied the following criteria: both primers contained the desired mismatch and 
annealed to the same sequence on opposite strands of the template plasmid; all were 25 
- 45 nucleotides in length with an annealing temperature of approximately 75 - 80 °C; 
the mutation was situated as close as possible to the middle of the primer, with at least 
12 bases of perfectly annealing sequence on either side; each primer had a GC content 
of at least 40 %, and terminated in at least 2 G or C bases.  The extension reaction 
consisted of 125 ng of each primer, 5, 15 or 50 ng of template plasmid (to empirically 
determine the optimal conditions), 5 µl of 10x reaction buffer, 1 µl of the dNTP mix, 
ddH20 to 49 µl, and 1 µl (2.5 U) Pfu DNA polymerase.  Cycling parameters were: 95 °C 
for 30 seconds, followed by 12 (for point mutations) or 16 (for two or more point 
mutations) cycles of: 95 °C for 30 seconds, 55 °C for 1 minute, and 68 °C for 2 
minutes/kb of plasmid length.  Following  temperature cycling, the reaction was cooled 
to 37 °C and after the addition of 1 µl DpnI was incubated for at least 2 hours at 37 °C.  
Once DpnI-digestion was complete, 1 µl of the extension mix was added to pre.thawed 
Epicurian Coli XL1-Blue competent cells in a pre-chilled Falcon® 2059 polypropylene 
tube, mixed by swirling and incubated on ice for 30 minutes.  The cells were then 
exposed to a 45 second heat shock at 42 °C, and after 2 minutes on ice, 500 µl SOC 
medium was added.  Antibiotic resistance was elaborated by incubation for at least 1 
hour at 37 °C at 220rpm in a shaking incubator, after which a 250 µl aliquot was plated 
on an LB agar plate, supplemented with antibiotics specific for the plasmid used, and 
incubated at 37 °C overnight.  On the following day, transformants were used to 
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innoculate a LB culture from which plasmid DNA was isolated and sequenced to 
confirm that only the desired mutation(s) had taken place.   
 
3.1.4 cDNA Sequencing and Analysis  
 
Both strands of the cDNAs generated in this study were sequenced by dye terminator 
cycle sequencing (Applied Biosystems) with M13/pUC sequencing primers (Fermentas) 
or insert-specific primers, respectively (automatic sequencer: ABI Prism, Applied 
Biosystems).   
 
Reagents 
Linear template, OR  100 ng 
Plasmid template  200-500 ng 
Primer    4 pmol 
Sequencing premix  4 µl (Ready Reaction BigDye Terminator Kit: AmpliTaq® 
    DNA polymerase FS, thermostable pyrophosphate, dNTPs 
    dITP, BigDye labelled ddNTPs, buffer (PE Biosystems)) 
dH2O    to 20 µl 
 
Each PCR comprised 25 cycles of: 96 °C for 10 s, 50 °C for 15 s, and 60 °C for 4 min.  
Amplification products were precipitated by the addition of 80 µl water, 10 µl 3M 
NaAcetate and 250 µl 100 % ethanol (room temperature) followed by centrifugation for 
15 min at 10 000 x g.  After washing with 70 % ethanol (also room temperature) and 
centrifugation for 5 minutes at 10 000 x g  the products were dried in the vacuum 
dessicator (Speedy Vac) and finally resuspended in sequence loading buffer (5:1 
formamide:EDTA (25 mM, pH 8)). The sequence was assembled and analyzed with 
various software packages, as listed in Table 2.5.  Sequence homology searches were 
performed at the National Centre for Biotechnology Information using the BLAST 
network service.  Sequence analyses were performed with various software packages 
and online providers (Table 2.5). 
 
3.1.5 Modification of nucleic acids 
 
3.1.5.1 Restriction digestion 
Restriction digestion was an integral part of many of the methods used.  Subcloning, 
generation of deletion mutants, and site-directed mutagenesis all required involved a 
restriction digestion stage.  
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Reagents: 
DNA to be cut  100 ng  5 µg 
Restriction enzyme  1-5 U/µg DNA, <10 % of the final reaction volume  
Enzyme buffer  10 % v/v; composition varies with enzyme  
 
After mixing, the reaction was incubated at 37 °C for 1-3 hours, depending on degree of 
digestion required.  In standard digestions, such as excision of open reading frames 
during subcloning, complete digestion was not required, so enzyme used and incubation 
time were minimized.  Where complete digestion was necessary, such as in the 
preparation of template for cRNA synthesis, a 3 hour digestion in combination with a 
higher ratio of enzyme to template was used. 
 
3.1.5.2 Ligation 
Ligation of two restricted DNA fragments with compatible ends was carried out using 
T4 DNA ligase.  Standard ligation reactions consisted of a 4:1 insert to vector ratio, 
with 1 unit ligase/µg DNA incubated in 10 or 20 µl 1x ligation buffer (66 mM Tris-HCl, 
5 mM MgCl2, 1 mM dithioerythritol, 1 mM ATP, pH 7.5) for at least 16 hours at 4 °C.  
Following incubation a 2 µl aliquot was used to transform the appropriate host strain 
(section 3.2.1.1). 
 
3.1.5.3 Vector dephosphorylation 
The ligation of a vector and insert restricted with the same enzyme is limited by 
intramolecular ligation of the vector.  To overcome this the vector can be treated with 
calf intestinal alkaline phosphatase (CIP), which prevents ligation of the two ends of the 
vector by removal of the 5 phosphate group.  This was used in an attempt to clone 
hROAT1 into the pGEMHE vector.  Following restriction 1 µg of linear pGEMHE was 
suspended in the buffer supplied, and 0.5 units of CIP were added (1 unit per pmol 
DNA ends).  After 1 hour incubation at 37 °C, EDTA was added to a final concentration 
of 5 mM and the reaction was then incubated at 75 °C for 10 minutes.  The DNA was 
extracted using the PCR purification kit following the manufacturers protocol, and 
eluted in 5 mM Tris buffer (pH 8).  The dephosphorylated vector was then used in a 
standard ligation reaction. 
 
3. Methods 36 
3.1.6 Isolation of nucleic acids 
 
3.1.6.1 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to isolate DNA molecules following PCR 
amplification or restriction digestion.  Gels were 0.7  2 %, depending on the size of the 
DNA molecule to be isolated, and consisted of agarose in TBE buffer (45 mM Tris, 45 
mM borate, 1 mM EDTA).  This solution was heated in a microwave to dissolve the 
agarose.  After cooling, 2 µl of a 10 mg/ml ethidium bromide solution was added per 
100 ml gel, the solution was mixed thoroughly, and the gel was poured.  Gels were 
routinely run at 70-100 V for 1-2 hours, depending on the degree of band separation 
required. 
 
3.1.6.2 Isolation of linear DNA molecules 
Linear DNA molecules generated by the various PCR methods detailed above, as well 
as those resulting from restriction digestion, were isolated either directly using a nucleic 
acid purification kit, or after agarose gel electrophoresis using a gel extraction kit from 
QIAgen or Machery-Nagel.  Fragments to be used as blunt-end inserts DNA were 
always eluted with water pH 8, to allow further concentration if required. 
 
3.1.6.3 Plasmid isolation 
Plasmid DNA was routinely isolated by alkaline lysis.  Cells from 1.5 ml to 100 ml of 
an overnight culture grown in LB medium were harvested by centrifugation.  The pellet 
was resuspended in 0.1 volumes of solution I by mechanical agitation using an auto 
vortex mixer.  Solution II was added at 0.2 volumes of the original culture volume and 
mixed gently by rolling of the centrifuge tube.  Once lysis had occurred (solution 
became clear and viscous), 0.15 volumes of solution III were added and mixed until a 
white precipitate formed and the solution was no longer viscous.  The precipitate was 
then collected by centrifugation (14 800 x g, 10 minutes at room temperature) and the 
supernatant transferred to a new tube.  DNA was precipitated with 2 volumes of ice cold 
100% ethanol, collected by centrifugation, washed with 1 mL of 70% ethanol and air 
dried before being dissolved in 20 µl of dH2O.  For sensitive applications such as 
sequencing, plasmid DNA was purified over columns obtained from QIAgen or 
Machery-Nagel, as per the manufacturers instructions.   
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3.1.7 Cloning of amplified products 
 
Depending on the polymerase used for amplification, different methods were used to 
clone PCR products.  For products generated by Taq polymerase, which are 
characterized by 3 deoxyadenosine overhangs, TA cloning was the method of choice.  
To clone blunt-end PCR products generated by polymerases with proof-reading 
exonucleolytic activity, such as Pfu polymerase or the Powerscript polymerase mixture, 
a range of methods specific for cloning blunt-end products were used.  Bacteria 
transformanted with vectors containing the lacZ reporter gene were screened with blue-
white selection followed by PCR screening (section 3.1.2.1).  Blue-white selection is 
based on the properties of the lacZ reporter gene, which cleaves a chromogenic 
substrate, X-gal, yielding blue bacterial colonies grown on LB agar (1 % tryptone, 1 % 
NaCl, 1% yeast extract, 1.5 % agar, pH 7.6) plates containing this substrate.  Insertion 
of DNA within the cloning site disrupts lacZ and the galactosidase gene product is not 
synthesized.  Thus, colonies arising from transformants with inserts cannot cleave X-gal 
and are white.  If the host bacterial strain encodes lacIq, a repressor of the lac promoter, 
IPTG is added to the LB agar plates to induce expression from the lac promoter. 
 
3.1.7.1 TA Cloning 
Degenerate PCR- and RACE-amplified products were cloned into pCR2.1 (Table 2.2) 
using the TA-cloning kit (Invitrogen).  This cloning method allows direct cloning of 
PCR products amplified by the Taq polymerase, obviating the need for enzymatic 
modification of the PCR products or amplification with primers containing restriction 
enzyme recognition sequences.  The TA Cloning method relies on a template-
independent activity of the Taq polymerase that leads to an addition of a single 
deoxyadenosine to the 3 ends of PCR products.  As the linearized pCR2.1 vector 
supplied with the kit has 3 deoxythymidine overhangs, ligation of insert and vector 
proceeds very efficiently.  
 
Reagents: 
linearized pCR2.1 vector 25 ng/µl in 10 mM Tris-HCl, 1 mM EDTA, pH8 
T4 DNA Ligase  4.0 Weiss units/µl 
10x Ligation Buffer  60 mM Tris-HCl pH7.5, 60 mM MgCl2, 50 mM NaCl,  
    1 mg/ml bovine serum albumin, 70 mM β- 
    mercaptoethanol, 1 mM ATP, 20 mM dithiothreitol,  
    10 mM spermidine. 
SOC medium   2 % Tryptone, 0.5 %  Yeast Extract, 10 mM NaCl,  2.5mM  
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    KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose  
    (dextrose). 
Competent cells  E. coli INVαF 
 
After PCR amplification, products were visualized by agarose gel electrophoresis, 
excised from the gel using a clean scalpel and then extracted from the gel using a 
column- or activated silica-based gel extraction kit (QIAgen, Macherey Nagel, 
respectively).  Following purification and quantification of the PCR product, the 
following formula was used to calculate the amount of insert required for a 1:1 molar 
ratio of insert to vector: 
 Xng PCR product =  (Ybp PCR product)(50 ng pCR®2.1)  
    (size of pCR®2.1 vector: 3900bp) 
Based on this equation, two ligation reactions were set up for each insert - a 1:1 and 4:1 
insert to vector ratio.  Each ligation reaction was carried out in a 10 µl volume with 1 µl 
10 x ligation buffer, 2 µl pCR®2.1 vector (50 ng), X µl PCR product (usually 2-3 µl as 
excess salt from larger volumes reduces efficiency), sterile water to 9 µl, and 1µl T4 
DNA Ligase (4 Weiss units), and incubated overnight at 14° C.  Following incubation, 
an aliquot from the ligation reaction was used to transform E. coli INVαF cells.  To a 
50 µl vial of chemically-competent E. coli INVαF cells, 2 µl of β-mercaptoethanol was 
added and gently stirred, after which 2 µl of the ligation reaction was added and mixed 
by stirring with the pipette tip, and the remaining ligation reaction was stored at -20° C.  
The vial was incubated for 30 minutes on ice and then the cells were subjected to a 30 
second heat shock at 42° C, and immediately placed on ice, before the addition of 250 
µl of room temperature SOC medium.  In order to allow elaboration of antibiotic 
resistance, the vial was incubated at 37° C for at least 1 hour at 220 rpm in a shaking 
incubator.  After this recovery period, aliquots of 50-200 µl were plated on LB agar 
(section 3.1.7) plates supplemented with 0.4 % X-gal and 50 µg/ml ampicillin, and 
incubated at 37° C overnight.  Following 2-3 hours colour development at 4 °C, single 
isolated white colonies were chosen for PCR screening.  
 
3.1.7.2 Blunt-end Cloning 
To clone Blunt-end cloning of products generated by proof-reading polymerases 
(Powerscript, Pfu Polymerase), PCR-Script cloning (Stratagene), Zero Blunt TOPO 
cloning (Invitrogen) were the methods of choice. 
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3.1.7.2.1 PCR-Script cloning 
Using the PCR-Script cloning kit, blunt-end PCR products generated by proof-reading 
polymerases can be ligated into the pPCR-Script vector.  The basis of the PCR-Script 
cloning kit is the use of the linearized pPCR-Script vector, the ends of which, in the 
case of intramolecular vector ligation, form the recognition site for the SrfI restriction 
enzyme.  By inclusion of the SrfI during the ligation step, and hence restriction of 
ligated vector molecules, the efficiency of ligation of blunt-end PCR products is 
increased.  The lacZ gene contained in the pPCR-Script vector allows blue-white 
selection of transformants. 
 
Reagents: 
linear pPCR Script vector 10 ng/µl 
PCR-Script reaction buffer composition not provided by manufacturer 
rATP    10 mM 
SrfI restriction enzyme 5 U/µl  
T4 DNA Ligase  4 U/µl 
β-mercaptoethanol  concentration not provided by manufacturer 
Competent cells  Epicurian Coli® XL10-Gold Kan ultracompetent cells 
SOC Medium   2 % Tryptone, 0.5 %  Yeast Extract, 10 mM NaCl,  2.5mM  
    KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose  
    (dextrose). 
 
Following amplication by Pfu polymerase, purification using a gel extraction kit, and 
quantification of the purified insert, the molar ratio of insert to vector was calculated 
using the following formula: 
 
Xng of PCR product =  (size of PCR product in bp)(10 ng of pPCR Script vector) 
     size of pPCR Script: 2961 bp 
 
The equation above provides the amount of insert required for a 1:1 insert-to-vector 
ratio, however, the manufacturers recommend a insert-to-vector ratio of between 40:1 
and 100:1.  For this reason, the elution of the PCR products during the purification step 
was always carried out with dH2O, pH 8.  Thereafter, the concentration of the insert 
could be increased by evaporation in the Speedy-Vac, enabling the ligation to take place 
with a insert-to-vector ratio of at least 50:1.  The prescribed ligation reaction consisted 
of the following components, added in order: 1 µl linear pPCR-Script Amp SK (+) 
vector (10 ng), 1 µl PCR-Script 10x reaction buffer, 0.5 µl rATP, 2-4 µl blunt-end PCR 
product, 1 µl SrfI restriction enzyme (5 U), 1 µl T4 DNA Ligase (4 U), and finally 
dH2O to 10 µl.  However, as the required insert-to-vector ratio was so high, and the 
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concentration of insert frequently remained low even after evaporation in the Speedy-
Vac, the ligation reaction was prepared as above with the following exceptions: 0.5 µl 
vector, 0.8 µl SrfI, 0.8 µl T4 DNA ligase, 4 - 6.4 µl insert.  After gentle mixing, the 
ligation reaction was incubated for 1 hour at room temperature, and was then heated for 
10 minutes at 65° C, and stored on ice.  For transformation, XL 10-Gold Kan 
ultracompetemt cells were thawed on ice and transferred to a pre-chilled 15 ml Falcon 
2059 polypropylene tube, after which 1.6 µl of the β-mercaptoethanol mix provided was 
added to the cells, gently mixed and incubated on ice for 10 minutes with occassional 
swirling.  After this incubation period, 2 µl of the ligation mix was added to the cells, 
which were then incubated on ice for a further 30 minutes.  Following this incubation 
period, the cells were exposed to a heat shock of 30 seconds at 42° C and then returned 
to ice for two minutes.  Finally, 450 µl of SOC medium was added and the cells were 
incubated at 37° C for at least 1 hour at 220 rpm in a shaking incubator.  Aliquots of 
250 - 500 µl were then plated on LB agar (section 3.1.7) plates supplemented with 50 
µg/ml ampicillin, X-gal and IPTG, and incubated at 37° C overnight, after which white 
colonies were selected for screening. 
3.1.7.2.2 Zero Blunt TOPO Cloning 
The cloning of blunt-end products with the Zero Blunt TOPO cloning kit relies on 
the same principle as that for the TOPO-XL kit detailed above - the activation of the 
linear vector with topoisomerase.  In addition, the pCR©-Blunt II-TOPO vector 
contains the lethal E. coli ccdB gene fused to the C-terminus of the lacZ gene, so that 
only transformants containing inserts are able to grow. 
 
Reagents: 
pCR©-Blunt II-TOPO  10 ng/µl plasmid DNA in: 50 % glycerol, 50 mM Tris- 
    HCl pH 7.4, 1 mM EDTA, 2 mM DTT,  
    0.1 % Triton X-100, 100µg/ml BSA, bromophenol blue. 
6x TOPO stop solution 0.3 M NaCl, 0.06 M MgCl2 
SOC Medium   2 % Tryptone, 0.5 %  Yeast Extract, 10 mM NaCl,  2.5mM  
    KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose  
    (dextrose). 
Competent cells  E. coli TOP10F One Shot cells 
 
The blunt-end PCR product was purified by gel extraction using a column- or activated 
silica-based kit (QIAgen or Macherey Nagel, respectively) and quantified using the 
GeneQuant photometer (Pharmacia Biotech, Uppsala, Sweden).  As the Zero Blunt 
TOPO Cloning Kit proved to be highly efficient it was not necessary to further 
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concentrate the insert.  The ligation mix suggested by the manufacturers (0.5 - 4 µl PCR 
product, sterile water to 4 µl and 1µl pCR©-Blunt II-TOPO vector) was altered, and 
consisted of mixing 4.5 µl of the PCR product with 0.5 µl of the pCR©-Blunt II-TOPO 
vector.  The ligation mix was incubated for 5 minutes at room temperature, after which 
1 µl of 6x TOPO Stop Solution was added, mixed for 10 seconds and placed on ice.  
From this ligation mix, 2 µl were added to a vial of pre-thawed One Shot competent 
cells, gently mixed, and incubated on ice for 30 minutes.  Following this incubation 
period, the cells were exposed to a heat shock of 30 seconds at 42° C, returned to ice for 
2 minutes, and finally 250 µl of room temperature SOC medium was added.  The cells 
were then incubated for at 37° C for at least 1 hour at 220 rpm in a shaking incubator.  
After elaboration of antibiotic resistance, 100 and 200 µl aliquots were plated on LB 
agar (section 3.1.7) plates supplemented with 50 µg/ml kanamycin and incubated at 37° 
C overnight.  On the following day, colonies were PCR-screened to isolate positive 
clones with an insert of the appropriate size. 
 
3.1.8 cRNA synthesis 
 
The synthesis of cRNA was carried out using the T7 mMESSAGE mMACHINE kit 
(Ambion).  This kit enables the synthesis of large amounts of capped cRNA from a 
linear cDNA template, by incorporation of a 7-methyl guanosine cap analogue 
(m7G(5)ppp(5)G) during polymerisation.  Capped cDNAs can then be used for 
microinjection of oocytes. 
 
Reagents: 
10 x Enzyme mix  bacteriophage T7 RNA polymerase, ribonuclease inhibitor  
    and other unlisted components 
10 x Transcription Buffer composition not provided by manufacturer 
2 x Ribonucleotide mix buffered solution containing 10 mM ATP, CTP, UTP,  
    2 mM GTP and 8 mM Cap analogue 
DNaseI   RNase-free in 50 % glycerol buffer. 
Precipitation solution  7.5 M LiCl, 75 mM EDTA 
Nuclease-free H2O  to 20 µl 
Template DNA  NotI-cut, at a concentration of at least 160 ng/µl 
      
Template cDNA was digested with NotI (5U / µg DNA) for 3 h at 37 °C, and column-
purified using the PCR-purification kit from QIAgen.  The linearized product was 
eluted in 30 µl elution buffer and the concentration was determined.  For cRNA 
synthesis, the following reagents were added in order, to a 1.5 ml microfuge tube: 2 µl 
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10x transcription buffer, 10 µl 2x ribonuceotide mix, 6 µl linearized template, and 2 µl 
enzyme mix.  The reaction was incubated at 37 °C for 2 - 3 hours, after which template 
DNA was removed by the addition of 1 µl RNase-free DNaseI and further incubation at 
37 °C for 15 minutes.  The reaction was terminated by adding 30 µl of nuclease-free 
dH2O and 25 µl LiCl precipitation solution, and after thorough mixing the sample was 
incubated at -20 °C for 1 hour.  Following incubation, the cRNA was collected by 
centrifugation for 15 minutes at 4 °C, washed with one volume 70 % ethanol, and 
centrifuged once more for 5 minutes.  After careful removal of the ethanol, the cRNA 
was resuspended in nuclease-free dH2O and the concentration was determined.   
Samples were diluted to either 1 or 2 µg/µl and were stored at 80°C. 
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3.2 CELLULAR 
 
3.2.1 Bacteriological   
 
All strains used were grown routinely at 37 °C.  Overnight cultures were inoculated 
from single colonies present on selective plates and were grown under the appropriate 
antibiotic selection.  For long term storage, strains were stored in a mixture of LB plus 
5% glycerol at  -80°. 
 
3.2.1.1 Transformation 
 
Heat shock 
To transform E. coli with plasmid DNA other than that generated with kits detailed 
above, a standard heat shock protocol was used.  Competent cells (Stratagene, 
Invitrogen) in 40 or 50 µl aliqouts were thawed on ice to maintain competence, and in 
the case of cells from Stratgene were transferred to Falcon 2059 polypropylene tubes.  
Once thawed, Stratagene cells were further treated by the addition of 1.6 µl β-mercapto-
ethanol (concentration not provided by manufacturer) and the cells were incubated on 
ice for a further 5 min.  After the addition of the desired DNA sample, corresponding to 
between 10 and 100 ng of DNA, and a further 30 minute incubation on ice, cells were 
exposed to heat shock at a 42°C water bath for 30 seconds (for Invitrogen cells) or 45 
seconds (Stratagene cells) and then transferred immediately to ice for 2 min.   Following 
addition of SOC, transformants were elaborated for at least 1 h at 37°C at 220 rpm in a 
shaking incubator.  Aliquots were then spread on LB agar (1 % tryptone, 1 % NaCl, 1% 
yeast extract, 1.5 % agar, pH 7.6) plates supplemented with the appropriate antibiotic, 
and with X-gal and IPTG if blue-white seletion was required. 
 
Electroporation 
Electrocompetent cells were prepared as described by the manufacturer and stored at 
-80°C.  Electroporation was carried out using an Easyject (Equibio) electroporator set 
with capacitance at 25 µF, pulse-controlled resistance at 200 Ω, and voltage at 1.8 kV 
using a cuvette with a 0.1cm gap.  Following electroporation, cells were placed on ice 
for 1 minute, after which 500 µl SOC was added.  These cultures were incubated at 37 
°C with shaking at 200 rpm for at least 1 hour to allow expression of the antibiotic 
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resistance.   Transformants were selected by plating on LB agar plates (section 3.1.7) 
supplemented with the appropriate antibiotic.  
 
3.2.2 Xenopus laevis oocytes 
 
The determine the function of the hROAT1 and hOAT2 clones generated in this study, 
Xenopus laevis oocytes were injected with cRNA derived from wild-type, mutant or 
chimera cDNAs, and uptake assays were carried out as outlined below.  
 
Figure 3.6: The oocyte assay system.  Isolated or in vitro synthesized poly(A)+-RNA, with cap and poly-
A tail, is injected into the vegetal pole of the oocyte.  After translation of the polypeptide encoded by the 
RNA, and its processing and insertion, uptake assays can be carried out in which uptake of a radioactively 
labelled substance can be measured. 
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3.2.2.1 Preparation of oocytes. 
Reagents 
Barths  88 mM NaCl, 1 mM KCl, 0.3 mM Ca(NO3)2, 0.41 mM CaCl2,  
   0.82 mM MgSO4, 15 mM HEPES,  
   10 mg/l Steptomycin or Gentamicin 
   pH set at 7.6 with NaOH 
 
Individual oocytes were separated from ovarian lobes manually or by collagenase 
treatment.  Manual dissection was carried out with pincers and surgical scissors; oocytes 
were cut away from the lobe and then as much ovarian tissue as possible was removed 
without damaging the oocyte.  Suitable oocytes were incubated in Barths solution at 18 
°C overnight prior to injection.  Collagenase treatment involved overnight incubation of 
several ovarian lobes in 20 ml Barths solution containing 5 mg/ml collagenase.  The 
oocytes were washed several times with Barths on the following day, and after sorting 
were then incubated for 10 min in Ca2+ free medium.  Oocytes were then returned to 
Barths solution and maintained at 18 °C until required for injection. 
 
3.2.2.2 Injection of cRNA 
Oocytes were routinely injected with 25-50 ng of cRNA in a 23-46 nl volume, or the 
equivalent volume of nanopure water as a control, using a Nanolitre injector. Glass 
capillaries (World Precision Instruments) were loaded with the cRNA to be tested, or 
with water as a control.  Oocytes were arranged on a specially designed plastic 
receptacle with grooves to facilitate the injection process.  Injection took place in the 
vegetal pole, and consisted of one or two injections of 25 nl separated by a 5 s pause. 
 
3.2.2.3 Transport assays. 
Reagents 
ORI   90 mM NaCl, 3 mM KCl, 2 mM CaCl2,  
   1 mM MgCl2, 5 mM HEPES,  
   pH set at 7.6 with 1 mM Tris 
 
Prior to transport assays, on either the second or third day after injection, surviving 
oocytes were sorted to remove unhealthy or matured oocytes.  The selected oocytes 
were divided into groups of 8-14 and transferred to 2 ml of ORI per well of a 24-well 
plate.  After equilibration in ORI, oocytes were transferred to ORI uptake medium 
containing radioactively labelled-PAH, with or without desired test substrates at the 
appropriate concentrations, in a 10 ml vial.  For the ion dependence studies, the uptake 
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medium was of altered ion composition, as detailed in results.  For cis-inhibition 
studies, stock solutions of each potential inhibitor were made in ORI.  Final 
concentrations in uptake experiments were 1 mM in all cases except for bile acids, were 
only 100 µM was used.  The concentration of radioactivity in a standard assay was 5 
µCi/ml.  The PAH concentration in a standard transport assay consisted of 5 µCi 3H-
PAH (specific activity 1.28-4.08 µCi/nmol) and the final concentration was set at 10 
µM by the addition of unlabelled PAH.  For determination of Km, total radioactivity was 
1-5 µCi, with the final PAH concentration achieved by the addition of the appropriate 
quantity of unlabelled PAH.  Uptake took place from 10 minutes to 1 hour, as required, 
with agitation at room temperature. Upon completion of the incubation period, uptake 
was stopped by the addition of ice-cold ORI.  The uptake medium was aspirated, and 
the oocytes were washed three times with ice-cold ORI.  Following the final washing 
step, individual oocytes were transferred to 5 ml scintillation vials, to which 100 µl 1N 
NaOH was added.  After incubation overnight, the dissolved oocytes were neutralized 
by addition of 100 µl 1 N HCl, and finally 4.5 ml Lumasafe scintillation fluid (Lumac-
LSC) was added.  This mixture was shaken thoroughly and after 1 hour 3H-PAH content 
was determined over 10 minutes in a scintillation counter.  
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4 RESULTS 
 
4.1 CLONING AND FUNCTIONAL CHARACTERIZATION OF hROAT1, A 
HUMAN ORGANIC ANION TRANSPORTER 
 
The human kidney efficiently secretes organic anions such as PAH via a multispecific 
organic anion transporting system.  As a number of previously cloned proteins from 
other species, known collectively as OAT1, satisfy the physiological characteristics of 
the basolateral system involved (Sekine et al, 1997, Sweet et al, 1997, Wolff et al, 
1997), a homology cloning approach was adopted to clone a human OAT1 homologue. 
 
4.1.1 Cloning hROAT1 
 
4.1.1.1 Degenerate PCR 
In order to isolate a human PAH transporter by homology cloning, a degenerate PCR 
strategy was used.  The first step of this process involved the design of degenerate 
primers based on the amino acid sequence of previously cloned organic anion and 
organic cation transporters.  Six transporters, three organic anion transporters from 
flounder (fROAT), rat (OAT1) and mouse (NKT), a related transporter isolated from rat 
liver (NLT) and two rat organic anion transporters (rOCT1 and rOCT2), were aligned as 
shown in Figure 4.1.  The rationale was to choose regions of greatest homology 
between the anion transporters that simultaneously provided divergence from the cation 
transporters, thus increasing the probability of amplifying an organic anion transporter.  
The regions chosen are shown in Figure 4.1 and are detailed in Table 4.1.   
 
The thermocycling parameters for the PCR used were empirically determined, as an 
appropriate annealing temperature could not be calculated from the degenerate sequence 
of the primers.  Initially, a PCR was carried out using the fROAT clone as a positive 
control with all possible primer pairs and a product of approximately 1 kb was 
successfully amplified from fROAT using primers 13 and 16, enabling an approximate 
annealing temperature range to be determined.  Although the homology of the primers 
to the human sequence was unknown, these PCRs suggested an annealing temperature 
of around 40 °C.  However, applying these parameters to a human kidney cDNA  
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Primer  amino acid sequence nucleotide sequence primers in pool degeneracy factor 
5.1 M/L M A S H N 5’TIATGGCNWSNCAYAAY3’ 256 1024 
5.2 G T C A A F/Y 5’GGIACITGYGCNGCNTWY3’ 128 2048 
3.1 L G Y Y A F 5’ARNCCRTARTANGCRAA3’ 256 256 
3.2 G F I V Q I 5’NCCRAADATNACYTGDAT3’ 576 576 
3.3 A L C G K G 5’GCNARRCANCCYTTNCC3’ 512 512 
Table 4.1:  Degenerate primers used to amplify hROAT1.  The five degenerate primers designed to 
PCR-amplify hROAT1.  The amino acid sequence corresponds to the shaded regions in figure 4.1; the 
nucleotide sequence represents the degenrate sequence of the primer.  I = inosine, N = A/C/G/T, W = 
A/T, S = C/G, Y = C/T, R  = A/G, D = A/G/T.  The number of primers in each pool equals the total 
number of different primers; degeneracy factor represents the total number of sequences with which each 
primer might theoretically bind. 
5.1
. : . : . : . : . : . : . : . : . : 90
fROAT -MPFSELLEQVGSTGRFQVLHVTLLCIPVLMMASHNLLQNFVATVPSHYCNAHANLSQARLS-LEESLLITV------PLDGAGKPQRCQ 82
OAT1 -MAFNDLLKQVGGVGRFQLIQVTMVVAPLLLMASHNTLQNFTAAIPPHHCRPPAN---ANLS-KDGGLEAWL------PLDKQGQPESCL 79
NKT -MAFNDLLKQVGGVGRFQLIQVTMVVAPLLLMASHNTLQNFTAAIPAHHCRPPAN---ANLS-KDGGLEARL------PLDKQGRPESCL 79
NLT -MGFEDLLDKVGGFGPFQLRNLVLMALPRMLLPMHFLLPVFMAAVPAHHCALPG--APANLSHQDLWLEAHL------PRETDGSFSSCL 81
OCT1 MPTVDDVLEQVGEFGWFQKQAFLLLCLISASLAPIYVGIVFLGFTPGHYCQNPGVAELSQRCGWSQAEELNYTVPGLGPSDEASFLSQCM 90
OCT2 MSTVDDILEHIGEFHLFQKQTFFLLALLSGAFTPIYVGIVFLGFTPDHHCWSPGAAKLSQRCGWSQAEELNYTVPGLGPSDEASFLSQCM 90
. : . : . : . : . : . : . : . : . : 180
fROAT RYAAPQWHLLGKNGTSGSGDLADATESMDAALQECSDGWSYNSTVRSSTIISEWHLVCDMHSFKQMGQTIYMGGVLVGALLFGGLSDRYG 172
OAT1 RFTSPQWGPPFYNGTEANGT---------RVTEPCIDGWVYDNSTFPSTIVTEWNLVCSHRAFRQLAQSLYMVGVLLGAMVFGYLADRLG 160
NKT RFPFP------HNGTEANGT---------GVTEPCLDGWVYDNSTFPSTIVTEWNLVCSHRAFRQLAQSLFMVGVLLGAMMFGYLADRLG 154
NLT RFAYPQTVPNVTLGTEVSNS---GEPEGEPLTVPCSQGWEYDRSEFSSTIATEWDLVCQQRGLNKITSTCFFIGVLVGAVVYGYLSDRFG 168
OCT1 RYEV-DWNQSTLDCVDPLSSLVANRSQLP--LGPCEHGWVYDTP--GSSIVTEFNLVCGDAWKVDLFQSCVNLGFFLGSLVVGYIADRFG 175
OCT2 RYEV-DWNQSTLDCVDPLSSLAADRNQLP--LGPCEHGWVYNTP--GSSIVTEFNLVCAHSWMLDLFQSVVNVGFFIGAMMIGYLADRFG 175
5.2
. : . : . : . : . : . : . : . : . : 270
fROAT RRILLLISNLLMAVSGTCAAFSSSFSLFCVFRFGCGLALSGLGLNTFSLIVEWIPTRIRTAVGTTTGYCYTLGQLILVLLAYFIRDWRWL 262
OAT1 RRKVLILNYLQTAVSGTCAAYAPNYTVYCVFRLLSGMSLASIAINCMTLNVEWMPIHTRAYVGTLIGYVYSLGQFLLAGIAYAVPHWRHL 250
NKT RRKVLILNYLQTAVSGTCAAYAPNYTVYCIFRLLSGMSLASIAINCMTLNMEWMPIHTRAYVGTLIGYVYSLGQFLLAGIAYAVPHWRHL 244
NLT RRRLLLVAYVSSLVLGLMSAASINYIMFVVTRTLTGSALAGFTIIVLPLELEWLDVEHRTVAGVISTVFWSGGVLLLALVGYLIRSWRWL 258
OCT1 RKLCLLVTTLVTSVSGVLTAVAPDYTSMLLFRLLQGMVSKGSWVSGYTLITEFVGSGYRRTTAILYQMAFTVGLVGLAGVAYAIPDWRWL 265
OCT2 RKFCLLVTILINAISGALMAISPNYAWMLVFRFLQGLVSKAGWLIGYILITEFVGLGYRRMVGICYQIAFTVGLLILAGVAYVIPNWRWL 265
. : . : . : . : . : . : . : . : . : 360
fROAT TLAVSLPFYVFFLIAWWFHESSRWLALSNRTEHALKNLKSVARFNGRHEEAEKLDIKMLHESMKKEMSCTQGSYSILDLFNTPAMRKRTL 352
OAT1 QLVVSVPFFIAFIYSWFFIESARWYSSSGRLDLTLRALQRVARINGKQEEGAKLSIEVLRTSLQKELTLSKGQASAMELLRCPTLRHLFL 340
NKT QLAVSVPFFVAFIYSWFFIESARWYSSSGRLDLTLRALQRVARINGKQEEGAKLSIEVLQTSLQKELTLNKGQASAMELLRCPTLRRLFL 334
NLT LLAATLPCVPGIISIWWVPESARWLLTQGRVEEAKKYLLSCAKLNGRPVGEGSLSQEALNNVVTMERALQRPS--YLDLFRTSQLRHISL 346
OCT1 QLAVSLPTFLFLLYYWFVPESPRWLLSQKRTTRAVRIMEQIAQKNGKVPPAD------LKMLCLEEDASEKRSPSFADLFRTPNLRKHTV 349
OCT2 QFAVTLPNFCFLLYFWCIPESPRWLISQNKIVKAMKIIKHIAKKNGKSVPVS------LQNLTPDEDAGKKLKPSILDLVRTPQIRKHTL 349
3.1 3.2
. : . : . : . : . : . : . : . : . : 450
fROAT CLSAVWLSTSFAYYGLAMDLDKFGVDIYLIQVIFGAVDIPAKVVVVVSMSLIGRRRSQCAVLVVAGITILLNLLVPYDKQTIRTCLAVLG 442
OAT1 CLSMLWFATSFAYYGLVMDLQGFGVSMYLIQVIFGAVDLPAKFVCFLVINSMGRRPAQMASLLLAGICILVNGIIPKSHTIIRTSLAVLG 430
NKT CLSMLWFATSFAYYGLVMDLQGFGVSMYLIQVIFGAVDLPAKFVCFLVINSMGRRPAQLASLLLAGICILVNGIIPRGHTIIRTSLAVLG 424
NLT CCMMVWFGVNFSYYGLTLDVSGLGLNVYQTQLLFGAVELPSKIMVYFLVRRLGRRLTEAGMLLGAALTFGTSLLVSLETKSWITALVVVG 436
OCT1 ILMYLWFSCAVLYQGLIMHVGATGANLYLDFFYSSLVEFPAAFIILVTIDRIGRIYPIAASNLVTGAACLLMIFIPHELHWLNVTLACLG 439
OCT2 ILMYNWFTSSVLYQGLIMHMGLAGDNIYLDFFYSALVEFPAAFIIILTIDRVGRRYPWAVSNMVAGAACLASVFIPDDLQWLKITIACLG 439
3.3
. : . : . : . : . : . : . : . : . : 540
fROAT KGCLAASFNCCYLYSGELFPTIIRQNGMGWVSMMARIGAMVAP-MVLLTRDYIPWLPGLIYGGAPILSGLAAIFLPETLGYPLPDTIQDV 531
OAT1 KGCLASSFNCIFLYTGELYPTVIRQTGLGMGSTMARVGSIVSP-LVSMTAEFYPSMPLFIFGAVPVVASAVTALLPETLGQPLPDTVQDL 519
NKT KGCLASSFNCIFLYTGELYPTMIRQTGLGMGSTMARVGSIVSP-LISMTAEFYPSIPLFIFGAVPVAASAVTALLPETLGQPLPDTVQDL 513
NLT KAFSEAAFTTAYLFTSELYPTVLRQTGLGLTALMGRLGASLAR-LAALLDGVWLLLPKVAYGGIALVAACTALLLPETKKAQLPETIQDV 525
OCT1 RMGATIVLQMVCLVNAELYPTFIRNLGMMVSALCDLGGIFTPFMVFRLMEVWQALPLILFGVLGLTAGAMTLLLPETKGVALPETIEEAC 529
OCT2 RMGITMAYEMVCLVNAELYPTYIRNLGVLVCSSMCDIGGIITPFLVYRLTDIWMEFPLVVFAVVGLVAGALVLLLPETKGKALPETIEDA 529
. : . : . : . : . : . : . : . : . : 630
fROAT EESGSGRKSKMSTKETITLQDKQANLLKQSA 562
OAT1 KSRSRGKQNQQQQEQQKQMMPLQASTQEKNGL 551
NKT KSRSRGKQKQQQLEQQKQMIPLQVSTQEKNGL 545
NLT E-----RKSTQEEDV 535
OCT1 ENLGRRKSKAKENTIYLQVQTGKSSST 556
OCT2 ENMQRPRKKERKENLPPSQASRPSAKLKRKGIIAAGADFALSEARDGASLSPPPKPTQTNLTYP 593
Figure 4.1: Degenerate primer design.  An alignment of three organic anion transporters (fROAT, 
OAT1, NKT), a related liver transporter (NLT) and two organic cation transporters (OCT1 and OCT2) is 
shown.  Amino acid residues shaded black are identical to those in fROAT.  Grey residues signify the 
regions used for degenerate primer design. Arrows designate primer directionality - forward (→) and 
reverse (←)  and numbers are primer names.  5.1 and 3.2 represent the primer pair with which the initial 
PCR product of approximately 1 kb was amplified.  The numbers in the right column represent amino 
acid number. 
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template, did not yield any specific amplification.  In order to increase the potential for 
amplification from poorly annealed primers, an additional pre-extension step of 50 °C 
was added.  A successful amplification, the faint band in Figure 4.2, was eventually 
obtained using these PCR cycling parameters.  After reamplification, the 1 kb amplicon 
was cloned into pCR2.1 and sequenced (Figure 4.2).  The sequence data yielded was 
used to search the GenBank sequence databank, and the product was found to have high 
identity to the OAT1 and NKT sequences (85-88 %) and significant homology to the 
fROAT clone. 
 
 
Figure 4.2: Amplification of a human OAT1 homologue by degenerate PCR.  The arrow denotes the 
successful amplification of a 1 kb product (lane 2), which was then reamplified (lane 3) to facilitate 
cloning.  Sizes of relevant bands from the 1 kb standard are shown in kb.  Lane 1 is a negative control. 
 
 
 
4.1.1.2  5 and 3 RACE 
Using the sequence obtained from the initial PCR product, sequence-specific primers 
were designed with which to carry out 5- and 3-RACE reactions.  The 3-RACE 
reaction yielded a product of 850 bp, which was sequenced and also found to have 
similar levels of homology to the clones listed above.  The sequence contained the 
remainder of the 3-coding sequence and the 3-untranslated region (UTR), including a 
polyadenylation signal.  With the 5-RACE reaction, a product of around 300 bp was 
amplified.  The sequence from this clone yielded an additional 89 bp of new sequence, 
including the 2nd and 3rd nucleotides of what was assumed to be the start codon. 
Although no direct comparison with the Kozak consensus sequence for transcriptional 
start sites could be carried out, a multiple alignment of these related carriers strongly 
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suggested that the assumed start codon obtained from 5 RACE would be the favored 
site for transcription in vivo (see Figure 4.4).   
 
4.1.1.3  PCR-amplification of the complete hROAT1 open reading frame 
A sequence contig was generated using the PCR products and was analyzed using the 
GCG Wisconsin Package (Table 2.7).  A Blast search of the GenBank database revealed 
the contig sequence to be 88% identical to the rat organic anion transporter 
(OAT1/ROAT), and 85% identical to the then functionally uncharacterized mouse 
homologue (NKT). Thus, the contig, named hROAT1, represents the first reported 
cloning of a human homologue of the renal organic anion transporter (Reid et al, 1998).  
Based on the sequence contig, specific primers were designed to amplify the entire 
known sequence  the full coding sequence as well as the 3UTR.  The successfully 
amplified product was cloned into pPCR-Script, confirmed by sequencing and deposited 
in the GenBank database where it was assigned the accession number AF057039. 
 
 
4.1.1.4 Sequence characteristics of hROAT1 
Further analysis of the sequence was performed to identify features of the primary 
amino acid sequence and the predicted secondary structure.  In addition to the high 
homology to the rat and mouse OAT1 homologues (88 and 85 %, respectively), there 
was significant homology  48% identity - to the flounder homologue (fROAT).  
hROAT1 also showed 36% identity to a related liver transporter from the rat 
(NLT/rOAT2) and the organic cation transporter family; a sequence alignment is shown 
in Figure 4.4.  The open reading frame of 550 amino acids predicts a calculated 
molecular mass of 60 kDa.  Hydropathy analysis with the TopPred2 program (window 
setting of 11-21, upper cut-off 1.0, lower cut-off 0.6; von Heijne 1992) predicted twelve 
transmembrane domains  with intracellular N- and C- termini; a model of the predicted 
secondary structure is shown in Figure 4.5.  hROAT1 was also found to contain: 
consensus sites for N-glycosylation in the large extracellular loop between 
transmembrane domains 2 and 3 (Asn39,56,92,97,113), four conserved cysteine residues 
(C49,78,105,128) that could be involved in disulfide bond formation, and consensus sites for 
phosphorylation by protein kinase C (Ser271,278, Thr284,334, Ser521), protein kinase A 
(Ser276, Thr318,334, Ser469), tyrosine kinases (Tyr536) and casein kinase II (Thr325,515) in the 
large intracellular loop between transmembrane domains 6 and 7 and also in the C-
terminal region (Figure 4.5).    
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M A F N D L L Q Q V G G V G R F Q Q I Q V T L V V L P L L L 30
1 ATGGCCTTTAATGACCTCCTGCAGCAGGTGGGGGGTGTCGGCCGCTTCCAGCAGATCCAGGTCACCCTGGTGGTCCTCCCCCTGCTCCTG
✱ ✱
M A S H N T L Q N F T A A I P T H H C R P P A D A N L S K N 60
61 ATGGCTTCTCACAACACCCTGCAGAACTTCACTGCTGCCATCCCTACCCACCACTGCCGCCCGCCTGCCGATGCCAACCTCAGCAAGAAC
G G L E V W L P R D R Q G Q P E S C L R F T S P Q W G L P F 90
181 GGGGGGCTGGAGGTCTGGCTGCCCCGGGACAGGCAGGGGCAGCCTGAGTCCTGCCTCCGCTTCACCTCCCCGCAGTGGGGACTGCCCTTT
✱ ✱ ✱
L N G T E A N G T G A T E P C T D G W I Y D N S T F P S T I 120
241 CTCAATGGCACAGAAGCCAATGGCACAGGGGCCACAGAGCCCTGCACCGATGGCTGGATCTATGACAACAGCACCTTCCCATCTACCATC
∇ 
V T E W D L V C S H R A L R Q L A Q S L Y M V G V L L G A M 150
361 GTGACTGAGTGGGACCTTGTGTGCTCTCACAGGGCCCTACGCCAGCTGGCCCAGTCCTTGTACATGGTGGGGGTGCTGCTCGGAGCCATG
V F G Y L A D R L G R R K V L I L N Y L Q T A V S G T C A A 180
421 GTGTTCGGCTACCTTGCAGACAGGCTAGGCCGCCGGAAGGTACTCATCTTGAACTACCTGCAGACAGCTGTGTCAGGGACCTGCGCAGCC
F A P N F P I Y C A F R L L S G M A L A G I S L N C M T L N 210
541 TTCGCACCCAACTTCCCCATCTACTGCGCCTTCCGGCTCCTCTCGGGCATGGCTCTGGCTGGCATCTCCCTCAACTGCATGACACTGAAT
V E W M P I H T R A C V G T L I G Y V Y S L G Q F L L A G V 240
601 GTGGAGTGGATGCCCATTCACACACGGGCCTGCGTGGGCACCTTGATTGGCTATGTCTACAGCCTGGGCCAGTTCCTCCTGGCTGGTGTG
A Y A V P H W R H L Q L L V S A P F F A F F I Y S W F F I E 270
721 GCCTACGCTGTGCCCCACTGGCGCCACCTGCAGCTACTGGTCTCTGCGCCTTTTTTTGCCTTCTTCATCTACTCCTGGTTCTTCATTGAG
 Ψ 
S A R W H S S S G R L D L T L R A L Q R V A R I N G K R E E 300
781 TCGGCCCGCTGGCACTCCTCCTCCGGGAGGCTGGACCTCACCCTGAGGGCCCTGCAGAGAGTCGCCCGGATCAATGGGAAGCGGGAAGAA
Ψ ∇
G A K L S M E V L R A S L Q K E L T M G K G Q A S A M E L L 330
901 GGAGCCAAATTGAGTATGGAGGTACTCCGGGCCAGTCTGCAGAAGGAGCTGACCATGGGCAAAGGCCAGGCATCGGCCATGGAGCTGCTG
Ψ
R C P T L R H L F L C L S M L W F A T S F A Y Y G L V M D L 360
961 CGCTGCCCCACCCTCCGCCACCTCTTCCTCTGCCTCTCCATGCTGTGGTTTGCCACTAGCTTTGCATACTATGGGCTGGTCATGGACCTG
Q G F G V S I Y L I Q V I F G A V D L P A K L V G F L V I N 390
1081 CAGGGCTTTGGAGTCAGCATCTACCTAATCCAGGTGATCTTTGGTGCTGTGGACCTGCCTGCCAAGCTTGTGGGCTTCCTTGTCATCAAC
S L G R R P A Q M A A L L L A G I C I L L N G V I P Q D Q S 420
1141 TCCCTGGGTCGCCGGCCTGCCCAAATGGCTGCACTGCTGCTGGCAGGCATCTGCATCCTGCTCAATGGGGTGATACCCCAGGACCAGTCC
I V R T S L A V L G K G C L A A S F N C I F L Y T G E L Y P 450
1261 ATTGTCCGAACCTCTCTTGCTGTGCTGGGGAAGGGTTGTCTGGCTGCCTCCTTCAACTGCATCTTCCTGTATACTGGGGAACTGTATCCC
T M I R Q T G M G M G S T M A R V G S I V S P L V S M T A E 480
1321 ACAATGATCCGGCAGACAGGCATGGGAATGGGCAGCACCATGGCCCGAGTGGGCAGCATCGTGAGCCCACTGGTGAGCATGACTGCCGAG
Ψ
L Y P S M P L F I Y G A V P V A A S A V T V L L P E T L G Q 510
1441 CTCTACCCCTCCATGCCTCTCTTCATCTACGGTGCTGTTCCTGTGGCCGCCAGCGCTGTCACTGTCCTCCTGCCAGAGACCCTGGGCCAG
∇  
P L P D T V Q D L E S R K G K Q T R Q Q Q E H Q K Y M V P L 540
1501 CCACTGCCAGACACGGTGCAGGACCTGGAGAGCAGGAAAGGGAAACAGACGCGACAGCAACAAGAGCACCAGAAGTATATGGTCCCACTG
∇
Q A S A Q E K N G F • 550
1621 CAGGCCTCAGCACAAGAGAAGAATGGATTTTGAGGACTGAGAAGGGGCCTTACAGAACCCTAAAGGGAGGGAAGGTCCTACAGGTTTCCG
1681 GCCACCCACACAAGGAGGAGGAAGAGGAAATGGTGACCCAAGTGTGGGGGTTGTGGTTCAGGAAAGCATTTTCCCAGGGGTCCACCTCCC
1741 TTTATAAACCCCACCAGAACCACATCATTAAAAGGTTTGACTGCGC 1801
 
Figure 4.3:  hROAT1 open reading frame: nucleotide and amino acid sequence.  The hROAT1 
cDNA sequence (numbers in the left-hand column) and the amino acid sequence (numbers in the right-
hand column) of the 550 amino acid open reading frame.  Transmembrane domains predicted by the 
TopPred 2 program are underlined.  Symbols represent consensus sequence sites for N-linked 
glycosylation (✱), and phosphorylation by protein kinase C (), protein kinase A (Ψ), tyrosine kinase 
(), and casein kinase II (∇). 
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. : . : . : . : . : . : 60
hROAT1 MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCRPPAD---ANL 57
NKT MAFNDLLKQVGGVGRFQLIQVTMVVAPLLLMASHNTLQNFTAAIPAHHCRPPAN---ANL 57
ROAT1 MAFNDLLKQVGGVGRFQLIQVTMVVAPLLLMASHNTLQNFTAAIPPHHCRPPAN---ANL 57
fROAT MPFSELLEQVGSTGRFQVLHVTLLCIPVLMMASHNLLQNFVATVPSHYCNAHANLSQARL 60
. : . : . : . : . : . : 120
hROAT1 SKNGGLEVWLPRDRQGQPESCLRFTSPQWGLPFLNGTEANGT---------GATEPCTDG 108
NKT SKDGGLEARLPLDKQGRPESCLRFPFP------HNGTEANGT---------GVTEPCLDG 102
ROAT1 SKDGGLEAWLPLDKQGQPESCLRFTSPQWGPPFYNGTEANGT---------RVTEPCIDG 108
fROAT SLEESLLITVPLDGAGKPQRCQRYAAPQWHLLGKNGTSGSGDLADATESMDAALQECSDG 120
. : . : . : . : . : . : 180
hROAT1 WIYDNSTFPSTIVTEWDLVCSHRALRQLAQSLYMVGVLLGAMVFGYLADRLGRRKVLILN 168
NKT WVYDNSTFPSTIVTEWNLVCSHRAFRQLAQSLFMVGVLLGAMMFGYLADRLGRRKVLILN 162
ROAT1 WVYDNSTFPSTIVTEWNLVCSHRAFRQLAQSLYMVGVLLGAMVFGYLADRLGRRKVLILN 168
fROAT WSYNSTVRSSTIISEWHLVCDMHSFKQMGQTIYMGGVLVGALLFGGLSDRYGRRILLLIS 180
********** ********************
. : . : . : . : . : . : 240
hROAT1 YLQTAVSGTCAAFAPNFPIYCAFRLLSGMALAGISLNCMTLNVEWMPIHTRACVGTLIGY 228
NKT YLQTAVSGTCAAYAPNYTVYCIFRLLSGMSLASIAINCMTLNMEWMPIHTRAYVGTLIGY 222
ROAT1 YLQTAVSGTCAAYAPNYTVYCVFRLLSGMSLASIAINCMTLNVEWMPIHTRAYVGTLIGY 228
fROAT NLLMAVSGTCAAFSSSFSLFCVFRFGCGLALSGLGLNTFSLIVEWIPTRIRTAVGTTTGY 240
********
. : . : . : . : . : . : 300
hROAT1 VYSLGQFLLAGVAYAVPHWRHLQLLVSAPFFAFFIYSWFFIESARWHSSSGRLDLTLRAL 288
NKT VYSLGQFLLAGIAYAVPHWRHLQLAVSVPFFVAFIYSWFFIESARWYSSSGRLDLTLRAL 282
ROAT1 VYSLGQFLLAGIAYAVPHWRHLQLVVSVPFFIAFIYSWFFIESARWYSSSGRLDLTLRAL 288
fROAT CYTLGQLILVLLAYFIRDWRWLTLAVSLPFYVFFLIAWWFHESSRWLALSNRTEHALKNL 300
. : . : . : . : . : . : 360
hROAT1 QRVARINGKREEGAKLSMEVLRASLQKELTMGKGQASAMELLRCPTLRHLFLCLSMLWFA 348
NKT QRVARINGKQEEGAKLSIEVLQTSLQKELTLNKGQASAMELLRCPTLRRLFLCLSMLWFA 342
ROAT1 QRVARINGKQEEGAKLSIEVLRTSLQKELTLSKGQASAMELLRCPTLRHLFLCLSMLWFA 348
fROAT KSVARFNGRHEEAEKLDIKMLHESMKKEMSCTQGSYSILDLFNTPAMRKRTLCLSAVWLS 360
. : . : . : . : . : . : 420
hROAT1 TSFAYYGLVMDLQGFGVSIYLIQVIFGAVDLPAKLVGFLVINSLGRRPAQMAALLLAGIC 408
NKT TSFAYYGLVMDLQGFGVSMYLIQVIFGAVDLPAKFVCFLVINSMGRRPAQLASLLLAGIC 402
ROAT1 TSFAYYGLVMDLQGFGVSMYLIQVIFGAVDLPAKFVCFLVINSMGRRPAQMASLLLAGIC 408
fROAT TSFAYYGLAMDLDKFGVDIYLIQVIFGAVDIPAKVVVVVSMSLIGRRRSQCAVLVVAGIT 420
. : . : . : . : . : . : 480
hROAT1 ILLNGVIPQDQSIVRTSLAVLGKGCLAASFNCIFLYTGELYPTMIRQTGMGMGSTMARVG 468
NKT ILVNGIIPRGHTIIRTSLAVLGKGCLASSFNCIFLYTGELYPTMIRQTGLGMGSTMARVG 462
ROAT1 ILVNGIIPKSHTIIRTSLAVLGKGCLASSFNCIFLYTGELYPTVIRQTGLGMGSTMARVG 468
fROAT ILLNLLVPYDKQTIRTCLAVLGKGCLAASFNCCYLYSGELFPTIIRQNGMGWVSMMARIG 480
******
. : . : . : . : . : . : 540
hROAT1 SIVSPLVSMTAELYPSMPLFIYGAVPVAASAVTVLLPETLGQPLPDTVQDLESR-KGKQT 527
NKT SIVSPLISMTAEFYPSIPLFIFGAVPVAASAVTALLPETLGQPLPDTVQDLKSRSRGKQK 522
ROAT1 SIVSPLVSMTAEFYPSMPLFIFGAVPVVASAVTALLPETLGQPLPDTVQDLKSRSRGKQN 528
fROAT AMVAPMVLLTRDYIPWLPGLIYGGAPILSGLAAIFLPETLGYPLPDTIQDVEESGSGRKS 540
*****
. : . : . : . : . : . : 600
hROAT1 RQQQEHQKYMVPLQASAQEKNGF 550
NKT QQQLEQQKQMIPLQVSTQEKNGL 545
ROAT1 QQQQEQQKQMMPLQASTQEKNGL 551
fROAT KMSTKETITLQDKQANLLKQSA 562
 
Figure 4.4:  Alignment of hROAT1 with other OAT1 homologues.  Residues shaded black are those 
identical in the human, mouse, rat and flounder homologues.  Asterisks below the sequence represent the 
motifs conserved in members of the amphiphilic solute facilitator family (see text for details). 
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Figure 4.5:  Model of the predicted secondary structure of hROAT1.  This model represents the 
topology of the hROAT1 as predicted by TopPred 2.  Shaded residues represent amino acid residues 
conserved in mammalian OAT1s (light and dark) and all OAT1s (dark)).  The consensus sites for 
enzymatic modification are also shown: Y = N-glycosylation, * = protein kinase C, ∇  = protein kinase A, 
= casein kinase II, T = tyrosine kinase. 
 
hROAT1 also contains motifs common to members of the amphiphilic solute facilitator 
(ASF) family of solute transporters (Schömig et al 1998), which belongs to the major 
facilitator superfamily (MFS) (Marger and Saier 1993).  These sequences include: 
GX3GX4GX3DRXGRRK in the second transmembrane domain and the first 
intracellular loop (G144-K163); EX6R (E
212-R219) in the second intracellular loop; 
TIXXEWDLVC (T119-C128) in the large external loop between transmembrane domains  
1 and 2; ELYPTL (E447-M452; substitution of M for terminal L) between transmembrane 
domains 10 and 11; and LPETL (L504-L508) after transmembrane domain 12.  Table 4.2 
shows the amino acid consensus sites for potential modification shared by the human, 
rat, mouse and flounder OAT1 homologues.  Whether any of these sites are involved in 
regulation of physiological function of these transporters has yet to be elucidated. 
 
OAT homologue N-glycosylation protein kinase C casein kinase II 
hROAT1 56, 92 Ser271, Ser278 Ser325, Thr515 
NKT 56, 86 Ser265, Ser272 Ser319, Thr509 
ROAT1 56, 92 Ser271, Ser278 Ser319, Thr515 
fROAT 54, 95 Ser283, Ser290 Ser337, Thr527 
 
Table 4.2: Potential modification sites identical in all OAT homologues.  Numbers denote position of 
consensus site within the amino acid sequence of the respective OAT homologue. 
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4.1.1.5 Comparison of hROAT1 with other cloned human OAT1 homologues 
During the course of this study other reports appeared in the literature concerning the 
cloning of human organic anion transporter homologues.  A comparison of all 
independently cloned human organic anion transporters is presented in Table 4.3.  As 
seen from the table, five independently cloned versions of hROAT1 (hROAT1 (this 
study), hOAT1-2 (Hosoyamada et al 1999), hOAT1 (Cihlar et al 1999), hPAHT (Lu et 
al 1999), and hOAT1 (Race et al 1999)) now exist in the GenBank sequence database, 
all representing the same protein.  A further cDNA, hOAT1-1, the open reading frame 
of which predicts a protein thirteen amino acids longer than all others, has also been 
cloned (Hosoyamada et al).  A Blast comparison of the nucleotide sequences revealed 
that hROAT1 is greater than 99% identical to each of the other clones, with 3 to 7 non-
identical nucleotides throughout the entire open reading frame. On the protein level, the 
only differences between hROAT1 and the other human OAT1 clones is the exchange 
of the last leucine residue for a phenylalanine in hROAT1, and the presence of a serine 
residue at position 14 in hPAHT, which is a glycine residue in all other open reading 
frames.  Importantly, none of these sequence differences leads to a change in the 
predicted secondary structure of the protein; neither glycine/serine at position 14, nor 
leucine/phenylalanine at position 550, occur within a predicted transmembrane domain 
or conserved sequence motif. 
 
human OAT1 
clonea 
nucleotide 
identity in ORF 
Accession 
number 
Appearance 
in GenBank 
Authors 
hROAT1 1653/1653 AF057039 04.11.98 Reid et al (1998), this study
hPAHT 1646/1653 AF104038 28.01.99 Lu et al (1999) 
hOAT1-2 1650/1653 AB009698 16.02.99 Hosoyamada et al (1999) 
hOAT1 1649/1653 NM_004790 07.05.99 Race et al (1999)  
hOAT1 1650/1653 AF124373 16.09.99 Cihlar et al (1999) 
 
Table 4.3:  Comparison of human OAT1 clones in the GenBank database.  a = Since the first report 
of the cloning of a human OAT1 (hROAT1), the same clone has appeared four more times in the 
GenBank database and has four distinct names. 
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4.1.2 Construction of an hROAT1 functional clone 
 
As mentioned above, the entire reading frame plus 3UTR of hROAT1 was amplified 
from human kidney cRNA using specific primers based on the contig sequence.  This 
amplification product was cloned and verified by sequencing.  As described above, the 
5RACE reaction terminated prematurely at the end of the start codon, and no sequence 
from the 5UTR was obtained.  For expression, both 5 and 3 UTRs are necessary for 
cRNA translation, thus PCR amplification of this region was attempted.  Using primers 
based on the most conserved regions of the 5 UTRs from the mouse and rat 
homologues, it was possible to amplify approximately 200 bp corresponding to the 5 
UTR of hROAT1.  This sequence, shown in figure 4.6, has 75 % and 76 % identity to 
the rat and mouse OAT1 5UTRs, and also supported the supposition that the earlier 5 
RACE had reached the start codon, as the sequence showed 100 % homology from the 
3rd nucleotide of the open reading frame. 
. : . : . : . : . :
-244 cgaagtgaggagaagctgcaagggaaaagggagggacagatcagggagac
. : . : . : . : . :
-194 cggggaagaaggaggagcagccaaggaggctgctgtccccccacagagca
. : . : . : . : . :
-144 gctcggactcagctcccggagcaacccagctgcggaggcaacggcagtgc
. : . : . : . : . :
-94 tgctcctccagcgaaggacagcaggcaggcagacagacagaggtcctggg
. : . : . : . : +1 :
-44 actggaaggcctcagcccccagccactgggctgggcctggcccaATG
 
Figure 4.6:  hROAT1 5UTR sequence.  The above sequence was PCR-amplified using primers based 
on the rat and mouse 5UTRs.  The ATG start codon is shown at +1, and the 5UTR is labelled 1 to -244  
 
From this additional sequence data (Figure 4.6) and the sequence already known from 
the 3 RACE reactions (Figure 4.3), a further sequence specific primer was designed 
with which to amplify an entire clone containing both 5 and 3 UTRs to be used as an 
expression clone.  Despite several attempts, it was not possible to specifically amplify 
the desired product from the cDNA template, perhaps due to diminished template 
integrity after repeated freeze thaw cycles. 
 
As a full-length expression clone proved recalcitrant to cloning using PCR 
amplification, it was decided to use a Xenopus-specific expression vector. The vector 
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pGEMHE (see Material) a Xenopus-specific vector containing the 5 and 3 UTRs from 
the Xenopus laevis β-globin gene, was used with kind permission from E. Liman (Mass. 
General Hospital, Boston, Liman et al 1992).  The hROAT1 coding region was 
reamplified with primers incorporating BamHI and XbaI sites, and then both the vector 
and the hROAT1 coding region were sequentially digested with BamHI and XbaI.  
Several attempts to ligate these products produced no positive clones, and neither 
dephosphorylation of the vector by CIP-treatment, nor the incorporation of additional 
restriction sites in the multiple cloning site by linker addition, enabled insertion of the 
hROAT1 open reading frame.  Thus, construction of an hROAT1 expression clone was 
not possible using pGEMHE. 
 
The next strategy used in an attempt to construct a functional clone involved the 
modification of a flounder sodium dicarboxylate cotransporter, fNaDC-3, which is 
expressed to very high levels in oocytes.  The fNaDC-3 clone, a gift from J. Steffgen, 
(Dept. of Nephrology, Uni Klinik Göttingen, Steffgen et al 1999) was manipulated to 
enable the fNaDC-3 coding region to be replaced by the hROAT1 coding region (Figure 
4.7).  This was carried out by first disrupting the BamHI and XbaI sites of the vector 
using site-directed mutagenesis (Figure 4.7B), then PCR-amplifying the entire fNaDC-3 
clone away from the coding region (Figure 4.7C).  The primers used in this 
amplification incorporated BamHI and XbaI as close as was practical to the start and 
stop codons, respectively, to enable subsequent subcloning.  Both the fNaDC-3 
amplification product and the previously constructed hROAT1 coding region flanked by 
BamHI and XbaI sites, were then sequentially digested with BamHI and XbaI and 
ligated together.  This yielded a construct consisting of the hROAT1 coding region 
flanked by the 5 and 3 UTRs of fNaDC-3 (Figure 4.7A).  The full sequence of this 
expression clone is found in the appendix. 
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A
pSport:fNaDC 5‘UTR:ATG fNaDC TGA:fNaDC 3‘UTR:pSport
pSport:fNaDC 5‘UTR:ATG hROAT1 TGA:fNaDC 3‘UTR:pSport
B                                  BamHI      XbaI 
5’:::pSport:::CTT GGATCC TCTAGA GCG:::pSport:::3’
:::pSport:::GAA CCTAGG AGATCT GCG:::pSport:::
   
  site-directed mutagenesis 
BamHI XbaI
5’:::pSport:::CTT GGATCG ACTAGA GCG:::pSport:::3’
:::pSport:::GAA CCTAGC TGATCT GCG:::pSport:::
 
C 
pSport:fNaDC-3 5‘UTR:GCGATGAA: fNaDC ORF :TCTGATC:fNaDC-3 3‘UTR:pSport
pSport:fNaDC-3 5‘UTR:CGCTACTT: fNaDC ORF :AGACTAG:fNaDC-3 3‘UTR:pSport
     PCR amplification 
     incorporating new 
     restriction sites 
 
pSport:fNaDC-3 5‘UTR:GCGATGAA: fNaDC ORF :TCTGATC:fNaDC-3 3‘UTR:pSport
CCCTAGGT
TCTAGAC
pSport:fNaDC-3 5‘UTR:CGCTACTT: fNaDC ORF :AGACTAG:fNaDC-3 3‘UTR:pSport
  DpnI digestion, purification 
D BamHI XbaI
pSport:fNaDC-3 5‘UTR:GGGATCCA TCTAGAC:fNaDC-3 3‘UTR:pSport
pSport:fNaDC-3 5‘UTR:CCCTAGGT AGATCTT:fNaDC-3 3‘UTR:pSport
 
   Double digest 
E    BamHI/XbaI 
 
pSport:fNaDC-3 5‘UTR:GG CTAGAC:fNaDC-3 3‘UTR:pSport
pSport:fNaDC-3 5‘UTR:CCCTAG TT:fNaDC-3 3‘UTR:pSport
 
 
Figure 4.7:  Modification of fNaDC-3  A. Outline of proposed method, showing replacement of the 
coding region (ORF) of the fNaDC-3 cDNA with the hROAT1 coding region, to yield a clone with the 
hROAT1 coding region flanked by the 5 and 3 UTRs of the fNaDC-3.  B.  Part of the multiple cloning 
site of the pSport vector, into which fNaDC-3 was cloned; site-directed mutagenesis was used to disrupt 
the BamHI and XbaI restriction sites.  C.  Using PCR to create new restriction sites (C), using primer 
oligomers (solid arrows) corresponding to the junctions between the fNaDC-3 UTRs and the coding 
region (partial sequence shown) and also containing mismatches (nucleotides shaded black).  PCR 
amplification was directed away from the fNaDC-3 coding region (C), leading to amplification of the 
UTRs and the entire vector (D, in bold), with terminal restriction sites.  After restriction digestion of the 
amplification product (E), the amplified vector was ready to receive the hROAT1 coding region. 
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4.1.3 Functional characterization of hROAT1 
 
The function of hROAT1 was investigated by injection of Xenopus laevis oocytes with 
cRNA derived from the expression clone created in 4.1.2.  As seen in Figure 4.8, 
hROAT1-cRNA injected oocytes incubated in uptake medium containing 10 µM total 
PAH took up 2.5 pmol PAH/oocyte per hour, a three-fold increase in PAH uptake as 
compared with water injected control oocytes.  This uptake was completely inhibited by 
the presence of 1 mM of either probenecid or glutarate in the uptake medium.  The 
observed uptake values for hROAT1 were, however, considerably lower than those 
previously reported for the OAT1/ROAT and fROAT homologues (Sekine et al 1997, 
Sweet et al 1997, Wolff et al 1997).  In an attempt to increase this low activity, two 
strategies were adopted.  First, the oocytes were incubated with glutarate, either 200 µM 
overnight or 1 mM for 2 hours prior to the transport assay.  Secondly, oocytes were 
co-injected with hROAT1 and fNaDC-3 cRNA.  The second approach lead to an 
increase in uptake of PAH (data not shown), but the overall uptake remained low 
relative to the rat and flounder clones. 
 
Figure 4.8:  hROAT1-mediated PAH uptake. Uptake of PAH by the hROAT1 expression clone, 
compared with water-injected controls, in the presence and absence of 1 mM probenecid.  The figure 
shows a representative of two independent experiments.  Values are mean +/- SE for 9-12 oocytes. 
 
hROAT1
control
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Subsequent analysis of the sequence of the hROAT1 coding region contained within the 
expression clone revealed a single amino acid substitution, an exchange of a lysine 
residue for a proline residue (Figure 4.9).  Moreover, this proline lies in a predicted 
transmembrane domain and is conserved in both OATs and OCTs.  The amino acid 
substitution was reversed via site-directed mutagenesis, and the restored wild-type 
sequence was again tested for function by injection of oocytes with hROAT1 cRNA.  
Figure 4.10 compares PAH uptake by the restored clone with the original expression 
clone, demonstrating a substantial increase in the uptake activity of the restored clone - 
12 pmol/oocyte*hr compared with 2 pmol/oocyte*hr for the original clone. 
 
A.   
Query: 246 ctgtgccccactggcgccacctgcagctactggtctctgcgcttttttttgccttcttca 305
|||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||
Sbjct: 728 ctgtgccccactggcgccacctgcagctactggtctctgcgcctttttttgccttcttca 787
C770T nucleotide exchange resulting in an amino acid exchange:P257L
B.   
hROAT1 GTLIGYVYSLGQFLLAGVAYAVPHWRHLQLLVSAPFFAFFIYSWFFIESARWHSSSGRLD 282
NKT GTLIGYVYSLGQFLLAGIAYAVPHWRHLQLAVSVPFFVAFIYSWFFIESARWYSSSGRLD 276
ROAT1 GTLIGYVYSLGQFLLAGIAYAVPHWRHLQLVVSVPFFIAFIYSWFFIESARWYSSSGRLD 282
fROAT GTTTGYCYTLGQLILVLLAYFIRDWRWLTLAVSLPFYVFFLIAWWFHESSRWLALSNRTE 294
NLT/rOAT2 GVISTVFWSGGVLLLALVGYLIRSWRWLLLAATLPCVPGIISIWWVPESARWLLTQGRVE 290
hOCT1 AIMYQMAFTVGLVALTGLAYALPHWRWLQLAVSLPTFLFLLYYWCVPESPRWLLSQKRNT 296
rOCT1 AILYQMAFTVGLVGLAGVAYAIPDWRWLQLAVSLPTFLFLLYYWFVPESPRWLLSQKRTT 297
mOCT1 AILYQVAFTVGLVGLAGVAYAIPDWRWLQLAVSLPTFLFLLYYWFVPESPRWLLSQKRTT 297
hOCT2 GIFYQVAYTVGLLVLAGVAYALPHWRWLQFTVALPNFFFLLYYWCIPESPRWLISQNKNA 297
mOCT2 GICYQIAFTVGLLILAGVAYALPNWRWLQFAVTLPNFCFLLYFWCIPESPRWLISQNKNA 297
rOCT2 GICYQIAFTVGLLILAGVAYVIPNWRWLQFAVTLPNFCFLLYFWCIPESPRWLISQNKIV 297
C. 
 
Figure 4.9:  Amino acid exchange in hROAT1 resulting from PCR amplification.  A. Part of the 
Blast comparison of the PCR-amplified hROAT1 expression clone sequence and the original hROAT1 
sequence, showing the C770T nucleotide exchange (bold), which results in the P257L amino acid 
exchange.  B. Partial OAT/OCT alignment showing the absolute conservation of the Pro257 (white) 
within the sixth transmembrane domain (grey).  C. The position of the P257L amino acid exchange in a 
secondary structure model of hROAT1, showing the predicted transmembrane location.   The mutation 
was corrected by site-directed mutagenesis. 
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Figure 4.10:  PAH uptake mediated by the restored hROAT1 clone.  Uptake of PAH by the first 
expression clone and the restored clone, compared with water-injected controls, in the presence and 
absence of 1 mM glutarate.  The figure shows a representative of two independent experiments.  Values 
are mean +/- SE for 9-12 oocytes. 
 
 
4.1.3.1 Determination of Km of hROAT1 for PAH  
The uptake of PAH into hROAT1-injected oocytes was found to be a linear process 
from 0-15 minutes (data not shown), therefore a period of 10 minutes was chosen to 
determine the Km of the transporter for PAH.   
 
Figure 4.11 shows a representative from three independent determinations of the Km for 
PAH of hROAT1-injected oocytes.  The Km value of approximately 10 µM calculated 
using the EZ-Fit enzyme kinetics software program (Perrella Scientific, Inc), is 
consistent with that reported for the other human OAT1 clones (Hosoyamada et al 1999, 
Lu et al 1999), and is also similar to that obtained with the rat OAT1 clone (Sekine et al 
1997). 
control
expression clone
restored clone
+ 1 mM Glutarate
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Figure 4.11:  Determination of the Km of hROAT1 for PAH.   Concentration-dependent PAH uptake is 
shown in a representative of three independent experiments.  PAH uptake was determined for 1, 5, 10, 20, 
50, 100, 200 and 500 µM total PAH.  Values shown are mean +/- SE for 7-11 oocytes. 
 
 
4.1.3.2 Ion dependence of hROAT1-mediated PAH uptake 
Many features of the multispecific organic anion system were known from functional 
studies using the various systems outlined in the introduction.  The process had been 
shown to be pH-independent and electroneutral with an indirect requirement for sodium 
ions and also some involvement of chloride ions in the transport process (Pritchard and 
Miller 1993).  To test whether the hROAT1 clone shared these properties, uptake 
experiments were carried out with altered transport media.  Chloride dependence was 
demonstrated using ORI in which chloride was replaced by gluconate, and as seen in 
Figure 4.12, this decreased PAH uptake by approximately 80 %.  In ORI medium in 
which sodium was replaced with choline, there was also a slight decrease of 
approximately 30 % in PAH uptake in hROAT1-injected oocytes (Figure 4.12).  To test 
the effect of membrane depolarization on hROAT1-mediated PAH transport, oocytes 
were pre-incubated in ORI containing 23 mM KCl instead of the usual 3 mM, with a 20 
mm reduction in NaCl concentration to 70 mM.  Subsequent uptake in the same 
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medium resulted in an unexpected increase of approximately 60 % in PAH uptake 
(Figure 4.12). 
 
 
 
Figure 4.12:  Inorganic ion dependence of hROAT1-mediated PAH uptake.  The effect of changes in 
the composition of the uptake medium on hROAT1 mediated PAH uptake is shown.  Control levels of 
PAH uptake are represented by the bar labelled None.  Na-free  and Cl-free indicate uptake experiments 
in transport medium where sodium and chloride were replaced by choline and gluconate, respectively.  23 
mM K represents uptake in medium containing 23 mM KCl and 70 mM NaCl, which leads to membrane 
depolarization in the oocyte. 
 
 
4.1.3.3 Cis-inhibition of hROAT1-mediated PAH uptake 
In order to associate hROAT1 more closely with one of the renal organic anion 
transporting systems that had already been functionally characterized, a number of 
organic anions were tested for their ability to inhibit hROAT1-mediated PAH uptake.  
As seen previously, both probenecid, the classical inhibitor of the multispecific organic 
anion transporting system, and glutarate, a dicarboxylate, inhibited PAH uptake in 
hROAT1-injected oocytes by more than 95 %.  In further cis-inhibition studies, the 
effects of a number of organic anions on hROAT1-mediated PAH uptake were tested, 
including clinically relevant compounds such as loop diuretics and sulfated bile acids, 
as well as a range of dicarboxylates. 
 
As hROAT1 appears to be an organic anion / dicarboxylate exchanger, cis-inhibition 
studies were carried out with various dicarboxylates in order to determine 
dicarboxylates that could serve as possible exchange partners.  Candidate dicarboxylates 
tested included unsubstituted dicarboxylates with carbon backbone of 2-8 carbon atoms, 
Na-free
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Cl-free
None
2000 150
PAH uptake (percentage of control)
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as well as members of the tricarboxylic acid cycle. hROAT1-dependent PAH uptake 
was carried out in the presence of 1 mM of each dicarboxylate, the results of which are 
shown in the following two figures. 
 
As seen in Figure 4.13, oxalate, malonate and succinate (with 2, 3 or 4 carbon atoms, 
respectively) did not significantly inhibit hROAT1-dependent PAH uptake.  All 
unsubstituted dicarboxylates with a carbon backbone ≥ 5 carbon atoms reduced PAH 
uptake by at least 90 %.  This is consistent with inhibition studies of fROAT, which is 
inhibited by glutarate and suberate, but not malonate or succinate (Wolff et al 1997). 
 
 
Figure 4.13:  Cis-inhibition of hROAT1-mediated PAH uptake by unsubstituted dicarboxylates of 
increasing length.  The effect on control levels of hROAT1-mediated PAH uptake (None) of is shown. 
The dicarboxylates were present in the uptake medium at a concentration of 1 mM.  Control uptake levels 
were set to 100 %.  Uptake in the presence of each dicarboxylate are shown as percentage of control 
uptake, +/- SE.  Results were obtained from 3 independent experiments with 7-12 oocytes per group (*  = 
P < 0.05, **  = P < 0.01). 
 
 
Figure 4.14 shows the effect on PAH uptake by members of the TCA cycle.  Malate, 
fumarate, succinate and oxalacatate did not significantly inhibit PAH uptake, consistent 
with previous studies of fROAT (Wolff et al 1997), whereas α-ketoglutarate reduced 
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hROAT1-dependent uptake by approximately 90 %, consistent with the assertion that 
α-ketoglutarate functions as the physiological counterion in basolateral PAH uptake in 
the proximal tubule (Pritchard and Miller 1993).  Citrate, which has a substituted 5 
carbon atom backbone, did not inhibit PAH uptake.  
 
 
Figure 4.14:  Cis-inhibition of hROAT1-mediated PAH uptake by TCA cycle intermediates. The 
effect on control levels of hROAT1-mediated PAH uptake (None) is shown. The dicarboxylates were 
present in the uptake medium at a concentration of 1 mM.  Control uptake levels were set to 100 %.  
Uptake in the presence of each dicarboxylate are shown as percentage of control uptake, +/- SE.  Results 
were obtained from 3 independent experiments with 7-12 oocytes per group (**  = P < 0.005). 
 
Several clinically relevant compounds were also tested for their ability to cis-inhibit 
hROAT1-mediated PAH uptake.  The loop diuretics bumetanide and furosemide had 
previously been shown to interact with the organic anion transporting system (Møller 
and Sheikh, 1983), and urate, the end product of purine catabolism, is thought to share 
the transport system for PAH in many species (Pritchard and Miller 1993).  In addition, 
lithocholic acid derivatives are excreted by the kidney to a greater extent than other bile 
acids (Palmer 1971). 
 
Figure 4.15 shows that both bumetanide and furosemide strongly inhibit (>95 %) the 
uptake of PAH by hROAT1-injected oocytes.  Urate also inhibits this process to a lesser 
extent (50 %).  Taurolithocholate (TLC) slightly inhibited PAH uptake, an effect 
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increased by sulfation (TLC-S), whereas neither form of glycolithocholate (GLC and 
GLC-S) affected hROAT1-mediated PAH uptake. 
 
 
 
Figure 4.15:  Effect of various organic anions on hROAT1-mediated PAH uptake. The effect organic 
anions on control levels of hROAT1-mediated PAH uptake (None) of is shown. The substances were 
present in the uptake medium at a concentration of 1 mM (100 µM for bile acids).  Control uptake levels 
were set to 100 %.  Uptake in the presence of each dicarboxylate are shown as percentage of control 
uptake, +/- SE.  Results were obtained from 3 independent experiments with 7-12 oocytes per group (*  = 
P < 0.05, **  = P < 0.01). 
 
4.1.3.1 hROAT1-mediated bumetanide uptake 
As the PAH uptake in oocytes expressing hROAT1 was inhibited by more than 95 % by 
the loop diuretics bumetanide and furosemide, uptake experiments with radioactively-
labelled bumetanide were carried out.  During a 1 hour incubation, no significant uptake 
of bumetanide by hROAT1-injected oocytes was observed in comparison with water 
controls (3.5 ± 0.4  pmol/hr*oocyte versus 3.4  ± 0.4  pmol/hr*oocyte).   
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4.1.4 Mutational analysis 
 
Mutational analysis of hROAT1 was undertaken in an attempt to identify those regions 
of the protein involved in the transport process.  To this end a combination of point 
mutations and deletions were generated, and the effect of these alterations on the 
hROAT1-mediated PAH uptake was observed. 
 
4.1.4.1 hROAT1 point mutants  
Upon closer examination of the alignment of the related OATs and OCTs it became 
apparent that certain charged amino acid residues identical in all members of one group 
are substituted in all members of the other group for a residue of opposite or neutral 
charge.  Three positions satisfy this criterion: the positively charged residues at 
positions 34 (histidine), 382 (lysine) and 466 (arginine) in hROAT1 align with 
isoleucine (neutral), alanine (neutral) and aspartate (positive) residues found at the 
corresponding positions in all OCTs.  Of these single amino acid differences, lysine at 
position 382 and arginine at position 466 were chosen for further study (Figure 4.16).  
Using site-directed mutagenesis, the lysine at position 382 of hROAT1 was replaced by 
an alanine, the amino acid residue found at this position in all OCTs, and the arginine at 
position 466 was replaced by an aspartic acid, as found in all OCTs.  These mutants, 
K382A and R466D, were sequenced to ensure polymerase fidelity, and expressed in 
oocytes. 
 
hROAT1 LCLSMLWFATSFAYYGLVMDLQGFGVSIYLIQVIFGAVDLPAKLVGFLVINSLGRRPAQM 399
NKT/mOAT LCLSMLWFATSFAYYGLVMDLQGFGVSMYLIQVIFGAVDLPAKFVCFLVINSMGRRPAQL 393
ROAT1 LCLSMLWFATSFAYYGLVMDLQGFGVSMYLIQVIFGAVDLPAKFVCFLVINSMGRRPAQM 399
fROAT LCLSAVWLSTSFAYYGLAMDLDKFGVDIYLIQVIFGAVDIPAKVVVVVSMSLIGRRRSQC 411
NLT-rOAT2 LCCMMVWFGVNFSYYGLTLDVSGLGLNVYQTQLLFGAVELPSKIMVYFLVRRLGRRLTEA 405
hOCT1 FILMYLWFTDSVLYQGLILHMGATSGNLYLDFLYSALVEIPGAFIALITIDRVGRIYPMA 407
rOCT1 VILMYLWFSCAVLYQGLIMHVGATGANLYLDFFYSSLVEFPAAFIILVTIDRIGRIYPIA 408
mOCT1 LILMYLWFSCAVLYQGLIMHVGATGANLYLDFFYSSLVEFPAAFIILVTIDRIGRIYPIA 408
hOCT2 MILMYNWFTSSVLYQGLIMHMGLAGDNIYLDFFYSALVEFPAAFMIILTIDRIGRRYPWA 408
mOCT2 LILMYNWFTSSVLYQGLIMHMGLAGDNIYLDFFYSALVEFPAAFIIILTIDRIGRRYPWA 408
rOCT2 LILMYNWFTSSVLYQGLIMHMGLAGDNIYLDFFYSALVEFPAAFIIILTIDRVGRRYPWA 408
                                   tmd 7      tmd 8  
 
hROAT1 MGSTMARVGSIVSP-LVSMTAELYPSMPLFIYGAVPVAASAVTVLLPETLGQPLPDTVQD 518
NKT/mOAT MGSTMARVGSIVSP-LISMTAEFYPSIPLFIFGAVPVAASAVTALLPETLGQPLPDTVQD 512
ROAT1 MGSTMARVGSIVSP-LVSMTAEFYPSMPLFIFGAVPVVASAVTALLPETLGQPLPDTVQD 518
fROAT WVSMMARIGAMVAP-MVLLTRDYIPWLPGLIYGGAPILSGLAAIFLPETLGYPLPDTIQD 530
NLT/rOAT2 LTALMGRLGASLAR-LAALLDGVWLLLPKVAYGGIALVAACTALLLPETKKAQLPETIQD 524
hOCT1 VCSSLCDIGGIITPFIVFRLREVWQALPLILFAVLGLLAAGVTLLLPETKGVALPETMKD 527
rOCT1 VCSALCDLGGIFTPFMVFRLMEVWQALPLILFGVLGLTAGAMTLLLPETKGVALPETIEE 528
mOCT1 VCSALCDLGGIFTPFMVFRLMEVWQALPLILFGVLGLSAGAVTLLLPETKGVALPETIEE 528
hOCT2 ICSSMCDIGGIITPFLVYRLTNIWLELPLMVFGVLGLVAGGLVLLLPETKGKALPETIEE 528
mOCT2 VCSSMCDIGGIVTPFLVYRLTDIWLEFPLVVFAVVGLVAGGLVLLLPETKGKALPETIED 528
rOCT2 VCSSMCDIGGIITPFLVYRLTDIWMEFPLVVFAVVGLVAGALVLLLPETKGKALPETIED 528
    tmd 11    tmd 12 
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Figure 4.16:  Construction of two hROAT1 point mutants.  Top: An alignment of the cloned OATs 
(above) and OCTs (below), showing the position of the conserved lysine and arginine chosen for 
mutational analysis.  Residues shaded grey represent transmembrane domains.  Transporter names are as 
for Figure 4.1.  Bottom: Position of these amino acids in the secondary structure model of hROAT1.  
 
The results of uptake experiments involving each mutant are shown in Figure 4.17.  In 
comparison with wild-type hROAT1, neither K382A nor R466D could mediate uptake 
PAH uptake  these amino acid substitutions completely disrupted the function of the 
transporter. 
 
 
Figure 4.17  PAH uptake by two hROAT1 point mutants.  Uptake of PAH by the two hROAT1 point 
mutants, K382A and R466D, compared with hROAT1 and water controls, in the absence and presence of 
1 mM glutarate.  The values represent the mean +/- SE for 8-12 oocytes in a representative of three 
independent experiments. 
control
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4.1.4.2 hROAT1 deletion mutants 
To determine whether the entire hROAT1 open reading frame is required for transport 
activity, deletion mutants were generated.  These N- and C-terminal mutants were 
generated by PCR from the hROAT1 expression clone with artificially introduced start 
or stop codons, respectively, as detailed in Methods.  That the entire coding region may 
not be essential to the transport function of hROAT1 was first suggested by the 
observation that rOCT1, a member of the related organic cation transporter family, is 
also expressed as an alternatively spliced short form, rOCT1A.  This isoform is missing 
the N-terminal portion of the protein corresponding to the first two transmembrane 
domains, but still mediates transport function (Zhang et al 1997).  To test whether 
hROAT1 could mediate PAH uptake without the first two transmembrane domains, an 
artificially shortened open reading frame was generated with PCR techniques.  Figure 
4.18 shows the results of uptake experiments with oocytes injected with the shortened 
hROAT1 cRNA with the wild-type hROAT1 as control.  In contrast to the functional 
rOCT1A, a similarly shortened hROAT1 was not able to mediate transport above 
control levels. 
 
Transcripts from the hOAT1 gene are also alternatively spliced, and four distinct 
isoforms of hROAT1 are known (Hosoyamada et al 1999, Bahn et al 2000).  All four 
isoforms differ in the splicing of exons 9 and 10 (Bahn et al 2000).  To determine 
whether these two exons are essential for transport function, both exon 10 alone and 
exons 9 and 10 together were artificially removed from the hROAT1 open reading 
frame.  This corresponded to the removal of the terminal 28 and 94 amino acids of the 
hROAT1 reading frame, as depicted in Figure 4.18.  Figure 4.19 shows uptake of PAH 
by oocytes injected with cRNA synthesized from these deletion mutants, in comparison 
with wild-type hROAT1 cRNA.  The deletion of exons 9 and 10 completely abolished 
the ability of hROAT1 to mediate PAH uptake.  In contrast, deletion of exon 10 alone 
lead to an increase of approximately two-fold in PAH uptake. 
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Figure 4.18: Construction of hROAT1 deletion mutants.  The location of exon 9 (light shading) and 
exon 10 (dark shading)  superimposed upon the hROAT1 secondary structure.  Exon positions are taken 
from Bahn et al 2000. 
 
 
 
Figure 4.19:  PAH uptake mediated by two hROAT1 deletion mutants.  PAH uptake mediated by 
oocytes injected with cRNA derived from hROAT1 with deletion of exon 10, and exons 9 & 10, is shown 
in comparison with water- and hROAT1-injected controls. The values represent the mean +/- SE for 8-12 
oocytes in a representative of three independent experiments.  *  = P < 0,05. 
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4.2 CLONING AND EXPRESSION OF A HUMAN OAT2 HOMOLOGUE 
 
The cloning of hROAT1, detailed above, represents the first reported cloning of a 
human OAT1 homologue, a transporter involved in the initial basolateral uptake step in 
the transepithelial renal secretion of organic anions such as PAH.  As outlined in the 
introduction, this step had already been characterized by functional studies in many 
species, and the previous cloning of several homologues facilitated the cloning of 
hROAT1.  In contrast, a role in the luminal exit of organic anions secreted in the kidney 
has yet to be assigned to a known protein.  The luminal efflux of PAH has been shown 
to be a low affinity, uniport system, and a protein with these properties would therefore 
be a candidate for transport of PAH into the tubular lumen.  As the rat NLT/OAT2 
satisfies these criteria (Sekine et al 1998), a human homologue was sought. 
 
4.2.1 Human EST-based cloning of hOAT2 
 
4.2.1.1 Retrieval of ESTs from the human dbEST database 
The initial step in cloning the human homologue of the rat NLT/rOAT2 consisted of a 
Blast search of the human expressed sequence tag (EST) database using the rat 
NLT/OAT2 nucleotide sequence as a search query.  This lead to the retrieval of three 
human ESTs (accession numbers: AI016020, T73363, T68667) with high homology to 
the rat NLT/OAT2, corresponding to the beginning (EST1: AI016020), middle (EST2: 
T73363) and end (EST3: T73363) of the rat NLT/OAT2 coding region.  Aligning the 
amino acid sequence derived from each EST to the amino acid of rat NLT/OAT2 
revealed 76, 77 and 83 % identity to the rat sequence for EST1, 2 and 3, respectively.   
 
From the amino acid alignment, it was observed that the EST aligning with the 5 end of 
the rat NLT/OAT2 sequence included the probable start codon of the human 
NLT/OAT2 homologue.  In contrast, the EST corresponding to the 3 region aligned 
only until amino acid 478 of the predicted reading frame after which the sequences were 
completely divergent.  The nucleotide sequence of the terminally-aligning EST was then 
edited, based on a comparison with the rat NLT/OAT2 nucleotide sequence, to remove 
any obvious sequencing errors common in ESTs - additional bases or deletions - that 
had perhaps caused frameshifts resulting in the sudden divergence seen in the sequence.   
When the derived amino acid sequence corresponding to the edited EST was aligned 
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with the rat NLT/OAT2, the homology between the two sequences continued until 
residue 528 of the rat sequence (Figure 4.20).   
 
. : . : . : . : . : . : 60
HNLT-EST1 MGFEELLEQVGGFGPFQLRNVALLALPRVLLPLHFLLPIFLAAVPAHRCALPGAPANFSH 60
NLT/ROAT2 MGFEDLLDKVGGFGPFQLRNLVLMALPRMLLPMHFLLPVFMAAVPAHHCALPGAPANLSH 60
. : . : . : . : . : . : 120
HNLT-EST1 QDVWLEAHLPREPDGTLSSCLRFAYPQALPNTTLGEERQSRGELEDEPATVPCSQGWEYD 120
NLT/ROAT2 QDLWLEAHLPRETDGSFSSCLRFAYPQTVPNVTLGTEVSNSGEPEGEPLTVPCSQGWEYD 120
. : . : . : . : . : . : 180
HNLT-EST1 HSEFSSTIATE 131
NLT/ROAT2 RSEFSSTIATEWDLVCQQRGLNKITSTCFFIGVLVGAVVYGYLSDRFGRRRLLLVAYVSS 180
. : . : . : . : . : . : 240
NLT/ROAT2 LVLGLMSAASINYIMFVVTRTLTGSALAGFTIIVLPLELEWLDVEHRTVAGVISTVFWSG 240
. : . : . : . : . : . : 300
HNLT-EST2 QGILSLWWVPESARWLLTQGHVKEAHRYLLHCA 33
NLT/ROAT2 GVLLLALVGYLIRSWRWLLLAATLPCVPGIISIWWVPESARWLLTQGRVEEAKKYLLSCA 300
. : . : . : . : . : . : 360
HNLT-EST2 RLNGRPVCEDSFSQEVWSKVAAGERVVRRPSYLDLFRTPRLRHISLCCVVVWFGVNFSYY 93
NLT/ROAT2 KLNGRPVGEGSLSQEALNNVVTMERALQRPSYLDLFRTSQLRHISLCCMMVWFGVNFSYY 360
. : . : . : . : . : . : 420
HNLT-EST2 GLSLDVSGLGLNVYQTQLLFG 114
NLT/ROAT2 GLTLDVSGLGLNVYQTQLLFGAVELPSKIMVYFLVRRLGRRLTEAGMLLGAALTFGTSLL 420
. : . : . : . : . : . : 480
HNLT-EST3 SDMKSWSTVLAVMGKAFSEAAFTTAYLFTSELYPTVLRQTGMGLTALVGRLGGSLARL 58
NLT/ROAT2 VSLETKSWITALVVVGKAFSEAAFTTAYLFTSELYPTVLRQTGLGLTALMGRLGASLARL 480
. : . : . : . : . : . : 540
HNLT-EST3 AALLDGVXLSLPKLTYGGIXLLAAGTALLLPETRQAQLPETIQDVERK 106
NLT/ROAT2 AALLDGVWLLLPKVAYGGIALVAACTALLLPETKKAQLPETIQDVERKSTQEEDV 535
 
Figure 4.20: Alignment of hESTs with NLT/rOAT2.  Amino acid alignment of the three hESTs 
retrieved (top) with NLT/rOAT2 Residues shaded grey are identical in both human EST and rat sequence.   
 
Sequence-specific primers then enabled amplification, from a human liver cDNA 
template, of a product of 1575 bp representing the first 528 amino acids of a human 
homologue of the rat NLT/OAT2  (Figure 4.21).  This initial amplification product 
exhibited 78 % identity with the rat clone when the nucleotide sequences were 
compared, and the derived amino acid sequences showed 85 % identity. 
 
1kb 1 2 3
2.0 kb
1.6 kb
1.0 kb
0.5 kb
Figure 4.21:  Amplification of hOAT2 from human 
 liver cDNA.  Lane 1: initial amplification; lane 2: re-
amplification; lane 3: negative control.  1 kb: 1kb standard,
 with band sizes labelled left.  The amplification product 
from which  the initial hOAT2 product was cloned is 
signified by the white arrow
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4.2.1.2  3 RACE 
To complete the coding region and enable functional characterization, 3RACE with an 
hOAT2-specific primer was carried out, again using human liver cDNA as a template.  
Unfortunately, no successful amplification product was obtained after several attempts 
with a range of annealing temperatures.  The same 3 RACE reaction was then carried 
out using a human kidney cDNA template, and this yielded a product of approximately 
600 bp with an in frame stop codon and poly-A tail.  From the sequence of the 3 RACE 
product amplified from the kidney, it appeared likely that this was expressed from the 
same gene as the initial product amplified from the liver cDNA, as the overlapping 
sequence of 240 nucleotides was 100 % identical.   
 
Based on a contig of these two sequences, sequence-specific primers were designed 
with which to amplify the full-length hOAT2 expressed in the kidney. Following 
successful amplification of the full-length hOAT2 coding region and verification by 
sequencing, the hOAT2 sequence was submitted to the GenBank database, where it was 
assigned the accession number AF210455. 
 
4.2.1.3 Analysis of the hOAT2 sequence  
The complete coding sequence of hOAT2 is seen in Figure 4.22.  The coding region of 
the hOAT2 cDNA consists of 1626 nucleotides followed by a 3 UTR of 200 
nucleotides (not shown).  hOAT2 encodes a protein of 541 amino acids, with a 
predicted mass of 59 kDa. Based on TopPred2 analysis (window setting of 11-21, upper 
cut-off 1.0, lower cut-off 0.4), hOAT2 is predicted to contain 12 transmembrane 
domains with intracellular N- and C-termini, as seen for other members of the OAT 
family.  A model of the predicted secondary structure of hOAT2 including sites for 
potential enzymatic modification is seen in Figure 4.23.  Further analysis of the primary 
structure revealed a number of conserved motifs.  In the large extracellular loop 
between transmembrane domains 2 and 3 are two consensus sites for N-glycosylation 
(N57 and N91).  Also present in the primary amino acid sequence are a number of 
consensus sites for phosphorylation by various kinases: protein kinase A (S333, T405), 
protein kinase C (T340, S396), and casein kinase II (S333, T522).   
 
hOAT2, like hROAT1, contains sequence motifs common to the ASF subfamily of the 
major facilitator superfamily.  These motifs are: GX3GX4GX3DRXGRRK, with the  
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M G F E E L L E Q V G G F G P F Q L R N V A L L A L P R V L 30
1 ATGGGCTTTGAGGAGCTGCTGGAGCAGGTGGGCGGCTTTGGGCCCTTCCAACTGCGGAATGTGGCACTGCTGGCCCTGCCCCGAGTGCTG
∗
L P L H F L L P I F L A A V P A H R C A L P G A P A N F S H 60
91 CTACCACTGCACTTCCTCCTGCCCATCTTCCTGGCTGCCGTGCCTGCCCACCGATGTGCCCTGCCGGGTGCCCCTGCCAACTTCAGCCAT
*
Q D V W L E A H L P R E P D G T L S S C L R F A Y P Q A L P 90
181 CAGGATGTGTGGCTGGAGGCCCATCTTCCCCGGGAGCCTGATGGCACGCTCAGCTCCTGCCTCCGCTTTGCCTATCCCCAGGCTCTCCCC
∗
N T T L G E E R Q S R G E L E D E P A T V P C S Q G W E Y D 120
271 AACACCACGTTGGGGGAAGAAAGGCAGAGCCGTGGGGAGCTGGAGGATGAACCTGCCACAGTGCCCTGCTCTCAGGGCTGGGAGTACGAC
∇
H S E F S S T I A T E S Q W D L V C E Q K G L N R A A S T F 150
361 CACTCAGAATTCTCCTCTACCATTGCAACTGAGTCCCAGTGGGATCTGGTGTGTGAGCAGAAAGGTCTGAACAGAGCTGCGTCCACTTTC

F F A G V L V G A V A F G Y L S D R F G R R R L L L V A Y V 180
451 TTCTTCGCCGGTGTGCTGGTGGGGGCTGTGGCCTTTGGATATCTGTCCGACAGGTTTGGGCGGCGGCGTCTGCTGCTGGTAGCCTACGTG
S T L V L G L A S A A S V S Y V M F A I T R T L T G S A L A 210
541 AGTACCCTGGTGCTGGGCCTGGCATCTGCAGCCTCCGTCAGCTATGTAATGTTTGCCATCACCCGCACCCTTACTGGCTCAGCCCTGGCT
G F T I I V M P L E L E W L D V E H R T V A G V L S S T F W 240
631 GGTTTTACCATCATCGTGATGCCACTGGAGCTGGAGTGGCTGGATGTGGAGCACCGCACCGTGGCTGGAGTCCTGAGCAGCACCTTCTGG
T G G V M L L A L V G Y L I R D W R W L L L A V T L P C A P 270
721 ACAGGGGGCGTGATGCTGCTGGCACTGGTTGGGTACCTGATACGGGACTGGCGATGGCTTCTGCTAGCTGTCACCCTGCCTTGTGCCCCA

G I L S L W W V P E S A R W L L T Q G H V K E A H R Y L L H 300
811 GGCATCCTCAGCCTCTGGTGGGTGCCTGAGTCTGCACGCTGGCTTCTGACCCAAGGCCATGTGAAAGAGGCCCACAGGTACTTGCTCCAC
Ψ
C A R P N G R P V C E D S F S Q E A V S K V A A G E R V V R 330
901 TGTGCCAGGCCCAATGGGCGGCCAGTGTGTGAGGACAGCTTCAGCCAGGAGGCTGTGAGCAAAGTGGCCGCCGGGGAACGGGTGGTCCGA
∇ 
R P S Y L D L F R T P R L R H I S L C C V V V W F G V N F S 360
991 AGACCTTCATACCTAGACCTGTTCCGCACACCACGGCTCCGACACATCTCACTGTGCTGCGTGGTGGTGTGGTTCGGAGTGAACTTCTCC
Y Y G L S L D V S G L G L N V Y Q T Q L L F G A V E L P S K 390
1081 TATTACGGCCTGAGTCTGGATGTGTCGGGGCTGGGGCTGAACGTGTACCAGACACAGCTGTTGTTCGGGGCTGTGGAACTGCCCTCCAAG
 Ψ
L L V Y L S V R Y A G R R L T Q A G T L L G A A L A F G T R 420
1171 CTGCTGGTCTACTTGTCGGTGCGCTACGCAGGACGCCGCCTCACGCAAGCCGGGACACTGCTGGGCGCGGCCCTGGCGTTCGGCACTAGA
L L V S S D M K S W S T V L A V M G K A F S E A A F T T A Y 450
1261 CTGCTAGTGTCCTCCGATATGAAGTCCTGGAGCACTGTCCTGGCAGTGATGGGGAAAGCTTTTTCTGAAGCTGCCTTCACCACTGCCTAC
L F T S E L Y P T V L R Q T G M G L T A L V G R L G G S L A 480
1351 CTGTTCACTTCAGAGTTGTACCCTACGGTGCTCAGACAGACAGGGATGGGGCTGACTGCACTGGTGGGCCGGCTGGGGGGCTCTTTGGCC
P L A A L L D G V W L S L P K L T Y G G I A L L A A G T A L 510
1441 CCACTGGCGGCCTTGCTGGATGGAGTGTGGCTGTCACTGCCCAAGCTTACTTATGGGGGGATCGCCCTGCTGGCTGCCGGCACCGCCCTC
∇
L L P E T R Q A Q L P E T I Q D V E R K R C V H R T V S V Y 540
1531 CTGCTGCCAGAGACGAGGCAGGCACAGCTGCCAGAGACCATCCAGGACGTGGAGAGAAAGAGGTGTGTGCACAGGACTGTGTCTGTGTAC
V • 541
1621 GTGTGA  
Figure 4.22:  hOAT2 nucleotide and amino acid reading frame. The hOAT2 cDNA sequence (left-
hand column) and the amino acid sequence (right-hand column) of the 541 amino acid open reading 
frame.  Transmembrane domains predicted by the TopPred 2 programme are underlined.  Symbols 
represent consensus sequence sites for N-linked glycosylation (✱), and phosphorylation by protein kinase 
C (), protein kinase A (Ψ), and casein kinase II (∇). 
 
 
exception of a substitution of R at the last position, present in the first intracellular loop; 
(G154-K173); EX6R (E
222-R229) in the fourth transmembrane domain and second 
intracellular loop; TIXXEWDLVC (T127-C138) is present in the second transmembrane 
domain, although it is disrupted by the insertion of  serine and glutamine  between 
glutamate and tryptophan; ELYPTL (E455-V460; substitution of V for terminal L) 
between transmembrane domains 10 and 11; and LPETL (L520-I524 ; substitution of I for 
terminal L) after transmembrane domain 12. As mentioned earlier, the physiological 
significance of these motifs has yet to be elucidated. 
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Figure 4.23:  Model of the secondary structure of hOAT2.  This model shows the secondary structure 
of hOAT2 as predicted by TopPred2, each circle representing an amino acid.  Shaded residues are 
identical in hOAT2 and the rat OAT2.  Darker shading represents those residues also identical in 
hROAT1.  The consensus sites for enzymatic modification are also shown: Y = N-glycosylation, * = 
protein kinase C,   X  = protein kinase A,   ∇= casein kinase II. 
 
 
4.2.1.4 Comparison of hOAT2 with a human OAT2 homologue expressed in the liver 
Subsequent to the cloning of hOAT2, a homology search revealed the presence of a 
second human NLT/rOAT2 homologue in the GenBank database.  This clone, termed 
hNLT, was cloned from human liver cDNA and on the amino acid level is 100 % 
identical to the hOAT2 cloned in this study until position 528, after which the sequences 
are completely divergent.  Furthermore, the high homology hOAT2 and hNLT to the rat 
OAT2 sequence ends at the same position.  Comparing hOAT2 and hNLT with the rat 
OAT2 cDNA and genomic sequences predicts that the observed divergence corresponds 
to the last of 10 predicted exons.  To determine whether hNLT is also expressed in the 
kidney, hNLT-specific primers corresponding to the beginning and end of the hNLT 
reading frame were used in a PCR with human kidney cDNA as template.  Specific 
amplification using these primers was not observed, in contrast to the amplification of 
hOAT2 used as a positive control.  From this PCR result, it appears that the hNLT is not 
expressed at detectable levels in human kidney, and as such hOAT2 and hNLT appear 
to represent kidney- and liver-specific transcripts of the same transporter.   
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4.2.1.5 Isolation of alternatively spliced hOAT2 transcripts 
During amplification of hOAT2 using primers directed against the beginning and end of 
the predicted open reading frame, three distinct species of cDNA were amplified.  In 
addition to the transcript encoding a predicted protein of 541 amino acids, termed 
hOAT2, two transcripts encoding shortened open reading frames were also amplified.  
These transcripts were named hOAT2-2 and hOAT2-3, and contain shortened reading 
frames encoding proteins of 295 and 271 amino acids, respectively.  The differences in 
the length of the hOAT2-2 and hOAT2-3 open reading frames correspond to three 
changes on the nucleotide level.  The hOAT2-2 transcript has deletions of nucleotides 
394-399 and nucleotides 888-952.  On the amino acid level, the first deletion 
corresponds to an in-frame deletion of two amino acids: S132 and Q133.  The second 
deletion results in a frame shift: a stop codon (nucleotides 956-958) is brought in frame.  
The hOAT2-3 transcript also contains these two deletions, but in addition contains an 
insertion of 116 nucleotides at position 652, which changes the derived amino acid 
sequence from this point.  In both hOAT2-2 and hOAT2-3, translation of these 
transcripts is predicted to terminate following the second deletion.  Comparing hOAT2-
2 with the genomic sequence of the rat NLT/OAT2, known as TI-LTP (Simonson and 
Iwanij 1995), an approximation of the exon organization is obtained (see appendix).   
This comparison suggests that two internal deletions are a result of alternative splicing 
events.  The first deletion appears to take place during the removal of intron 2, whereas 
the second deletion seems to be a partial deletion of exon 5 together with intron 5.  The 
extra sequence in hOAT2-3 appears to originate from an unspliced intron between 
exons 3 and 4 (Appendix 2). 
 
4.2.2 Heterologous expression of hOAT2 in Xenopus oocytes 
 
4.2.2.1 Expression clone construction 
To enable the in vitro transcription of hOAT2 cRNA, the hOAT2 open reading frame 
was subcloned into pSport between the fNaDC-3 5 and 3 UTRs, as detailed for 
hROAT1.  The hOAT2 open reading frame was excised from the Zero Blunt II TOPO 
vector by double digestion with BamHI and XbaI, and ligated into the similarly 
restricted pSport::fNaDC-3-UTRs vector, creating a clone in which the hOAT2 open 
reading frame is flanked by the 5 and 3 UTRs of fNaDC-3.   
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4.2.2.2 Uptake experiments 
The ability of hOAT2 to mediate the uptake of various radioactively-labelled substrates 
was tested in the Xenopus laevis oocyte expression system.  As it had already been 
shown that the rat homologue, NLT/rOAT2, mediates the uptake of glutarate and alpha-
ketoglutarate into oocytes, these substrates, as well as PAH, were used in uptake 
experiments with hOAT2-injected oocytes.  As shown in figure 4.24, hOAT2 was not 
able to mediate uptake of the above mentioned substrates at levels significantly higher 
than those observed with control oocytes. 
 
 
 
Figure 4.24:  Uptake experiments with hOAT2.  hOAT2-mediated uptake of a-ketoglutarate, glutarate 
and PAH into oocytes.  The results shown are from a representative of 2 independent experiments, and 
values are mean +/- SE for 8-12 oocytes. 
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4.3 CONSTRUCTION OF AN hOAT2:hROAT1 CHIMERA 
 
4.3.1 Chimera construction 
 
Chimeric proteins can often provide insights into the location of functional domains of 
proteins.  This approach has proved successful in the determination of the substrate-
binding domains of, among others, MDR (Zhou et al 1999) and MRP (Stride et al 1999) 
multidrug resistance proteins, the sodium-sulfate and sodium-dicarboxylate 
cotransporters (Pajor et al 1998) and the sodium-dependent nucleoside transporters 
(Wang and Giacomini 1997).  In an attempt to further characterize the functional 
domains of the OAT proteins isolated in this study, a chimera of hOAT2 and hROAT1 
was constructed by the overlapping PCR technique described in section 3.1.2.6.  The 
amplification product consisted of the first half of hOAT2 (nucleotides 1-831 of the 
coding region; amino acids M1-P277) fused to the second half of hROAT1 (nucleotides 
811-1653 of the coding region; amino acids S271-F550), yielding a chimeric coding 
region of 1674 nucleotides encoding 558 amino acids.  Based on TopPred 2 analysis, 
the chimera was predicted to contain the first six transmembrane domain of hOAT2 
joined to the large internal loop and last six transmembrane domains of hROAT1 (see 
Figure 4.25).   
 
 
Figure 4.25  Predicted secondary structure of the hOAT2:hROAT1 chimera.  The N-terminal part of 
the molecule (light shading) is derived from hOAT2, and is fused to the C-terminal half of hROAT1 (dark 
shading).  
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Analysis of the chimera itself predicted the same twelve transmembrane domains 
corresponding to those from each half (Figure 4.25).  The ability of the 
hOAT2:hROAT1 chimera to mediate PAH uptake was tested in oocytes.  Chimera-
injected oocytes were unable to mediate uptake of PAH at levels significantly greater 
than those in control oocytes (1.53 ± 0.33 pmol / hour*oocyte vs 1.48± 0.25 pmol / 
hour*oocyte). 
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5 DISCUSSION 
 
5.1 CLONING  AND CHARACTERIZATION OF hROAT1 
 
5.1.1 Cloning and analysis of an hROAT1 cDNA 
 
A vast array of potentially toxic anions of both endogenous and exogenous origin are 
eliminated from the body by the multispecific organic anion transporting system located 
in the proximal tubule of the kidney.  Shared by almost all vertebrates and invertebrates 
studied to date, the system consists of the well-defined uptake of the model organic 
anion PAH at the basolateral membrane in exchange for intracellular α-ketoglutarate.  
Since the advent of molecular biology and expression cloning techniques, the organic 
anion transporting system has come under increasing scrutiny.    
 
In 1997, using the Xenopus laevis oocyte expression cloning system, cDNAs were 
isolated from rat (Sekine et al, Sweet et al) and flounder (Wolff et al) which mediated 
uptake of labeled PAH when expressed in oocytes.  All satisfied the functional 
characteristics of the tertiary active basolateral step of organic anion transport and were 
named OAT1*.  The major goal of this study was to clone and characterize a human 
homologue of the OAT1.  The isolation of the rat and flounder clones, and a non-
functional mouse clone, opened the possibility to clone a human OAT1 homologue 
using a degenerate PCR-based cloning strategy.  Using this strategy, it was possible to 
amplify part of a human OAT1 reading frame, which was completed using RACE.  The 
clone, which was named hROAT1 (human Renal Organic Anion Transporter) 
represents the first reported cloning of a human OAT1 homologue (Reid et al 1998). 
 
The cloning of hROAT1, concisely reported here, posed a number of problems.  
Although it was hoped to bypass the labour intensive process of library construction and 
screening successfully employed to isolate the rat, mouse and flounder homologues, the 
degenerate PCR approach proved just as time consuming.  Considering that the 
degenerate primers used in the successful amplification comprised a pool of at least 
1500 distinct primers, necessitating the higher than normal primer concentration , and 
that the low annealing temperature gave a low stringency, the successful amplification 
was probably serendipitous.   
* OAT1 is the generic name for the homologues of this transport protein in different species, which has 
been variously combined with a lower case initial designating the species of origin and occasionally R to 
denote renal.  Isoforms have also been isolated and are represented by -1, -2 etc. 
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Following the publication of the hROAT1 sequence, four further reports of the cloning 
of a human OAT1 homologue appeared.  Of these clones, hOAT1 (Race et al, 1999) and 
hPAHT (Lu et al, 1999) were generated by PCR techniques, and hOAT1-1 and 1-2 
(Hosoyamada et al, 1999) and hOAT1 (Cihlar et al, 1999) were isolated from cDNA 
libraries.  The sequences deposited in GenBank are greater than 99 % identical on the 
nucleotide level, and from the seven nucleotide differences, only two amino acid 
changes result  the serine at position 14 of hPAHT, and the phenylalanine at position 
550 in hROAT1.  Cihlar et al (1999) suggest that the differences are errors incorporated 
by the polymerase during PCR.  This conclusion is supported by the observation that the 
open reading frame of their clone is 100 % identical to that of hOAT1-2, which was also 
isolated by screening a cDNA library (Hosoyamada et al, 1999).  The purchase of the 
poly(A)+ RNA used by each group in library construction from different companies also 
favours this argument.  However, this does not rule out the possibility that the changes 
observed in hROAT1 result from genetic differences in the patient from which the 
poly(A)+ RNA used in this study was isolated.  This suggestion is based on the 
independent occurrence of the same three nucleotide changes in both the initial 3RACE 
and the subsequent amplification of the full hROAT1 open reading frame.  Furthermore, 
the two amino acid differences found in the PCR-generated clones do not result in a 
change in any sequence or motif that is absolutely conserved throughout the entire OAT 
family.  Irrespective of the source of these sequence differences, it is apparent from the 
characterization of the different human OAT1s that these two differences in amino acid 
sequence do not have a noticeable effect on the function of the transporter. 
 
The reported cloning of human OAT1 homologues by five independent groups and the 
continual appearance of new members of the OAT family, has lead to a certain 
confusion in the nomenclature of these proteins.  The clone isolated in this study was 
named hROAT1 to coincide with the previously isolated rat and flounder clones, where 
R denotes renal expression of this protein.  It has since been demonstrated by Northern 
blot and RT-PCR that the human OAT1 gene is also transcribed in a number of other 
tissues, including brain (Hosoyamada et al 1999, Race et al 1999) and placenta 
(Hosoyamada et al 1999).  In addition, RT-PCR-derived sequences of four distinct 
OAT1 transcripts  have now been published, which appear to result from alternative 
splicing events (Hosoyamada et al 1999, Bahn et al 2000).  However, although the 
presence of mRNA isoforms can be detected by RT-PCR, this does not mean that such 
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transcripts are translated, nor does RT-PCR detect sequence differences in transcripts of 
similar length.  Immunological evidence is required before it can be concluded that 
these alternative transcripts represent isoforms of the human OAT1 transporter. 
 
5.1.2 Functional characterization of hROAT1 
 
5.1.2.1 Functional clone construction 
Using degenerate-PCR and RACE, it was possible to isolate the reading frame and 
3UTR of hROAT1.  As functional characterization in the oocyte expression system 
also requires the 5UTR, amplification of the hROAT1 5UTR was carried out to 
complete this clone.  Using primers based on conserved sequences in the rat and mouse 
5 UTRs together with a primer specific for the hROAT1 reading frame, a product was 
amplified with 100 % identity to the hROAT1 reading frame in the 3-terminal part of 
the sequence, strongly suggesting that this sequence was in fact the 5UTR of hROAT1.  
This assumption was confirmed by comparison of the sequence with the subsequently 
isolated human OAT1 clones, listed in Table 4.2, which shows greater than 99 % 
identity between the 5UTRs.  These results make the inability to amplify a full-length 
cDNA using primers specific to the 5 and 3 UTRs difficult to understand.  As it was 
possible to amplify 5 UTR sequence, this means that the initial RT-PCR successfully 
produced first-strand cDNAs corresponding to mature mRNAs.  The reason for the 
inability to amplify a product corresponding to a mature mRNA is uncertain, but may 
have been due to either a degradation of the cDNA template resulting from repeated 
freeze/thaw cycles, or a lack of specificity of the primers employed in the attempted 
PCR-amplification. 
 
In the second strategy used in an attempt to construct a functional clone, the Xenopus-
specific pGEMHE vector was obtained with the goal of subcloning the hROAT1 
reading frame between the β-globin UTRs contained within the vector.  The use of this 
vector in particular, and Xenopus-specific UTRs in general,  has been shown to improve 
the expression of mammalian cDNAs injected into oocytes (Liman et al 1994, Shih et al 
1998).  Despite several attempts, the hROAT1 open reading frame could not be 
subcloned into the pGEMHE vector, and the reasons for this remain unclear.  As it was 
possible to subclone the rat OAT2 open reading frame into pGEMHE using exactly the 
same strategy, this is even more perplexing.  Difficulties in modifying pGEMHE, such 
as dephosphorylation and linker addition, have been observed in similar applications 
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(FM Dautzenberg, pers. comm.).  The construction of a functional expression clone was 
ultimately achieved by subcloning the hROAT1 coding region between the UTRs of the 
flounder sodium dicarboxylate cotransporter, fNaDC-3 (Steffgen et al 1999).  This 
strategy yielded a clone that mediated PAH uptake when expressed in oocytes.  The 
expression was apparently unaffected by the incorporation, immediately upstream from 
the start codon, of the BamHI site used in the subcloning strategy.  This results in a 
weakened context for translation initiation, as predicted by Kozak, with A and T at 
positions -3 and -4 (Kozak 1987).  Comparison with the wild type cDNA as 
characterized by other groups suggests that the hROAT1 reading frame functions 
equally well in different UTR contexts.  The fNaDC-3 UTRs may in fact improve the 
expression of mammalian cDNAs in oocytes, a suggestion based on assays involving a 
recently cloned rabbit OAT1 clone, rbOAT1 (Bahn et al 2000).   In these assays, PAH 
uptake by a native rbOAT1 clone was approximately 20 % lower than uptake mediated 
by the open reading frame flanked by the fNaDC-3 UTRs (unpublished results).  
 
5.1.2.2 PAH uptake mediated by hROAT1 
The human OAT1 homologue, hROAT1, isolated in this study has functional 
characteristics of a renal basolateral organic anion/dicarboxylate exchanger.  Expressed 
in oocytes, hROAT1 mediated PAH uptake with a calculated Km of approximately 10 
µM and was inhibitable by probenecid, the classical inhibitor of the system.  Although 
PAH uptake by human basolateral membrane vesicles has been demonstrated, no Km 
was determined.  However, the Km value is similar to the range of 14-70 µM reported 
for the OAT1s isolated from rat, mouse and flounder (Sekine et al 1997, Sweet et al 
1997, Wolff et al 1997, Kuze et al 1999), and equivalent to that reported for other 
human OAT1 clones (Lu et al 1999, Hosoyamada et al 1999).  The structural and 
functional similarity of hROAT1 to the previously cloned OAT1 homologues from rat 
and flounder, strongly suggests that it represents a human OAT1 homologue mediating 
organic anion uptake across the basolateral membrane in the human kidney. 
 
The basolateral localization suggested by these functional characteristics is strongly 
supported by immunological studies of human and rat OAT1 clones.  Hosoyamada and 
coworkers (1999) showed staining of the basolateral membrane of the proximal tubule 
with an antibody specific for a peptide corresponding to the terminal 14 amino acids of 
hOAT1.  The rat OAT1 was also detected only at the basolateral membrane (Tojo et al 
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1999).  Thus, hROAT1 has both the functional properties and membrane localization of 
a transporter involved in basolateral PAH uptake in proximal tubule cells. 
 
5.1.2.3 Ion dependence of hROAT1-mediated PAH uptake 
The hROAT1-mediated PAH uptake was investigated in a range of media with different 
ion composition to determine whether it was consistent with the previously determined 
ion dependence of the organic anion transporting  system.  Substitution of gluconate for 
chloride ions in the uptake medium inhibited hROAT1-mediated PAH uptake by 80 %, 
consistent with previous studies showing a requirement for chloride in basolateral PAH 
uptake.  A study of PAH uptake by rat kidney basolateral membrane vesicles showed a 
chloride dependence which was sided, meaning that maximal stimulation occurred with 
chloride on the same side as PAH (Pritchard 1988).  However, the nature of the chloride 
involvement is complex, as PAH uptake was not stimulated by an inwardly directed 
chloride gradient, nor was chloride cotransported with PAH (Pritchard 1988).   Similar 
decreases in PAH uptake have also been demonstrated for the other human OAT clones 
when chloride was replaced by gluconate in the transport medium (Race et al 1999, 
Hosoyamada et al 1999).  For hOAT1 cloned by Race and co-workers, replacing 
chloride with gluconate decreased PAH uptake by 80 % in hOAT1-injected oocytes 
which were first passively pre-loaded with glutarate (Race et al 1999).  The longer 
human OAT1 splice-variant, hOAT1-1, also exhibited chloride dependence in oocytes 
pre-incubated with glutarate, transport of PAH in medium containing gluconate instead 
of chloride was reduced by 90 % (Hosoyamada et al 1999).  Although direct 
comparison of these results is hindered by the glutarate pre-treatment of the hOAT1- 
and hOAT1-1-injected oocytes prior to transport, and the use of the longer hOAT1-1 
isoform by Hosoyamada and co-workers, the qualitative effect is same. 
 
Previous studies on the influence of potassium on PAH uptake have shown that PAH/ 
α-ketoglutarate exchange is electroneutral.  In bovine basolateral membrane vesicles, 
PAH/α-ketoglutarate was shown to have a stoichiometry of 1:1, and as PAH carries one 
negative charge and α-ketoglutarate carries two at physiological pH, this predicts the 
transfer of one negative charge (Schmitt and Burckhardt 1993).  However, the process 
was found to be electroneutral as it was not stimulated by an inwardly directed 
potassium gradient, suggesting to the authors that perhaps either monovalent 
α-ketoglutarate is exchanged, or that an unknown anion or cation is cotransported 
(Schmitt and Burckhardt 1993).  The effect of an inwardly directed potassium gradient 
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was also investigated in the characterization of the rat OAT1 (Sweet et al 1997).  PAH 
uptake mediated by the rat OAT1 in oocytes was investigated in medium containing 
increased potassium concentration, which depolarizes the oocyte membrane 
(Gründemann et al, 1994).  Under these conditions no change in rat OAT1-mediated 
PAH uptake was observed, consistent with the predicted electroneutral nature of 
PAH/α-ketoglutarate exchange.  In light of these results the reason for the observed 
increase in PAH uptake into hROAT1-injected oocytes in the presence of an increased 
extracellular potassium concentration is unclear. 
 
According to the accepted model for renal organic anion transport, basolateral PAH 
uptake has an indirect requirement for sodium in which the sodium gradient drives the 
basolateral uptake of dicarboxylates in the functionally coupled system (Shimada et al 
1987, Pritchard et al 1987).  As such, the observed 30 % decrease in PAH uptake into 
hROAT1-injected oocytes in medium where sodium ions were replaced with choline 
was unexpected. However, a similar, albeit lesser, reduction of PAH uptake after 
sodium replacement was reported for the rat OAT1 and the human hOAT1-1 (Sekine et 
al 1997, Hosoyamada et al 1999).  PAH uptake in oocytes injected with the rat OAT1 
decreased by approximately 15 % in sodium-free medium, whereas the hOAT1-1-
mediated PAH uptake decreased by 10 % (Sekine et al 1997, Hosoyamada et al 1999).  
In the latter case, the oocytes were passively preloaded by overnight incubation in 
medium containing 1 mM glutarate (Hosoyamada et al 1999).  In addition, Sekine and 
co-workers showed that passive glutarate uptake into non-injected control oocytes was 
decreased by half when sodium was replaced by choline (Sekine et al 1997).  It has also 
been shown in studies of fROAT, ROAT1, and hOAT1 that passive glutarate loading of 
oocytes increases subsequent PAH uptake (Wolff et al 1997, Sweet et al 1997, Cihlar et 
al 1999).  Taken together, these results could indicate that replacing sodium with 
choline leads to inhibition of an endogenous sodium/dicarboxylate cotransporter in the 
oocytes.  Although the relative importance of re-uptake of exchanged dicarboxylates for 
transport of PAH by OAT1 in heterologous expression in oocytes is not certain, import 
of dicarboxylate back into the cells of rabbit proximal tubules has been calculated to 
contribute approximately 50 % of the dicarboxylate exchange partner for the uptake of 
the organic anion fluoresecein by this functionally coupled system (Welborn et al 2000).  
Removal of sodium could thus prevent recycling of exchanged α-ketoglutarate and 
slowly decrease the intracellular concentration available for continuing PAH uptake into 
the oocyte. 
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5.1.2.4 Cis-inhibition of hROAT1-mediated PAH uptake 
Various organic anions were tested for the ability to cis-inhibit PAH transport by 
hROAT1.  As hROAT1 is believed to be an organic anion/dicarboxylate exchanger, a 
range of dicarboxylates were tested for the ability to inhibit hROAT1-mediated PAH 
uptake.  Significant inhibition of hROAT1-mediated PAH uptake was observed with 
glutarate, adipate, pimelate and suberate, consistent with the predicted model for a 
minimum charge separation required for inhibition of PAH transport (Ullrich 1997). 
This is also consistent with in situ inhibition of PAH transport in stopped flow capillary 
perfusion studies of rat proximal tubules; for unsubstituted dicarboxylates, cis-inhibition 
was moderate with succinate and stronger for all larger dicarboxylates tested (Ullrich et 
al 1987).  In analysis of the rat OAT1 in oocytes, the inhibition spectrum was similar to 
the in vivo data with the exception that succinate did not inhibit PAH uptake (Uwai et al 
1998).  Furthermore, fROAT-mediated PAH uptake was only inhibited by unsubstituted 
dicarboxylates with a carbon backbone of five or more carbons (Wolff et al 1997).   
 
Inhibition by intermediates of the TCA cycle was also investigated, in order to ascertain 
whether common physiological dicarboxylates interact with hROAT1.  Of this group, 
only α-ketoglutarate significantly inhibited PAH uptake into hROAT1-injected oocytes.  
In contrast to the data of Ullrich and co-workers, PAH uptake into hROAT1-injected 
oocytes was not affected by fumarate (Ullrich et al 1987).  Although the potential 
inhibition of the rat OAT1 by fumarate was not tested, fumarate did not inhibit fROAT-
mediated PAH uptake (Wolff et al 1997).  Of the aliphatic dicarboxylates tested with 
the isolated OAT1 clones, only citrate affects PAH uptake in a species-dependent 
manner.  In contrast to its inability to inhibit hROAT1-mediated PAH uptake, citrate 
was shown to reduce PAH uptake by fROAT by 45 % (Wolff et al 1997).  In general 
however, the inhibition by dicarboxylates of heterologously expressed OAT1 
homologues corresponds to the previously obtained data from in situ studies. 
 
Like PAH, urate is also transported in the proximal tubule, but the system does not 
show the same conservation between species as seen for PAH transport by OAT1. 
Transport steps are shared by these anions in some species but not others, and 
furthermore, urate is either reabsorbed or secreted depending on the species investigated 
(Pritchard and Miller 1993).  In basolateral membrane vesicles from human kidney, 
urate transport was found to be electrogenic, and was not stimulated by α-ketoglutarate 
in the presence of an inwardly directed NaCl gradient, conditions which stimulated 
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PAH uptake, suggesting separate transport systems (Guisan and Roch-Ramel 1995).  
That urate only moderately inhibits hROAT1-mediated PAH transport is consistent with 
this report, and suggests that urate is not transported by hROAT1.  In support of this, 
PAH uptake by the human OAT1 clone of Race and co-workers was not inhibited by 
urate, nor was urate transported by hOAT1 (Race et al 1999).  In contrast, the longer 
human OAT1 isoform, hOAT1-1, was inhibited by over 90 %, although urate uptake 
was not reported (Hosoyamada et al 1999).  As the concentrations of PAH and urate 
applied varied in these studies, direct comparison is difficult.  Furthermore, PAH 
transport by the rat OAT1 was either inhibited (Sekine et al 1997) or unaffected (Sweet 
et al 1997) by urate.  In the former study, urate was also transported at low levels, 
contradicting the findings in rat basolateral membrane vesicles, where urate uptake was 
not stimulated by an inwardly directed sodium gradient and α-ketoglutarate,. meaning it 
could not have been exchanged by the PAH transport system (Polkowski and Grassl 
1993). 
 
Another class of compounds, the lithocholic acid derivatives, were tested for the ability 
to inhibit the transport of PAH by hROAT1.  Lithocholic acid is formed from the 
primary bile acid chenodeoxycholic acid by bacteria in the intestine (MacDonald et al 
1983), and is metabolized in humans by conjugation to glycine and taurine in the liver 
(Palmer and Bolt 1971).   Lithocholic acid and its conjugated derivatives are highly 
cholestatic in animals (van der Meer et al 1988), and although sulfation reduces the 
toxicity of taurolithocholic acid, it does not  affect that of glycolithocholic acid (Dorvil 
et al 1983).  Sulfation of these compounds, which increases polarity, takes place in the 
human liver (Kuiper et al 1985), and has been shown to increase renal excretion of 
glycolithocholic acid in rats (Palmer 1971).  During cholestasis, hepatic uptake of bile 
acids is decreased to protect hepatocytes from their toxic effects (Trauner et al 1998), 
consistent with the  increase in serum levels of sulfated lithocholates in children with 
cholestasis (Balistreri et al 1981).  In addition, renal excretion of bile acids in patients 
with liver cirrhosis increases, and approximately 80 % of the these bile acids are 
sulfated (Stiehl et al 1975).  Thus the potential involvement of hROAT1 in renal 
excretion of lithocholate derivatives was investigated by cis-inhibition studies.  In 
hROAT1-injected oocytes, taurolithocholate slightly inhibited PAH uptake, and this 
effect was increased by sulfation, similar to the inhibition of fROAT-mediated PAH 
transport by these compounds (NA Wolff, pers. comm.) suggesting the possibility of 
transport by hROAT1.  As intestinal reabsorption is not decreased by sulfation, which 
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lowers biliary excretion (van der Meer et al 1988), hROAT1 may be involved in the 
observed decrease in the toxicity of taurolithocholate following sulfation.  In contrast, 
neither form of glycolithocholate inhibited hROAT1-mediated PAH uptake.  This is 
consistent with the observations in healthy human probands, in which sulfation of 
glycolithocholate does not increase renal excretion (Cowen et al 1975).   
 
The loop diuretics bumetanide and furosemide also inhibited hROAT1-mediated PAH 
uptake into oocytes, consistent with the inhibition of the rat OAT1 and human OAT1 
isoform hOAT1-1 by furosemide (Sekine et al 1997, Hosoyamada et al 1999), and the 
inhibition of fROAT by bumetanide (Wolff et al 1997).  The pharmacological effect of 
loop diuretics is the inhibition of the Na+/K+/2Cl- cotransporter in the luminal 
membrane of the ascending limb of the loop of Henle (Jackson 1996).  As bumetanide 
and furosemide are extensively bound by plasma proteins yet efficiently cleared by the 
human kidney, they must be transported through the proximal tubule cell to reach their 
luminal site of action, and the human OAT1 has already been proposed to be the protein 
responsible (Jackson 1996, Hosoyamada et al 1999).  Although this is supported by the 
fROAT-mediated bumetanide uptake reported in oocytes (Burckhardt et al 1999), in 
some species bumetanide and furosemide seem to be transported by different 
transporters.  The excretion of furosemide and bumetanide in cats, where probenecid 
concentrations inhibiting PAH and furosemide clearance do not effect bumetanide 
clearance, suggests that furosemide, but not bumetanide, is a substrate of OAT1 
(Friedman and Roch-Ramel 1977).  In contrast, PAH excretion in dogs was slightly 
decreased by bumetanide, and the clearance of bumetanide itself was similar to that of 
PAH and was inhibited by probenecid (Østergaard et al 1972).  Moreover, furosemide 
causes diuresis in rats and inhibits the rat OAT1 (Sekine et al 1997), whereas 
bumetanide has no diuretic effect and is almost completely metabolized (Østergaard et 
al 1972).  When expressed in oocytes, hROAT1 did not stimulate uptake of labeled 
bumetanide suggesting that, like probenecid, bumetanide is a non-transportable inhibitor 
of hROAT1, and reaches the lumen via a system distinct from hROAT1.  Whether 
furosemide is transported by hROAT1 awaits uptake studies with labeled furosemide.  
 
5.1.3 Role of OAT1 in basolateral organic anion uptake 
 
Based on its transport properties, OAT1 appears to have a major role in the basolateral 
uptake step of renal organic anion transport.  Further evidence suggests that basolateral 
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uptake of organic anions is a more complex process than previously thought, and is 
mediated by a range of transporters with partly overlapping specificity.  As well as the 
loop diuretics bumetanide and furosemide discussed above, the uricosuric drug 
probenecid also has a luminal site of action and is secreted by the proximal tubule cell, 
but it is not transported by OAT1; in rOAT1-injected oocytes, no rOAT1-specific 
uptake was detected by high performance liquid chromatography following incubation 
with probenecid (Uwai et al 1998).  In addition, the OAT1 homologues from different 
species display varying spectra of substrate specificity.  Expressed in oocytes, the rat 
OAT1 transports, in addition to PAH, dicarboxylates, urate, and low levels of cyclic 
nucleotides, folate and its analogue methotrexate, and prostaglandin E2 (Sekine et al 
1997).  In contrast, the human OAT1 expressed in HeLa cells transported α-
ketoglutarate, but was neither inhibited nor able to transport methotrexate or 
prostaglandin E2 (Lu et al 1999), and did not transport urate when expressed in oocytes 
(Race et al 1999). 
 
In addition to the endogenous substrates listed above, recent studies have demonstrated 
the transport of exogenous organic anions of diverse structure: β-lactams and non-
steroidal anti-inflammatory drugs (NSAIDs) are transported by the rat OAT1 (Jariyawat 
et al 1999, Apiwattankul et al 1999), and nucleoside analogues are transported by both 
the rat and human OAT1 (Cihlar et al 1999).  Salicylate, acetylsalicylate and 
indomethacin, are NSAIDs transported by the rat OAT1, shown in a study also 
demonstrating that OAT1 can act as hetero- and homoexchanger, as PAH efflux was 
stimulated by PAH, glutarate and NSAIDs (Apiwattankul et al 1999).  These results 
suggest multispecificity of both the extracellular and intracellular substrate binding 
sites.  
 
Adding to the complexity of renal organic anion transport, a number of recently cloned 
and/or characterized transporters exhibit low level organic anion transport, and have 
been added to the OAT subfamily of the organic cation transporter family.  The OAT2 
transporter (discussed in more detail in section 5.2) cloned from rat liver, is also found 
in the human liver, and is expressed in the kidney of both species (Simonson et al 1994, 
Sekine et al, 1998b, authors own unpublished results).  The more recently characterized 
OAT3 from the rat is also expressed in the human kidney, but the human form has yet 
to be characterized (Kusuhara et al 1999, Race et al 1999).  A further member, OAT4, 
was cloned from human kidney and is also expressed in the placenta (Cha et al 2000).  
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These OAT proteins also interact with a diverse range of anionic substrates, although 
the driving force for these proteins has yet to be elucidated (Cha et al 2000); none has 
been shown to function by an exchange mechanism similar to OAT1.  In addition to 
these transporters, two as yet uncharacterized cDNAs were isolated from the kidney: 
RST from the mouse (Mori et al 1997) and UST1 from the rat (Schömig et al 1998).  
These show 49 and 39 % identity to hROAT1, respectively, and are considered 
members of the OAT family (Sekine et al 2000).  The potential involvement of these 
transporters in basolateral uptake of organic anions in the kidney, however, awaits 
studies of their subcellular localization, and in some cases function.  
 
5.1.4 Mutational analysis of hROAT1 
 
5.1.4.1 Site-directed mutagenesis 
Mutational analysis of hROAT1 was undertaken with the aim of defining regions 
essential for PAH transport.  As previous studies have shown that acidic residues are 
involved in the translocation of organic cations by a variety of transporters (Pourcher et 
al 1993, Merickel et al 1995), it is possible that basic residues play a role in interaction 
between the organic anion transporters and their substrates.  Comparing the known 
members of the organic anion-transporting OATs with the organic cation-transporting 
OCTs, it became apparent that three positively charged residues conserved in all OATs 
are negatively charged or neutral in OCTs.  The positively charged residues at positions 
34 (histidine), 382 (lysine) and 466 (arginine) in hROAT1 align with isoleucine 
(neutral), alanine (neutral) and aspartate (positive) residues found at the corresponding 
positions in all OCTs.  When these specific lysine and arginine residues in the fROAT 
were mutated to alanine and aspartate, respectively, PAH transport was reduced by 
approximately 90 %, suggesting an involvement of these residues in the interaction of 
fROAT with PAH (Wolff et al 2000).  Futhermore, mutation of the arginine residue 
changed the affinity of the transporter for PAH, and after both mutations, glutarate no 
longer inhibited PAH uptake (Wolff et al 2000).  For this reason, lysine at position 382 
and arginine at position 466 in hROAT1 were chosen for further study. 
 
Following site-directed mutagenesis of lysine 382 to alanine and arginine 466 to 
aspartate, the corresponding residues conserved in all OCTs, total abolition of PAH 
uptake was observed.  This result suggests an involvement of these residues in the 
interaction of hROAT1 with PAH.  However, such a conclusion must be treated with 
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caution.  The major problem with this assumption is lack of evidence for the proper 
targeting of these hROAT1 mutants to the plasma membrane.  Such a demonstration 
requires immunological evidence, usually obtained via antibody detection of the protein 
at the membrane, using either protein-specific antibodies or insertion of an epitope tag 
within the reading frame in conjunction with tag-specific antibodies (Shih et al 1998).  
Unfortunately, an antibody synthesized against a region of the large extracellular loop 
of hROAT1 detected multiple bands in solubilized native plasma membrane vesicles, 
and thus did not have the hoped for specificity (N. A. Wolff, pers. comm.).  Any 
definitive conclusions as to the effect of these point mutations on hROAT1 function 
await immunological proof of their appearance in the plasma membrane. 
 
Despite the lack of immunological proof for correct routing of the K382A and R466D 
hROAT1 mutants to the membrane, there is some evidence to suggest that they 
represent non-functional transporters localized in the membrane.  A similar analysis of 
fROAT, in which the same conserved residues were mutated, also lead to disruption of 
fROAT function (Wolff et al 2000), and these mutants appear to be properly targeted to 
the membrane (NA Wolff, pers. comm.).  However, the oocytes injected with the 
fROAT mutants were still able to transport PAH at levels significantly greater than 
those observed in control oocytes.  The overall effect of these mutations was to decrease 
the rate of PAH uptake by more than 90 %, from ~35 to ~3 pmol/oocyte*hr.  In the case 
of the hROAT1 mutants, such a decrease in PAH uptake would show no significant 
difference to that of control oocytes.   
 
Similar results were observed in a study of the rat OCT1, in which the conserved 
aspartate residue at position 475 was mutated to a basic residue (Gorboulev et al 1999).  
These mutants, when expressed in the HEK 293 cell line, were detected at the plasma 
membrane.  In this study, Vmax values for the transport of various organic cations were 
decreased by 89-98 %.  However, the high original values of transport mediated by 
wild-type rOCT1 meant that uptake by mutant-expressing cells, although greatly 
reduced, was still significantly higher than controls.  As such, expression of the K382A 
and R466D mutants in an appropriate cell line may provide more meaningful results.  In 
preliminary results with transiently transfected COS-7 cells for example, hROAT1 
mediated PAH uptake at levels more than 100-fold over that obtained in cells 
transfected with vector only (authors own observations).  Using this expression system 
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it may be possible to observe function of these mutants that is beyond detection in 
oocytes, which would in turn be complemented by immunological studies. 
 
5.1.4.2 Deletion mutants 
In addition to the point mutations discussed above, deletion mutants of hROAT1 were 
also created.  An N-terminal deletion mutant was constructed to resemble rOCT1A, an 
alternatively spliced isoform of the rat organic cation transporter rOCT1 that was shown 
to mediate organic cation transport despite the predicted loss of the first two 
transmembrane domains (Zhang et al 1997).  In contrast to the retention of function by 
rOCT1A, this shortened hROAT1 mutant was unable to mediate PAH uptake when 
expressed in oocytes.  As discussed previously for the two hROAT1 point mutants, it is 
not certain that the shortened hROAT1 cRNA directed the synthesis of a polypeptide 
that was correctly inserted into the plasma membrane of the oocyte.  Also, rOCT1A is a 
splice variant rather than a simple deletion mutant.  Translation of rOCT1A is predicted 
to begin in an alternate reading frame before returning to the reading frame that it shares 
with rOCT1 following the splicing event linking exons 1 and 2 (Zhang et al 1997).  
Thus, the initial 46 amino acids of rOCT1A show no homology to rOCT1, and therefore 
rOCT1A is not simply a deletion mutant.  If a similar removal of exon 2 from the 
hROAT1 reading frame occurred, it would yield a shortened protein due to an in frame 
stop codon, with no homology to hROAT1 following the splicing event.  Further 
investigation of the role in transport of the N-terminal part of hROAT1 awaits the 
ability to detect such mutants in the membrane. 
 
As mentioned earlier, the expression of four distinct transcripts from the human OAT1 
gene has been detected in the kidney.  All four appear to be generated by alternative 
splicing events involving exons 9 and 10.  To determine whether these exons contain 
regions essential to the transport process, two C-terminal deletion mutants were 
constructed in which either exon 10 alone (terminal 28 amino acids) or exons 9 and 10 
together (terminal 97 amino acids) were removed.  Following removal of both exons 9 
and 10, hROAT1 was no longer able to mediate PAH uptake.  Once more, it is not 
certain whether this mutant reaches the membrane.  If correct membrane insertion is 
assumed, the lack of function is not surprising as this region contains the conserved 
arginine at position 466 that appears to be involved in the transport process, and 
suggests that the first eight exons do not encode a polypeptide capable of mediating 
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PAH transport.  Again, further investigation of this mutant requires the ability to detect 
its presence in the membrane. 
 
The deletion from hROAT1 of exon 10 alone was more interesting.  This manipulation 
resulted in a two-fold increase in PAH uptake, strongly suggesting that this mutant  
reaches the membrane. The intracellular location of the C-terminal 26 amino acids 
encoded by exon 10 would suggest that they are not involved in substrate binding, and  
exon 10 is also the least conserved between members of the OAT family.  Although 
conclusions concerning the molecular basis of this effect require further investigation, 
the increased transport of PAH by removal of exon 10 may be due a disruption in the 
post-translational regulation of hROAT1. The amino acid sequences of the OAT1 
homologues from all species contain consensus sites for phosphorylation by several 
protein kinases.  Protein kinase-mediated down-regulation of the organic anion 
transporting system has been documented in a variety of systems (Roch-Ramel 1998).  
For example, recent studies have shown that activation of PKC leads to down-regulation 
of PAH transport by the human and rat OAT1 homologues (Lu et al 1999, Uwai et al 
1998).  The presence of PKC consensus sites in the cloned OAT1 homologues has lead 
to the suggestion that PKC-dependent OAT1 down-regulation results from direct 
phosphorylation (Uwai et al 1998). 
 
The mechanism responsible for this effect, however, has yet to be elucidated. Although 
phosphorylation of the mouse OAT1 homologue at serine residues does occur, as 
evidenced by an increased phosphorylation state following inhibition of protein 
phosphatase by okadaic acid, direct phosphorylation of the mouse OAT1 homologue by 
PKC was not observed (You et al 2000).  In any case, exon 10 does not encode 
consensus sites for phosphorylation by PKC, suggesting that the effect of deleting exon 
10 is not related to a change in PKC-dependent phosphorylation.  A consensus site for 
tyrosine kinase (TK) is found in this region, but the activation of this kinase showed no 
effect on hOAT1-mediated PAH uptake in transiently-transfected cells (Lu et al 1999).  
Furthermore, inhibition of TK in isolated S2 segments of the rabbit proximal tubule lead 
to a decrease of 25 % in PAH uptake (Gabriëls et al 1999).  Neither of these 
observations correspond to the effect of deleting exon 10 from hROAT1, suggesting 
that the mechanism responsible is also unrelated to phosphorylation involving TK.  The 
study by Gabriëls and co-workers also showed that inhibition of phosphatidylinositol 3-
kinase (PI3K) and mitogen-activated protein kinase (MAPK) decreased PAH uptake by 
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20-30 %, however, the hROAT1 amino acid sequence contains no predicted consensus 
sites for phosphorylation by these kinases. 
 
Also present in exon 10 is a consensus site for casein kinase II (CKII)-dependent 
phosphorylation, found in all members of the OAT family (Sweet and Pritchard 1999).  
The major roles of this kinase appear to be in signal transduction and  regulation of the 
cell cycle.  A recent review of the literature suggests that a role for CKII in the 
regulation of renal organic anion transport has not been investigated.  Interestingly, 
CKII has been shown to phosphorylate the vesicular monoamine transporter VMAT2, a 
monoamine neurotransmitter transporter found in the rat brain (Krantz et al 1997).  This 
phosphorylation occurs at sites near the end of the C-terminus, similar to the location of 
the CKII site found within the exon 10-encoded C-terminus of hROAT1, and is 
abrogated by mutation of the serine residues in the casein kinase II consensus sequence.  
In contrast, the related monoamine transporter VMAT1, which displays different 
subcellular localization, is not phosphorylated at the C-terminus by CKII (Krantz et al 
1997).   Furthermore, phosphorylation by CKII has been demonstrated to change the 
intracellular location of the endoprotease furin (Takahashi et al 1995).  Although the 
effect of CKII-dependent phosphorylation on the transport properties of VMAT2 has 
yet to be determined, it would be of interest to investigate whether mutation of the CKII 
site in the tenth exon of hROAT1 and/or specific inhibition of CKII have the same 
effect on transport as complete deletion of exon 10.  This would raise the possibility that 
CKII is responsible for the observed phosphorylation of mOAT1 at serine residues, as 
mOAT1 also has a CKII site at the C-terminal end.  
 
5.2 CLONING OF hOAT2 
 
5.2.1 Cloning and expression of an OAT2 homologue from human kidney  
 
In comparison with the active basolateral uptake of organic anions, efflux at the luminal 
membrane is poorly understood.  There are several possible reasons for this 
discrepancy.  Whereas a highly conserved system couples organic anion uptake to the 
sodium gradient at the basolateral membrane, such conservation is not observed in 
luminal efflux in which urate-secreting and urate-reabsorbing species differ.  
Furthermore, the high intracellular accumulation of organic anions in proximal tubule 
cells suggests that the luminal system has low affinity for transported substrates.  
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Isolation of proteins involved in luminal efflux using expression cloning is hindered by 
the lack of a sensitive assay that is not masked by OAT1-mediated PAH uptake, and in 
addition, both systems are inhibited by probenecid. 
 
As mentioned in previous sections, a number of recently cloned and characterized  
transporters are related to OAT1 on the sequence level.  One of these, NLT, was 
initially cloned from rat liver, but no function could be demonstrated (Simonson et al 
1994).  NLT was later characterized as an organic anion transporter, and consequently 
renamed rOAT2 (Sekine et al 1998). Expressed in oocytes, rOAT2 mediated low 
affinity PAH transport and could not be trans-stimulated by dicarboxylates, properties 
consistent with one of the luminal efflux systems for PAH observed in brush border 
membrane vesicles (Roch-Ramel 1998).  Northern blot analysis revealed highest levels 
of expression in the liver with lower levels present in the kidney (Simonson et al 1994, 
Sekine et al 1998).  To investigate the possibility that an OAT2 homologue has a role in 
the luminal efflux step of organic anion transport, it was first determined whether an  
OAT2 homologue is expressed in the human kidney.  
 
The expression of a human OAT2 homologue in human kidney was demonstrated using 
an EST-based cloning strategy, and lead to the isolation of a cDNA encoding a 541 
amino acid protein that was named hOAT2.   This cDNA sequence was deposited in 
GeneBank with the accession number AF210455, and is the first evidence for the 
presence of an OAT2 homologue in the human kidney.  Following subcloning of the 
open reading frame between the fNaDC-3 UTRs, the ability of hOAT2 to mediate the 
transport of organic anions was tested in oocytes. Uptake of PAH, glutarate or α-
ketoglutarate was not enhanced in oocytes injected with hOAT2, in contrast to the 
results obtained for the rOAT2 for which PAH and α-ketoglutarate uptake was 
demonstrated (Sekine et al 1998).  There are several possible explanations for this 
discrepancy.  Firstly, the affinity of the human and rat OAT2 clones for the substrates 
tested may not be identical.   Such a difference was also observed for the uptake of 
nucleoside analogues by the human and rat OAT1 homologues.  The calculated Km 
values of the rat OAT1 for cidofovir and adefovir are 6 and 9 times greater, 
respectively, than those of the human OAT1 (Cihlar et al 1999).  In addition, unlike the 
expression cloning strategy used to clone the OAT1 homologues, NLT was  originally 
cloned by immunological screening of an expression library to identify clones 
recognized by a monoclonal antibody specific for a hepatocyte membrane protein 
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(Simonson et al 1994).  The cDNAs encoding UST1 and RST from rat and mouse 
kidney, respectively, were also identified by sequence-based cloning strategies rather 
than expression cloning, and have yet to be functionally characterized (Schömig et al 
1998, Mori et al 1997).  The advantage of the expression cloning approach is that a 
suitable substrate for the transporter is already known.  In the case of hOAT2, a high 
affinity substrate has yet to be identified.    
 
Another possible explanation for the inability of hOAT2 to mediate transport of the 
organic anions tested is the disruption of the TIXXEWDLVC motif in the second 
transmembrane domain.  This motif is common to members of the ASF subfamily of the 
major facilitator superfamily, and is present in the sequences of all OATs isolated to 
date (Schömig et al 1998, personal observation).  In the reading frames of hOAT2 and 
hNLT this motif is interrupted by the insertion of serine and glutamine between the 
glutamate and tryptophan residues.  The importance of the conserved ASF motifs for 
the structure and/or function of these transporters has yet to be investigated, but it is of 
interest to note that the reading frame of rOAT2, the only functionally characterized 
OAT2 to date, does contain this sequence perturbance (Simonson et al 1994, Sekine et 
al 1998).   
 
Three distinct hOAT2 transcripts of similar size were isolated from human kidney 
cDNA, with predicted open reading frames encoding 541, 295 and 271 amino acids, 
respectively.  These transcripts appear to be the result of alternative splicing events.  
The synthesis of alternatively spliced transcripts has previously been reported for the 
human and rat OAT1 genes (Hosoyamada et al 1999, Bahn et al 2000, Jariyawat et al 
1999), and the related rat OCT1 (Zhang et al 1997).  Furthermore, a transcript very 
similar to the human OAT3 cloned by Race and co-workers recently appeared in the 
GenBank database.  From comparison of the two OAT3 nucleotide sequences, they also 
appear to be splice variants generated from the same gene, although confirmation of  
this suggestion awaits genomic characterization of the OAT3 gene.  In all of these 
examples, the size of the reading frame remains relatively constant in contrast to the 
dramatic shortening of the hOAT2 reading frame.  The characterization of the function, 
if any, of these shorter reading frames awaits the identification of a suitable substrate for 
hOAT2 with which to compare all three isoforms, and demonstration of the synthesis of 
the respective proteins in vivo. 
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5.2.2 Comparison of hOAT2 with a liver-specific OAT2 homologue 
 
As detailed in the results, the initial amplification of a human OAT2 sequence was 
carried out with a liver cDNA template, and was then cloned in its entirety from human 
kidney cDNA.  This was done to maximize the chance of amplifying an OAT2 
homologue, since it was previously shown in the rat that OAT2 is expressed at higher 
levels in the liver than in the kidney (Simonson et al 1994, Sekine et al 1998).  Similar 
to the difficulties reported for hROAT1, it was not possible to amplify the remainder of 
the OAT2 reading frame from the same liver cDNA template using the RACE 
technique.  Again, this result is probably due to degradation of the template, as 
amplification of a GAPDH internal standard was also unsuccessful in subsequent PCRs.  
Shortly after the isolation of the OAT2 sequence from human kidney, a second OAT2 
homologue, termed hNLT, appeared in the GenBank database.  The sequence represents 
a full OAT2 open reading frame from human liver, and is identical on both nucleotide 
and amino acid level to kidney-derived hOAT2 until the predicted start of exon 10, after 
which both sequences are fully divergent, predicting proteins with non-homologous C-
termini. The perfect homology between the first nine exons of the two nucleotide 
sequences and the inability to amplify the hNLT transcript from human kidney, suggests 
that hNLT is a liver-specific alternative transcript from the same gene. 
 
Divergence in exon 10 sequence, in comparison to the overall homology of the human 
and rat OAT2 clones, is consistent with analysis of sequence data from OAT1 
homologues, in which exon 10 is also the least conserved between species.  However, 
there is no precedence for the difference in sequence between two OAT cDNAs isolated 
from different tissues of the same species.  The four human OAT1 isoforms isolated to 
date all originate from the kidney (Hosoyamada et al 1999, Bahn et al 2000).  Human 
OAT1 has also been detected by Northern blots in placenta and brain (Hosoyamada et al 
1999) and by RT-PCR in pancreas, eye and brain (A Bahn pers. comm.), but possible 
tissue-specific sequence differences have yet to be investigated.  Interestingly, the 
amino acid sequences of the C-termini of hOAT2, hNLT and rOAT2 differ with respect 
to the protein kinase sites they encode.  Casein kinase II (CKII) sites present in the C-
termini of hNLT and rOAT2 (Simonson et al 1994), both isolated from the liver, are 
absent from the C-terminus of hOAT2.  As discussed previously, CKII phosphorylates 
the serine residues in the C-terminus of the monoamine transporter VMAT2, but does 
not phosphorylate the C-terminus of the related VMAT1 (Krantz et al 1997).  
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Furthermore, these proteins exhibit different subcellular localization and 
phosphorylation has been implicated in this process.  Thus, the involvement of 
alternative tissue-specific C-termini in regulation of the human OAT2 is an attractive 
hypothesis that requires further investigation. 
 
5.2.3 Apical proteins mediating organic anion transport 
 
As discussed earlier in this section, the ultimate goal of cloning hOAT2 to assess a 
possible role in luminal efflux of organic anions from the proximal tubule cell, must 
await functional characterization as well as studies of the subcellular localization in the 
kidney.  Interestingly, NPT1 and MRP2, two transporters localized to the luminal 
membrane in the proximal tubule cells, have recently been shown to transport PAH 
(Uchino et al 2000, Leier et al 2000).  NPT1was initially cloned and characterized as a 
sodium-dependent inorganic phosphate transporter (Miyamoto et al 1995).  PAH 
transport mediated by NPT1 was shown to be of low affinity, with a Km of 2.66 mM, 
and was influenced by chloride ions and pH.  The effect of increasing chloride 
concentration was a decrease in PAH uptake, consistent with the proposed in vivo 
efflux of PAH in the presence of an inwardly directed chloride gradient (Uchino et al 
2000).  MRP2 is a multidrug resistance protein which is located apically in polarized 
cells (Schaub et al 1997).  In membrane vesicles derived from HEK293 cells expressing 
MRP2, ATP-dependent PAH transport took place, with a calculated Km of 880 µM 
(Leier et al 2000).  Furthermore, this transport was inhibited by the mycotoxin 
ochratoxin A, which itself was shown to be transported by MRP2 (Leier et al 2000).  
Interestingly, based on its substrate specificity and apical localization, several authors 
have previously proposed a role for MRP2 in luminal efflux of the nephrotoxic 
nucleoside analogues and β-lactams (Cihlar et al 1999, Jariyawat et al 1999).  Transport 
of PAH by NPT1 and MRP2, therefore, represents the first reports of PAH transport by 
proteins located in the luminal membrane of proximal tubule cells, although their role in 
vivo awaits further investigation. 
 
5.3 CONSTRUCTION OF AN hROAT1: hOAT2 CHIMERA 
 
A chimera consisting of the N-terminal half of hOAT2 fused to the C-terminal half of 
hROAT1 was constructed.  The rational for creating this chimeric protein was based on 
evidence from studies of related transporters suggesting that the C-terminal half of these 
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proteins may have a significant role in the transport process.  Firstly, the C-terminal half 
of hROAT1 contains two of the three positively charged residues conserved in all OATs 
and negatively charged or neutral in OCTs.  As discussed previously, the conserved 
lysine and arginine residues in the eighth and eleventh transmembrane domains, 
respectively, appear to be involved in substrate interaction based on mutagenesis studies 
in fROAT (Wolff et al 2000).  Further support for this suggestion comes from a study of 
rOCT1A, an isoform of the rat organic cation transporter rOCT1 (Zhang et al 1997).  In 
this study, an artificially shortened reading frame was constructed that corresponded to 
one of the three possible reading frames of the rOCT1A cDNA.  This reading frame, 
termed Pro3, was predicted to encode a 354 amino acid protein resembling rOCT1 
without the first 202 amino acids encoded by the rOCT1 cDNA, corresponding to the 
first three transmembrane domains (Zhang et al 1997).  When expressed in oocytes, 
Pro3 not only mediated organic cation uptake, but did so at levels almost twice those 
mediated by rOCT1 itself (Zhang et al 1997).  It was therefore hoped that fusing the N-
terminal half of hOAT2 to the C-terminal half of hROAT1 may produce a functional 
transporter. 
 
When expressed in oocytes, the hOAT2:hROAT1 chimera was not able to mediate PAH 
uptake.  Whether this results from an inherent lack of function of the chimera, or failure 
to reach the membrane remains to be elucidated.  If found to be non-functional at the 
membrane, it may be that the parent transporters are too functionally distinct to yield 
functional chimeric proteins.  Although many functional chimera have been constructed 
from related transport proteins providing insights into the location of functional 
domains and substrate binding sites, these have tended to be more closely related on 
either the functional or structural level.  For example, functional chimera were 
generated from N1 and N2 type Na+-dependent nucleoside transporters.  These 
transporters have different substrate specificities (purine and pyrimidine selective, 
respectively) but both transport their respective substrate via cotransport with sodium 
and are structurally similar (Wang and Giacomini 1997).  Chimera between the rabbit 
Na+/dicarboxylate transporter from the rabbit and the Na+/sulfate transporter of the rat, 
which have only 43 % sequence identity, were nevertheless functional, probably 
because the respective substrates are similarly cotransported with sodium (Pajor et al 
1998). 
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5.4 OUTLOOK 
 
The human OAT1 homologue cloned and functionally characterized in this study is 
probably involved in the uptake of organic anions at the basolateral membrane during 
the excretion process.  The potential involvement of the human OAT2 homologue 
awaits functional characterization, which in turn requires the identification of a well-
transported substrate for this transporter.  The hROAT1 point mutants may be useful in 
further studies to determine regions of the transporter important for its multiple 
specificity.  Using the overlapping PCR technique, further chimera between hROAT1 
and hOAT2 could be constructed to aid this approach.  It may be possible to better 
characterize these mutants by expression in a mammalian system, for example the 
COS-7 cell line.  Epitope tagging of mutants and chimera will facilitate immunological 
studies to determine whether the mutants are correctly targeted to the membrane.  
Characterization of the hROAT1 deletion mutants suggest a possible regulatory role of 
the C-terminus encoded by exon 10.  This exon also appears to have a tissue specific 
expression in hOAT2.  Further mutational studies are needed to clarify the possible 
regulatory role of the C-termini of both transporters. 
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7 APPENDIX 
agcagagcaggttcctctcagctgcctgcagctcctttcccttcaaacggagccaaacta
ctttcctctggggatccATGGCCTTTAATGACCTCCTGCAGCAGGTGGGGGGTGTCGGCC
GCTTCCAGCAGATCCAGGTCACCCTGGTGGTCCTCCCCCTGCTCCTGATGGCTTCTCACA
ACACCCTGCAGAACTTCACTGCTGCCATCCCTACCCACCACTGCCGCCCGCCTGCCGATG
CCAACCTCAGCAAGAACGGGGGGCTGGAGGTCTGGCTGCCCCGGGACAGGCAGGGGCAGC
CTGAGTCCTGCCTCCGCTTCACCTCCCCGCAGTGGGGACTGCCCTTTCTCAATGGCACAG
AAGCCAATGGCACAGGGGCCACAGAGCCCTGCACCGATGGCTGGATCTATGACAACAGCA
CCTTCCCATCTACCATCGTGACTGAGTGGGACCTTGTGTGCTCTCACAGGGCCCTACGCC
AGCTGGCCCAGTCCTTGTACATGGTGGGGGTGCTGCTCGGAGCCATGGTGTTCGGCTACC
TTGCAGACAGGCTAGGCCGCCGGAAGGTACTCATCTTGAACTACCTGCAGACAGCTGTGT
CAGGGACCTGCGCAGCCTTCGCACCCAACTTCCCCATCTACTGCGCCTTCCGGCTCCTCT
CGGGCATGGCTCTGGCTGGCATCTCCCTCAACTGCATGACACTGAATGTGGAGTGGATGC
CCATTCACACACGGGCCTGCGTGGGCACCTTGATTGGCTATGTCTACAGCCTGGGCCAGT
TCCTCCTGGCTGGTGTGGCCTACGCTGTGCCCCACTGGCGCCACCTGCAGCTACTGGTCT
CTGCGCCTTTTTTTGCCTTCTTCATCTACTCCTGGTTCTTCATTGAGTCGGCCCGCTGGC
ACTCCTCCTCCGGGAGGCTGGACCTCACCCTGAGGGCCCTGCAGAGAGTCGCCCGGATCA
ATGGGAAGCGGGAAGAAGGAGCCAAATTGAGTATGGAGGTACTCCGGGCCAGTCTGCAGA
AGGAGCTGACCATGGGCAAAGGCCAGGCATCGGCCATGGAGCTGCTGCGCTGCCCCACCC
TCCGCCACCTCTTCCTCTGCCTCTCCATGCTGTGGTTTGCCACTAGCTTTGCATACTATG
GGCTGGTCATGGACCTGCAGGGCTTTGGAGTCAGCATCTACCTAATCCAGGTGATCTTTG
GTGCTGTGGACCTGCCTGCCAAGCTTGTGGGCTTCCTTGTCATCAACTCCCTGGGTCGCC
GGCCTGCCCAAATGGCTGCACTGCTGCTGGCAGGCATCTGCATCCTGCTCAATGGGGTGA
TACCCCAGGACCAGTCCATTGTCCGAACCTCTCTTGCTGTGCTGGGGAAGGGTTGTCTGG
CTGCCTCCTTCAACTGCATCTTCCTGTATACTGGGGAACTGTATCCCACAATGATCCGGC
AGACAGGCATGGGAATGGGCAGCACCATGGCCCGAGTGGGCAGCATCGTGAGCCCACTGG
TGAGCATGACTGCCGAGCTCTACCCCTCCATGCCTCTCTTCATCTACGGTGCTGTTCCTG
TGGCCGCCAGCGCTGTCACTGTCCTCCTGCCAGAGACCCTGGGCCAGCCACTGCCAGACA
CGGTGCAGGACCTGGAGAGCAGGAAAGGGAAACAGACGCGACAGCAACAAGAGCACCAGA
AGTATATGGTCCCACTGCAGGCCTCAGCACAAGAGAAGAATGGATTTTGAggtctagacc
ctcgcagaggagaagggtcagaggatcatcgtgtgaaggttcaacactaaacgtggactc
acgtcaacactgtgtcgctctgggagcttcagctttcacctgttgtgacgcttttcacaa
gcttttacattcaagtgtctttttaggctctcgaaagtgtcaagatttcattcagaacaa
gttcaaaacagctcgagctctgaagagttcgttttctatatttttgaaactccagtgtga
ctgcagagggcgctgtttgtattgatgaagaatgagagagaggcatctgtgaataattct
tttaaaaatatatatatatattttgggttgaaatcacccacagatcacgttacttgtgta
tttgttgtgttttaaatcttgtctgtattagcagatgaatcctgattaatgaacgtgtac
attttgttacagagtgatttgcaggtaatgcagtataaatgctgttacaaggaaaaaaaa
aaaaaaaaaaaaaaaaaaaaa
Appendix 1: Full nucleotide sequence of the hROAT1 expression clone.  The hROAT1 sequence is 
denoted by capital letters (start and stop codons underlined), and the fNaDC-3 5 and 3 UTRs sequences 
are italicized.  The BamHI and XbaI sites incorporated to enable subcloning are in bold. 
 
 
Appendix 2 (overleaf): Alignment of the hOAT2, hNLT and rOAT2 with the rat OAT2 gene, TI-
LTP.  The TI-LTP sequence is shaded grey, and intron sequences are in lower case.  The last homologous 
sequence shared by all three transcripts is shaded black. 
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TI-LTP tctgaggggcagactggactgcagaagaaagttcccagatggggccagcacagtccctggggtgacttagggcaaggtatgcgctccaga 90
catgggtgaggggtatgaggaaagtttggggtttaccagaaggcccccttacccaaggagaaccaagccctcattctgagccctgggctg 180
tgggccaaactgtgctgtggttgtaaatacacaagattgacctaaagcgttacaggacaaaggccaccgaggacagcgggcatcatgcca 270
ggggacctgttccccttatgtagcgttgaaggactaataagtaggtcgggcctcactgctttctccacacccagctggcctcctatggca 360
gcctggggttccccctcccctacctggttcctgaactccaatgtgtaaaggctcaagccgtagacaccatgatctccgatagatggcaac 450
acttccctttagatagaatctgtagaattgtgggtgatgggggagggcccaggcctggaccagccccctgaggggctggattctggctac 540
agattctccactcatcagtacaaccatttccacctccagagtccaagggtccatgtggtaagcagactgaaccgtcctagataccaaaga 630
hOAT2 ATGGGCTTTGAGGAGCTGCTGGAGCAGGTGGGCGGCTTTGGGCCCTTCCAACTGCGGAATGTGGCAC 7
hNLT ATGGGCTTTGAGGAGCTGCTGGAGCAGGTGGGCGGCTTTGGGCCCTTCCAACTGCGGAATGTGGCAC 7
rOAT2 ATGGGCTTCGAAGACCTGCTGGACAAGGTGGGCGGCTTTGGGCCCTTCCAACTTCGGAATCTGGTTC 80
TI-LTP gggacaccttgtgggtgggtagcATGGGCTTCGAAGACCTGCTGGACAAGGTGGGCGGCTTTGGGCCCTTCCAACTTCGGAATCTGGTTC 720
hOAT2 TGCTGGCCCTGCCCCGAGTGCTGCTACCACTGCACTTCCTCCTGCCCATCTTCCTGGCTGCCGTGCCTGCCCACCGATGTGCCCTGCCGG 127
hNLT TGCTGGCCCTGCCCCGAGTGCTGCTACCACTGCACTTCCTCCTGCCCATCTTCCTGGCTGCCGTGCCTGCCCACCGATGTGCCCTGCCGG 127
rOAT2 TGATGGCCCTGCCCCGAATGCTGCTCCCCATGCACTTTCTCCTGCCCGTCTTCATGGCCGCTGTGCCTGCCCACCATTGTGCCCTGCCCG 200
TI-LTP TGATGGCCCTGCCCCGAATGCTGCTCCCCATGCACTTTCTCCTGCCCGTCTTCATGGCCGCTGTGCCTGCCCACCATTGTGCCCTGCCCG 810
hOAT2 GTGCCCCTGCCAACTTCAGCCATCAGGATGTGTGGCTGGAGGCCCATCTTCCCCGGGAGCCTGATGGCACGCTCAGCTCCTGCCTCCGCT 187
hNLT GTGCCCCTGCCAACTTCAGCCATCAGGATGTGTGGCTGGAGGCCCATCTTCCCCGGGAGCCTGATGGCACGCTCAGCTCCTGCCTCCGCT 187
rOAT2 GTGCCCCTGCCAACCTCAGTCACCAGGACTTATGGCTGGAAGCCCATCTACCCCGGGAGACTGACGGCAGCTTTAGCTCCTGCCTCCGAT 260
TI-LTP GTGCCCCTGCCAACCTCAGTCACCAGGACTTATGGCTGGAAGCCCATCTACCCCGGGAGACTGACGGCAGCTTTAGCTCCTGCCTCCGAT 900
hOAT2 TTGCCTATCCCCAGGCTCTCCCCAACACCACGTTGGGGGAAGAAAGGCAGAGCCGT--------GGGGAGCTGGAGGATGAACCTGCCAC 303
hNLT TTGCCTATCCCCAGGCTCTCCCCAACACCACGTTGGGGGAAGAAAGGCAGAGCCGT--------GGGGAGCTGGAGGATGAACCTGCCAC 303
rOAT2 TTGCCTATCCCCAGACTGTCCCCAATGTCACTTTGGGGA--------CAGAGGTGTCCAACTCTGGGGAGCCTGAGGGTGAGCCCCTCAC 372
TI-LTP TTGCCTATCCCCAGACTGTCCCCAATGTCACTTTGGGGA--------CAGAGGTGTCCAACTCTGGGGAGCCTGAGGGTGAGCCCCTCAC 982
hOAT2 AGTGCCCTGCTCTCAGGGCTGGGAGTACGACCACTCAGAATTCTCCTCTACCATTGCAACTGAGTCCCAG-------------------- 359
hNLT AGTGCCCTGCTCTCAGGGCTGGGAGTACGACCACTCAGAATTCTCCTCTACCATTGCAACTGAGTCCCAG-------------------- 359
rOAT2 GGTGCCCTGCTCTCAGGGCTGGGAGTACGACCGCTCAGAATTCTCCTCCACCATTGCAACTGAG-------------------------- 432
TI-LTP GGTGCCCTGCTCTCAGGGCTGGGAGTACGACCGCTCAGAATTCTCCTCCACCATTGCAACTGAGgtacccaggcccagagggtgagggat 1072
TI-LTP gtgtgagtgggttgggcctgccgttctgttgggggtggtgtgggcccgagataaccttcctgtcttctcagagcttctcttccctgtgtg 1162
tagagagccagtggatttaaagctggattcagttcatttgtttataattcacctgaggtctaagggcagctccatggggttggaacagag 1252
gccgagaagtatatccctgtagtaagagaaagagaaactgcagaagcctccatttctcccctctttctcatttctatcccagggctggga 1342
tttatctgattcatccagagaggaaggggggtggggggactccccgaggagagagacgaccgcattccttggtggtggtgatggacctcc 1432
atgggaaaaagctcagcttcgggactagggagaggcaaagtctttgctttctgacgctgaggttgatggctagggatggggtatcttcca 1522
gaaagtcagagtcacctgggagcctggagaggaggggctggtgctggctggagaggggctcatacacatagagggccttccctgcctgtc 1612
hOAT2 -------TGGGATCTGGTGTGTGAGCAGAAAGGTCTGAACAGAGCTGCGTCCACTTTCTTCTTCGCCGGTGTGCTGGTGGGGGCTGTGGC 446
hNLT -------TGGGATCTGGTGTGTGAGCAGAAAGGTCTGAACAGAGCTGCGTCCACTTTCTTCTTCGCCGGTGTGCTGGTGGGGGCTGTGGC 446
rOAT2 -------TGGGATCTTGTGTGTCAGCAGAGAGGACTGAACAAAATTACGTCCACCTGCTTCTTCATTGGTGTGCTGGTGGGAGCCGTGGT 519
TI-LTP ttcgcagTGGGATCTTGTGTGTCAGCAGAGAGGACTGAACAAAATTACGTCCACCTGCTTCTTCATTGGTGTGCTGGTGGGAGCCGTGGT 1702
hOAT2 CTTTGGATATCTGTCCGACAGGT------------------------------------------------------------------- 499
hNLT CTTTGGATATCTGTCCGACAGGT------------------------------------------------------------------- 499
rOAT2 GTATGGATACTTGTCTGACAGGT------------------------------------------------------------------- 572
TI-LTP GTATGGATACTTGTCTGACAGGTgaattaagggaccagcgtggggacaggcctcatcatctgtatccgggaagccccatggaggacctga 1792
hOAT2 ----------------------TTGGGCGGCGGCGTCTGCTGCTGGTAGCCTACGTGAGTACCCTGGTGCTGGGCCTGGCATCTGCAGCC 537
hNLT ----------------------TTGGGCGGCGGCGTCTGCTGCTGGTAGCCTACGTGAGTACCCTGGTGCTGGGCCTGGCATCTGCAGCC 537
rOAT2 ----------------------TTGGCAGGCGCCGGCTTCTGCTGGTGGCCTACGTGAGCTCCCTGGTGCTGGGTCTGATGTCTGCAGCC 610
TI-LTP ccttgcatggcccttggcaggtTTGGCAGGCGCCGGCTTCTGCTGGTGGCCTACGTGAGCTCCCTGGTGCTGGGTCTGATGTCTGCAGCC 1882
hOAT2 TCCGTCAGCTATGTAATGTTTGCCATCACCCGCACCCTTACTGGCTCAGCCCTGGCTGGTTTTACCATCATCGTGATGCCACTGG----- 597
hNLT TCCGTCAGCTATGTAATGTTTGCCATCACCCGCACCCTTACTGGCTCAGCCCTGGCTGGTTTTACCATCATCGTGATGCCACTGG----- 597
rOAT2 TCCATCAACTACATCATGTTCGTAGTCACCCGTACACTCACCGGCTCAGCCCTGGCTGGCTTCACCATCATTGTGCTCCCACTGG----- 670
TI-LTP TCCATCAACTACATCATGTTCGTAGTCACCCGTACACTCACCGGCTCAGCCCTGGCTGGCTTCACCATCATTGTGCTCCCACTGGgtgag 1972
hOAT2 ------------------------------------------------------------------------------------------ 652
hNLT ------------------------------------------------------------------------------------------ 717
rOAT2 ------------------------------------------------------------------------------------------ 725
TI-LTP gcagacaaacatgggcgaggccagagggag------------------------gccgctggggtgagagggtccctgctaacggtctcc 2038
hOAT2 -----------------------AGCTGGAGTGGCTGGATGTGGAGCACCGCACCGTGGCTGGAGTCCTGAGCAGCACCTTCTGGACAGG 659
hNLT -----------------------AGCTGGAGTGGCTGGATGTGGAGCACCGCACCGTGGCTGGAGTCCTGAGCAGCACCTTCTGGACAGG 769
rOAT2 -----------------------AGTTGGAGTGGCTGGATGTGGAGCACCGCACTGTGGCCGGGGTCATCAGCACCGTCTTCTGGTCGGG 732
TI-LTP ccgtctcccgtgctggctcctagAGTTGGAGTGGCTGGATGTGGAGCACCGCACTGTGGCCGGGGTCATCAGCACCGTCTTCTGGTCGGG 2128
hOAT2 GGGCGTGATGCTGCTGGCACTGGTTGGGTACCTGATACGGGACTGGCGATGGCTTCTGCTAGCTGTCACCCTGCCTTGTGCCCCAGGCAT 779
hNLT GGGCGTGATGCTGCTGGCACTGGTTGGGTACCTGATACGGGACTGGCGATGGCTTCTGCTAGCTGTCACCCTGCCTTGTGCCCCAGGCAT 889
rOAT2 AGGCGTGCTGCTGCTGGCACTGGTGGGCTACCTGATCCGGAGCTGGCGCTGGCTTCTGCTGGCTGCCACCCTGCCGTGTGTCCCAGGCAT 852
TI-LTP AGGCGTGCTGCTGCTGGCACTGGTGGGCTACCTGATCCGGAGCTGGCGCTGGCTTCTGCTGGCTGCCACCCTGCCGTGTGTCCCAGGCAT 2218
hOAT2 CCTCAGCCTCTGGTG--------------------------------------------------------------------------- 824
hNLT CCTCAGCCTCTGGTG--------------------------------------------------------------------------- 934
rOAT2 CATCAGCATCTGGTG--------------------------------------------------------------------------- 897
TI-LTP CATCAGCATCTGGTGagagtggcgagcaagtgggagtgggagacacaacccaggcacaagcagttagagacgaagattcaaagacagggg 2308
TI-LTP cgggagaagtggcttagctgtaagcacacaccactcttctgaaggacccgtagcaggcagagtgaaagtcagtctgagagatcagacacc 2398
tctgggctctgtgggccacgcatacatacacacaccacacactagtactcgaagacacacacatacagacacagatacacacatagacac 2488
acccaaatacagatacatacatccaaacacacacacacacacacacacacaggcacacacacagatacatgtatccaaacacacacacac 2578
acacacacacacacaggcacatacacacacacagatacatatatccaaacacacacacataggcatacacacacacacacacacacacag 2668
atacatatatccaaacacacacacacacagatacatatatccaaacacacacacacacagatacatatatccaaacacacacacacacac 2758
acacacacacacacatacaggcacacacaggatgagttcagttggtaaagtgttttcctgccacacacaaaccctgggtttattatcttc 2848
agccctaaaaataatagaaacaaataaacaaagaacaagaagaccgagggccaggctgggagaactgactaagccagttgtgatggtgtg 2938
tacctccattcacaatacttaagaggtagaggcataagatcagaagttcaaggtcatgctcacctacctagggaatttaagggcagcctg 3028
ggttacagaagttcctgccttgaaaaaaaaaaaaaaagaggaaagaaaataaaagaaaacatctggagaacttggaagatctctcagttg 3118
gtaaaatgcttgccatgcaagcactaggacccgagttcagacccccagaacccatgtaggagcctggcacagaggtgagcatttataacc 3208
tcttgggaggctgagatgggaagatctgacacttgctggccagctgctctacctggataggggagttccaggctcaatgagagcctgtct 3298
cgaaaatctaaggtggagagtacttaagctagacccggcatgtcacccctgcatacatgtgtgtacatatacaaacatgtataaattcat 3388
aaacgatatcaagggaagtcagaaaactggaacacacacagcaggggggagtctaagagatgcagaaacagaatcggagaccaagagtca 3478
aaagcgacagaaagaagagggcacaagacacagaggcagagaacagacgtgaagagacagacggcccggagagaggcagtaacagagatg 3568
gagccgaaaggccaattcaaagggtcccgtggaaagacagcaaagacagtgatgaaggagtcagacgttgccaagtggaggctagggttg 3658
gccttcaagggacagggatggagcacggccagcatggtgatgggaactgaggcaggagaacggagggcctgtaaggtggggacagcgtta 3748
gctcctgacggtgaactgtgtatcagtctgtctgtccggcctccatctgcatccccatgccacagtgctggctgctggtgtgagctaagg 3838
ttctgagggtaaggaagggacccatggaggactggcggaacccaggcctgaacaaagccataaggggagaagaggtagctttaacaagag 3928
gggcctgaacaagagagcaaggggccgggcagtagacatggaggaggggactgcatggctgagaacctggagtgagcagcctaggatctc 4018
hOAT2 ----------------------------------------------------------------GGTGCCTGAGTCTGCACGCTGGCTTC 850
hNLT ----------------------------------------------------------------GGTGCCTGAGTCTGCACGCTGGCTTC 960
rOAT2 ----------------------------------------------------------------GGTTCCTGAGTCTGCACGGTGGCTTC 923
TI-LTP aagggcagaggtggtctgcaaggctggcttctggctgaaggtcctctggcttctcccttaggtgGGTTCCTGAGTCTGCACGGTGGCTTC 4108
hOAT2 TGACCCAAGGCCATGTGAAAGAGGCCCACAGGTACTTGCTCCACTGTGCCAGGCCCAATGGGCGGCCAGTGTGTGAGGACAGCTTCAGCC 910
hNLT TGACCCAAGGCCATGTGAAAGAGGCCCACAGGTACTTGCTCCACTGTGCCAGGCCCAATGGGCGGCCAGTGTGTGAGGACAGCTTCAGCC 992
rOAT2 TAACCCAGGGTCGTGTGGAGGAGGCAAAAAAATACTTGCTGAGCTGTGCCAAGCTCAATGGGCGGCCCGTGGGTGAGGGCAGCCTGAGCC 983
TI-LTP TAACCCAGGGTCGTGTGGAGGAGGCAAAAAAATACTTGCTGAGCTGTGCCAAGCTCAATGGGCGGCCCGTGGGTGAGGGCAGCCTGAGCC 4198
hOAT2 AGGAGG------------------------------------------------------------------------------------ 946
hNLT AGGAGG------------------------------------------------------------------------------------ 992
rOAT2 AGGAGG------------------------------------------------------------------------------------ 1019
TI-LTP AGGAGGtgagggtgtggacatgtatgagagagtacatggggatgggtggggagttcctgtctgagcgcccctccatcctgggcccaccat 4288
ataggaccagctctccagtggagagctccaggcttcggaataccccgcctggctctgatgggtcatcacctttcctctcggccctccatg 4378
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tgtactcccagcccaggactgctgaggacacagagaagcagagagaacacactggctcctgagacaagctctaaggtggaaatcttgctt 4468
hOAT2 ---------------CTGTGAGCAAAGTGGCCGCCGGGGAACGGGTGGTCCGAAGACCTTCATACCTAGACCTGTTCCGCACACCACGGC 991
hNLT ---------------CTGTGAGCAAAGTGGCCGCCGGGGAACGGGTGGTCCGAAGACCTTCATACCTAGACCTGTTCCGCACACCACGGC 1037
rOAT2 ---------------CCCTGAACAACGTGGTCACCATGGAAAGGGCGTTGCAAAGACCCTCATACTTAGACCTGTTCCGAACATCTCAGC 1064
TI-LTP tcttccccaaccaggCCCTGAACAACGTGGTCACCATGGAAAGGGCGTTGCAAAGACCCTCATACTTAGACCTGTTCCGAACATCTCAGC 4558
hOAT2 TCCGACACATCTCACTGTGCTGCGTGGTGGTGTGGT------------------------------------------------------ 1051
hNLT TCCGACACATCTCACTGTGCTGCGTGGTGGTGTGGT------------------------------------------------------ 1097
rOAT2 TCCGACATATCTCACTGTGCTGCATGATGGTGTGGT------------------------------------------------------ 1124
TI-LTP TCCGACATATCTCACTGTGCTGCATGATGGTGTGGTaagatggggtcgagttgtatctggtggagtgagggtgtgggagggaggggccaa 4648
gattgtaactggggagggtagagtgatcatcctggagctgggaaggggaaatctgactaccacaggtccagtgtagtcggcaacggagac 4738
acgtaggcccaactttaggctctatgacttccttaccgtgtgaccctggacaactgtctaaccactctgatccttaacatctatttttgt 4828
aaaacgagcagttttctgttaattcctgtgtcacagggttgctgctaagattggggtaaaggtgctttggccactggtatctacttgggg 4918
attgtggatggctgggggaagaggggcagagcctgggctgcggtctctgaagtgccaagtggcaggagagggttcttgaggggcactgca 5008
hOAT2 -------------TCGGAGTGAACTTCTCCTATTACGGCCTGAGTCTGGATGTGTCGGGGCTGGGGCTGAACGTGTACCAGACACAGCTG 1104
hNLT -------------TCGGAGTGAACTTCTCCTATTACGGCCTGAGTCTGGATGTGTCGGGGCTGGGGCTGAACGTGTACCAGACACAGCTG 1150
rOAT2 -------------TTGGAGTGAACTTTTCCTACTACGGCCTGACTCTGGACGTGTCTGGGCTGGGGCTGAACGTGTACCAGACACAGCTG 1177
TI-LTP actccattcaggtTTGGAGTGAACTTTTCCTACTACGGCCTGACTCTGGACGTGTCTGGGCTGGGGCTGAACGTGTACCAGACACAGCTG 5098
hOAT2 TTGTTCGGGGCTGTGGAACTGCCCTCCAAGCTGCTGGTCTACTTGTCGGTGCGC--TACGCAGGACGCCGCCTCACGCAAGCCGGGACAC 1164
hNLT TTGTTCGGGGCTGTGGAACTGCCCTCCAAGCTGCTGGTCTACTTGTCGGTGCGC--TACGCAGGACGCCGCCTCACGCAAGCCGGGACAC 1210
rOAT2 CTGTTTGGGGCTGTGGAGCTCCCCTCCAAAATTATGGTCTACTTCCTTGTGCGCCGTCTG--GGACGCCGTCTCACGGAGGCTGGGATGC 1237
TI-LTP CTGTTTGGGGCTGTGGAGCTCCCCTCCAAAATTATGGTCTACTTCCTTGTGCGCCGTCTG--GGACGCCGTCTCACGGAGGCTGGGATGC 5186
hOAT2 TGCTGGGCGCGGCCCTGGCGTTCGGCACTAGACTGCTAGTGTCCTCCGATATG------------------------------------- 1275
hNLT TGCTGGGCGCGGCCCTGGCGTTCGGCACTAGACTGCTAGTGTCCTCCGATATG------------------------------------- 1321
rOAT2 TGCTGGGCGCTGCTCTGACCTTTGGCACCAGCCTGCTGGTATCCT------TGG------------------------------------ 1343
TI-LTP TGCTGGGCGCTGCTCTGACCTTTGGCACCAGCCTGCTGGTATCCT------TGGgtaagccaggcctggcagttccttctgccctctgtg 5270
hOAT2 -------------------------------------------------------------------------AAGTCCTGGAGCACTGT 1292
hNLT -------------------------------------------------------------------------AAGTCCTGGAGCACTGT 1338
rOAT2 --------------------------------------------------------------------AGACTAAGTCATGGATCACTGC 1365
TI-LTP gggactctgcctcacatccagggggctcctggctccatcccctccctgaggaatccctttccctccagAGACTAAGTCATGGATCACTGC 5360
hOAT2 CCTGGCAGTGATGGGGAAAGCTTTTTCTGAAGCTGCCTTCACCACTGCCTACCTGTTCACTTCAGAGTTGTACCCTACGGTGCTCAG--- 1352
hNLT CCTGGCAGTGATGGGGAAAGCTTTTTCTGAAGCTGCCTTCACCACTGCCTACCTGTTCACTTCAGAGTTGTACCCTACGGTGCTCAG--- 1398
rOAT2 TCTGGTGGTGGTGGGGAAAGCTTTTTCTGAAGCTGCTTTTACTACGGCCTACCTGTTCACGTCCGAGTTGTACCCTACTGTGCTCAG--- 1425
TI-LTP TCTGGTGGTGGTGGGGAAAGCTTTTTCTGAAGCTGCTTTTACTACGGCCTACCTGTTCACGTCCGAGTTGTACCCTACTGTGCTCAGgta 5450
agccagggacccaggcgactgcctgccttaacctaggtgtctgtgttcacacactgcccacccattctttagctatagccagatacatcg 5540
atgcaccatgggtatttgtccaaatcttggggagcacagggaacttgatcttctgtactgggattgcctgcacaggaggggagccttgtg 5630
hOAT2 -------------------------------ACAGACAGGGATGGGGCTGACTGCACTGGTGGGCCGGCTGGGGGGCTCTTTGGCCCCAC 1438
hNLT -------------------------------ACAGACAGGGATGGGGCTGACTGCACTGGTGGGCCGGCTGGGGGGCTCTTTGGCCCCAC 1484
rOAT2 -------------------------------ACAGACAGGATTGGGACTTACTGCACTCATGGGCAGGCTAGGGGCCTCTCTGGCCCGAC 1511
TI-LTP acgaacggccccctcttcctttcctgaacagACAGACAGGATTGGGACTTACTGCACTCATGGGCAGGCTAGGGGCCTCTCTGGCCCCAC 5720
hOAT2 TGGCGGCCTTGCTGGATGGAGTGTGGCTGTCACTGCCCAAGCTTACTTATGGGGGGATCGCCCTGCTGGCTGCCGGCACCGCCCTCCTGC 1498
hNLT TGGCGGCCTTGCTGGATGGAGTGTGGCTGTCACTGCCCAAGCTTACTTATGGGGGGATCGCCCTGCTGGCTGCCGGCACCGCCCTCCTGC 1544
rOAT2 TGGCGGCCTTGCTGGATGGAGTGTGGCTGTTGCTGCCCAAAGTTGCTTACGGGGGGATTCCCTGGTGGCTGCCTGCACTGCACTCCTGCG 1571
TI-LTP TGGCGGCCTTGCTGGATGGAGTGTGGCTGTTGCTGCCCAAAGTTGCTTACGGGGGGATTGCCCTGGTGGCTGCCTGCACTGCACTCCTGC 5810
hOAT2 TGCCAGAGACGAGGCAGGCACAGCTGCCAGAGACCATCCAGGACGTGGAGAGAAAGAG-------------------------------- 1558
hNLT TGCCAGAGACGAGGCAGGCACAGCTGCCAGAGACCATCCAGGACGTGGAGAGAAAGAG-------------------------------- 1604
rOAT2 TGCCTGAGACGAAGAAGGCACAGCTGCCAGAGACCATCCAGGATGTGGAGAGGAAGAG-------------------------------- 1631
TI-LTP TGCCTGAGACGAAGAAGGCACAGCTGCCAGAGACCATCCAGGATGTGGAGAGGAAGAGgtatgtgtgcagtgcgtgcgtgtgtgcgtgtg 5900
tgtgtgtgtgagtgcgtgtgtgtgtgtgcgtgtgtgtgcatgtgagtgtgtgtgagtgtgtgagtgtgtgcatgtgagtgtgtgtgtatg 5990
tgtgtaagagtgtgtgagtgtggattcagatgcctaaggccctgacacttaggatgcaaagggaagacagttgcacagttacacttgcta 6080
cctatacatatgtgcacaggtgagtgtttgggtgtgtatatcctggtgtgtataacgtgtcatataaaatcaaacatgtctgtccttacc 6170
tttatatattcacgaatgcccaaaagagaggcacatatgcactctgagctatatacaccaagaatatgtccagacaagtgacttacttgt 6260
aggaggatgcgtgcatatatttgaggagctgggacagccccgagccagtccttgtaggctccaggactaacccccgaccacattcctgac 6350
rOAT2 -----------------------TACCCAGGAGGAAGATGTGTAG--------------------------------------------- 1666
TI-LTP acctttcttatggccttgtccagTACCCAGGAGGAAGATGTGTAGgtccgggactgagttggactagcgacagttctccacaggagctgg 6440
TI-LTP gcacagaaggcagcctcttgtgactgggacatcagactcctccacctaaggatggagctgctcctgatgccctctgcctgtgctctccag 6530
cagcagaacaacttcccgcagcactgggccgctgggattctggactcccctctcatggccgggggcttctataaataaagacggttgctc 6620
atgggttggggcagcagtgagattgggggaaaccctcagatggaaagccactgacttgatctgattccagtcttacactgcccatctccc 6710
aggtggacggcgaaacctcctagtggacaggatgttttgtggtgctcaaattgaacaaggtcatcctaggaatgtcgttaaagcacagtc 6800
ctgtagtcatttttagtaccgggaggccggtgggtgtactgtctccggtggaagggtagatcagcacaactccggggcaggggaccaata 6890
gatggttttcttgttgccagggctccctctgaagtagcagactcgtaccctacccctcaaatcactatctgggcttcacacctaaagaaa 6980
gagcagagtctggggccagcctggcctacagtgagctagcaggtggtaggtagggcacacctttaattccagcactccagaggcagaggc 7070
aagctagttgcagggctgcacaaagaaacctttctagaaaaaacaaaacagtcataaaacaaaacaaaacaaaaaagaaccaaaggtatg 7160
gggattgacattttattacggaatccagagagctcgacgacctttatgaatacactttatgaaactcaagcattgctgagagaaggactg 7250
hOAT2 ------------------------------TGTGCACAGGACTGTGTCTGTGTACGTGTGA 1626
TI-LTP ggagcccaggcaaccaccattctaagcgtgTGTG--------TGTGTGTGTGTGTGTGTGTgtgtgtgtgtgtgtgtgtgtgtgtgtgcc 7332
TI-LTP tccagttaggaatggggaaacacagaagtgggagagacagtctagactcaggtctaccacagagcctacacctaggtcccagcccccagg 7422
atgtcgcctgcttcctccccaaaggactaga 7453
hNLT TGCCCCAACCAGTCTTCAGGAGGAAGAGATGCCCATGAAGCAGGTCCAGAACTAA 1666
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